/Haochen Medical: 2025 Semi-Annual Report

NEWS

Haochen Medical: 2025 Semi-Annual Report

Shenzhen Stock Exchange

2025/08/29

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Haochen Medical Technology Co., Ltd. 2025 Semi-Annual Report

August 2025

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Section 1 Important Tips, Table of Contents and Definitions

The company's board of directors, board of supervisors and directors, supervisors and senior managers guarantee that the contents of the semi-annual report are true, accurate and complete, and that there are no false records, misleading statements or major omissions, and bear individual and joint legal liability.

The person in charge of the company, Lu Lu, the person in charge of accounting work, Deng Qiang, and the person in charge of the accounting department (accounting officer) Wang Yanxiao declare that they guarantee the authenticity, accuracy and completeness of the financial report in this semi-annual report. All directors have attended the board meeting to review this semi-annual report.

The future business plans and business goals mentioned in the semi-annual report do not represent the company's profit forecast, nor do they constitute the company's substantial commitment to investors. Whether they can be realized depends on changes in market conditions and other factors, and there are uncertainties. Investors are advised to pay attention to investment risks.

The risk factors that may exist in the company's operations have been described in the "10. Risks faced by the company and countermeasures" section of "Section 3 Management Discussion and Analysis" of this report. Investors are advised to read carefully and pay attention to the risks.

The company plans not to distribute cash dividends, give away bonus shares, or convert public reserve funds into share capital.

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

2. The originals of all company documents and announcements publicly disclosed on the information disclosure media designated by the China Securities Regulatory Commission during the reporting period;

3. The summary and full original copy of the 2025 semi-annual report signed by the company’s legal representative and stamped by the company;

The above documents are available for purchase at: Haochen Medical Securities Department, Room 1810, 18th Floor, Bank of East Asia Building, No. 5 Guanghua Road, Chaoyang District, Beijing.

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Definition

Interpretation item refers to the interpretation content company, group, Haochen Medical refers to the Company Law of Haochen Medical Technology Co., Ltd. refers to the Company Law of the People's Republic of China

Securities Law refers to the Securities Law of the People's Republic of China

This period, this reporting period, and reporting period refer to the period from January 1, 2025 to June 30, 2025. Switch Company, Yongda Electric refers to Jilin Yongda Electric Switch Co., Ltd. Rongyu Technology refers to Beijing Rongyu Technology Co., Ltd.

Delun Medical refers to Guangdong Delun Medical Group Co., Ltd. Rongyu Huatong refers to Rongyu Huatong Leasing (Tianjin) Co., Ltd. Huiyin Rifeng refers to Guangzhou Huiyin Rifeng Investment Partnership (Limited Partnership) Huiyin Aofeng refers to Guangzhou Huiyin Aofeng Equity Investment Fund Management Co., Ltd. Beijing Shouting Ronghui refers to Beijing Shouting Ronghui Investment Co., Ltd. Fushun Bank refers to Fushun Bank Co., Ltd.

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Section 2 Company Profile and Main Financial Indicators

1. Company Profile

Stock abbreviation Haochen Medical Stock code 002622 Stock abbreviation before change (if any) None

Stock exchange where stocks are listed Shenzhen Stock Exchange

The Chinese name of the company: Haochen Medical Technology Co., Ltd.

Company’s Chinese abbreviation (if any) Haochen Medical

Company's foreign name (if any) WHOLE SHINE MEDICAL TECHNOLOGY CO., LTD.

The abbreviation of the company’s foreign name (such as

WHOLE SHINE MEDICAL

Yes)

The legal representative of the company Lu Lu

2. Contact person and contact information

Secretary of the Board of Directors Name of Securities Affairs Representative Kang Chao Yao Heng

Century Fortune, No. 5 Guanghua Road, Chaoyang District, Beijing

Contact address: No. 98, Yingbin Road, Chuanying District, Jilin City, Jilin Province

Room 1810, 18th Floor, Central Bank of East Asia Building

Tel 0432-64602099 / 010-85660586 0432-64602099 Fax 010-85660586 0432-64602099 E-mail [email protected] [email protected]

3. Other situations

Company contact information

Whether the company's registered address, company office address and its postal code, company website, e-mail address, etc. have changed during the reporting period □Applicable Not applicable

The company's registered address, company office address and its postal code, company website, e-mail address, etc. did not change during the reporting period. For details, please refer to the 2024 annual report.

Information disclosure and preparation location

Whether the location of information disclosure and preparation changes during the reporting period

□Applicable Not applicable

The name and URL of the stock exchange website and media where the company discloses its semi-annual report. The company's semi-annual report preparation location did not change during the reporting period. For details, please refer to the 2024 annual report.

Other relevant information

Whether other relevant information has changed during the reporting period

□Applicable Not applicable

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

4. Main accounting data and financial indicators

Whether the company needs to retroactively adjust or restate previous years’ accounting data

□Yes No

This reporting period The same period last year This reporting period increased or decreased operating income (yuan) compared with the same period last year 313,635,948.22 382,010,234.10 -17.90% Net profit attributable to shareholders of listed companies

-23,751,065.12 553,485.18 -4,391.18% profit (yuan)

Deductions attributable to shareholders of listed companies

Net profit from non-recurring gains and losses -23,558,534.57 169,061.90 -14,034.86% (yuan)

Net cash flow from operating activities

-27,589,789.01 6,999,820.53 -494.15% (yuan)

Basic earnings per share (yuan/share) -0.0283 0.0007 -4,142.86% Diluted earnings per share (yuan/share) -0.0283 0.0007 -4,142.86% Weighted average return on equity -6.15% 0.13% -6.28%

End of the reporting period End of the previous year Increase or decrease in total assets at the end of the reporting period compared with the end of the previous year (yuan) 1,444,406,852.81 1,497,483,643.54 -3.54% Net assets attributable to shareholders of listed companies

372,781,577.47 398,035,174.16 -6.34% output (yuan)

5. Differences in accounting data under domestic and foreign accounting standards

Differences in net profit and net assets in financial reports disclosed in accordance with both international accounting standards and Chinese accounting standards

□Applicable Not applicable

During the reporting period, there was no difference between the net profit and net assets in the financial reports disclosed in accordance with international accounting standards and Chinese accounting standards.

Differences in net profit and net assets in financial reports disclosed in accordance with both foreign accounting standards and Chinese accounting standards

□Applicable Not applicable

During the reporting period, there was no difference between the net profit and net assets in the financial reports disclosed in accordance with foreign accounting standards and Chinese accounting standards.

6. Non-recurring profit and loss items and amounts

Applicable □Not applicable

Unit: Yuan

Item Amount Description

Gains and losses on disposal of non-current assets (including accrued

678,017.94

Offset portion of asset impairment provision)

Government subsidies included in current profits and losses (related to the company’s regular

Closely related to regular business operations and in compliance with national policies

483,223.52

stipulates, enjoys according to determined standards, and treats the company

Except for government subsidies that have a lasting impact on profits and losses)

Other non-operating income other than the above items and

-2,421,175.31

expenditure

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Less: Income tax impact -391,582.28

Amount of impact on minority shareholders’ equity (after tax) -675,821.02

Total -192,530.55

Details of other profit and loss items that meet the definition of non-recurring profits and losses:

□Applicable Not applicable

The company has no other specific circumstances of profit and loss items that meet the definition of non-recurring profits and losses.

Explanation on defining the non-recurring profit and loss items listed in the "Explanatory Announcement No. 1 on Information Disclosure of Companies that Offer Securities to the Public - Non-recurring Profit and Loss" as recurring profit and loss items

Applicable □Not applicable

Item Amount involved (yuan) Reason

Closely related to the company's normal business operations, it complies with the VAT levy and refund 2,352,373.97 national policies, and is based on certain standard quotas or

Quantity for continued enjoyment.

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Section 3 Management Discussion and Analysis

1. The main business of the company during the reporting period

During the reporting period, the company's core business covers dental medical services as well as the R&D, production and sales of permanent magnet switches and complete sets of high and low voltage switch equipment. It has now formed an industrial structure with dual main business operations of "oral medical services + industrial manufacturing".

(1) Industry conditions of the company during the reporting period

Oral medical service industry

With the trend of population aging intensifying, oral disease prevalence increasing, and per capita disposable income increasing, the demand for oral medical services in my country continues to expand. With oral medical service chain operation as its core, Delun Medical focuses on the diagnosis and treatment of oral diseases as well as oral health care and restoration services. Its business has covered Guangzhou, Foshan, Zhaoqing, and Huizhou, and it has strong regional brand influence in the field of oral medical services. In recent years, the country has introduced a series of policies and measures that are conducive to the development of the dental hospital industry, including the "Healthy China 2030 Planning Outline", The "China's Mid- and Long-term Plan for the Prevention and Treatment of Chronic Diseases (2017-2025)" and the "Healthy Oral Action Plan (2019-2025)" clearly set out action goals in terms of popularization of oral health behaviors, management optimization, capacity improvement, and industrial development. They aim to improve the national oral health level, promote the construction of the oral prevention and treatment system, promote the coordinated development of public and private dental institutions, encourage innovation and digital transformation, and provide strong guidance and guarantee for the development of the oral medical service industry.

At present, the trend of my country's population aging is gradually emerging, and the introduction of a number of encouraging and supportive policies such as centralized purchasing and medical service price adjustments will help further release the demand for dental medical services. According to the prediction of Zhongyan Puhua Industrial Research Institute, the market size will exceed 200 billion yuan in 2025 and will exceed 380 billion yuan in 2030. China's dental medical industry has entered a stage of rapid growth, and the oral medical service business is facing increasingly fierce industry competition.

Electrical industry

The company's permanent magnet switch business belongs to the electrical industry, and the manufacturing industry to which the electrical industry belongs is the foundation of my country's economic and social development. Faced with the complex international situation and the arduous and arduous tasks of domestic reform, development and stability, General Secretary Xi Jinping has repeatedly emphasized the important role and status of the manufacturing industry, especially the equipment manufacturing industry. The "14th Five-Year Plan" Intelligent Manufacturing Development Plan proposes to promote intelligent manufacturing based on the essence of manufacturing, closely following the characteristics of intelligence, with technology and equipment as the core, based on data, and relying on manufacturing units, workshops, factories, supply chains and other carriers to build an intelligent manufacturing system that integrates virtual and real, knowledge-driven, dynamic optimization, safe and efficient, green and low-carbon, and promotes the digital transformation, networked collaboration and intelligent transformation of the manufacturing industry. According to the "The Fourteenth Five-Year Plan for the National Economic and Social Development of the People's Republic of China and the Outline of Long-term Goals for 2035", it is necessary to thoroughly implement the strategy of manufacturing a strong country, adhere to independent controllability, safety and efficiency, promote the upgrading of the industrial base and modernize the industrial chain, maintain a basically stable proportion of the manufacturing industry, enhance the competitive advantages of the manufacturing industry, and promote high-quality development of the manufacturing industry.

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

In 2025, my country will focus on optimizing the main power grid, strengthening the distribution network, and serving the high-quality development of new energy, continue to promote the implementation of major projects, actively expand effective investment, and drive the upstream and downstream industrial chains. Researching and developing new products, exploring new markets, spawning new business formats, and cultivating new competitive advantages in the electrical industry under the new situation are still the current main tasks.

(2) The main business engaged in by the company during the reporting period

Oral medical service business

(1) Main business and products

The company's holding company, Delun Medical, is an enterprise with oral medical service chain operation as its core, focusing on the diagnosis and treatment of oral diseases, as well as oral health care, restoration services and other oral medical services. Delun Medical adheres to the business philosophy of "medical ethics, Delun heart" and takes "let all people have healthy teeth" as its mission. It is committed to promoting the development process of digital and intelligent diagnosis and treatment integration in the dental industry in South China, providing professional, accurate, minimally invasive, reliable, comfortable and long-lasting oral health diagnosis and treatment services to the general public in the Greater Bay Area to meet customers' lifelong oral medical and health care needs.

During the reporting period, Delun Medical had 31 chain outpatient clinics with an operating area of more than 40,000 square meters and more than 460 dental chairs. It was one of the largest chain dental medical service companies in South China. At present, Delun Medical's business has covered four cities: Guangzhou, Foshan, Zhaoqing and Huizhou, and it has strong regional brand influence in the field of dental medical services. Delun Medical currently operates "nine departments + three major centers", including nine specialty outpatient clinics including implantology, orthodontics, prosthodontics, endodontics, periodontics, pediatric dentistry, oral surgery, comfort anesthesia, and laboratory testing, as well as three major centers: digital center, dental cleaning center, and oral health center. It is equipped with auxiliary departments such as radiology rooms and sterilization supply rooms, which can fully meet the needs of oral patients.

(2) Main business model

As an oral medical service institution that specializes in providing patients with diagnosis and treatment of various types of oral diseases, as well as oral health care and restoration services, Delun Medical adopts an oral medical chain operation model. After years of development, Delun Medical has formed a chain development model of "city main hospital + regional branches". All hospital areas implement a unified system of medical quality, nursing quality, and service quality, implement unified model management, and standardize talent allocation.

Delun Medical draws on advanced experience in medical services at home and abroad to build an integrated model of digital and intelligent diagnosis and treatment, that is, a process service system of "appointment-triage-examination-interview-plan-treatment-return visit". Through the digital integrated system of five major business sectors, including digital information collection, digital diagnostic solutions, digital one-stop quality material processing, digital surgery execution, and digital diagnosis and treatment platform, we can achieve seamless connection between online customer service, medical guidance, customer service, doctors, nurses and other work links, and provide patients with standardized and high-quality medical services and treatment experience.

(3) Main performance drivers during the reporting period

During the reporting period, due to the impact of the market economic environment, there was a consumption downgrade in the industry. In addition, the number of private chain dental institutions and individual clinics continued to grow, and Delun Medical faced intensified competition in the same industry market. During the reporting period, the customer acquisition cost of Delun Medical industry increased, and the comprehensive customer unit price showed a significant decrease. In the first half of 2025, Delun Medical achieved operating income of 288 million yuan, a decrease of 17.39% from the same period last year, and net profit -

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

21.02 million yuan, a significant decrease compared with the same period last year. The gross profit margin decreased by 3.55% compared with the same period last year. Cost and expense control needs to be further strengthened.

Faced with the market pressure, Delun Medical adopts the core strategy of "consolidating the basic market and expanding into new markets" to deeply explore the markets of Guangzhou and Foshan, continue to promote cost reduction and increase efficiency, and at the same time expand into non-competitive first-tier city markets outside the Guangfo region to tap incremental space. In May 2025, Delun Medical Zhaoqing Outpatient Clinic officially opened. The Huizhou Outpatient Clinic is under preparation and is expected to be completed in the second half of 2025. Relying on the brand accumulation and management system accumulated by Delun Medical for many years, completing the layout in areas with low competition intensity and expected high unit price per customer may become a new performance growth point of Delun Medical.

R&D, production and sales of permanent magnet switches and complete sets of high and low voltage switch equipment products

(1) Main business and products

Jilin Yongda Electrical Switch Co., Ltd., a wholly-owned subsidiary, is a high-tech enterprise, one of the first batch of Jilin Province Science and Technology Little Giant Enterprises, a Jilin Province Patent Award Excellence Award Winner, Jilin Province Top Ten Integrity Enterprises, a 2020 Municipal Enterprise Technology Center, a 2022 Jilin Province Provincial It has many years of R&D and manufacturing experience in the field of permanent magnet switches and complete sets of high and low voltage switch equipment products. Yongda Electric is mainly engaged in the research and development, production and sales of permanent magnet switches and complete sets of high and low voltage switch equipment. After years of development, the product marketing network has spread across more than 20 provinces and cities across the country, able to provide customers with systematic services integrating "pre-sales, sales, and after-sales".

In order to cater to the needs of today's society and market, Yongda Electric has standardized, upgraded and optimized switchgear and low-voltage circuit breaker related products; the research and development of the intelligent circuit breaker series is in line with the development requirements of the national smart grid. It has fault judgment, recording, analysis and basic network interaction, and can realize the informatization, digitalization, automation and interactive requirements of the power grid.

Yongda Electric’s main products include KYN81-40.5 (Z), KYN61-40.5 (Z), XYN21-31.5 (Z)/D-31.5, KYN28-

KYN28-12, HXGN-12, DXG-12, XYN17-12, KYN2-12, KGN-12 and other high-voltage switch cabinets; GCS, GGD, YMNS, XL-21, JXF, YDGR and other low-voltage switch cabinets; ZN73A-12, ZN107-40.5, ZN107-A40.5, ZN114-27.5, YWL-12, YWL-40.5, YDDMB-12, YDZN-24, YDDMB-27.5, YDDMB-24, YDDMB-40.5, YDDMB-A (F) 40.5 and other series of permanent magnet indoor high-voltage vacuum circuit breakers; ZN73F-12, YDDMB-F12 solid-sealed pole series permanent magnet indoor high-voltage vacuum circuit breakers; YDD series permanent magnet high-voltage vacuum circuit breakers dedicated to electric arc furnaces; YDDMW series intelligent permanent magnet outdoor AC high-voltage vacuum column-mounted switches; YDDLB series universal low-voltage vacuum circuit breakers; EYSF-12, EYSL-12, YDDMF, YDDMC series permanent magnet high-voltage vacuum contactors; YDC1 permanent magnet low-voltage contactors; ICU4000 intelligent control device, KZC-2000 switch state controller; YZB (W)-12 outdoor box-type substation.

(2) Main business model

Since its establishment, Yongda Electric has been committed to the R&D, production and sales of permanent magnet switches and complete sets of high and low voltage switch equipment. It has an independent R&D and production base for intelligent permanent magnet switches. The factory area has a R&D technology center, an inspection and testing center, multiple production plants,

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

A variety of processing workshops and professional production lines, the core components and key technologies of the products are all derived from the company's independent intellectual property rights (7 invention patents, 17 utility models).

In terms of production, Yongda Electric adopts a full-cycle model, namely R&D→Sales→Production→Testing→After-sales→Optimization→R&D, which runs through all aspects from product design, raw material procurement, manufacturing, quality testing to after-sales service to ensure the high quality of products and customer satisfaction. In the field of sales, Yongda Electric mainly adopts a model that pays equal attention to regional operations and industry operations, and combines channel sales with business model operations to develop new industry incremental markets while maintaining the existing market to the greatest extent. At present, Yongda Electric has stable large customer resources. In the future, it will continue to pay attention to the development trends of new industries and gradually deploy new growth points. At the same time, it will pay attention to both products and services, and increase overall revenue and customer satisfaction on the premise of increasing added value.

(3) Main performance drivers during the reporting period

During the reporting period, Yongda Electric continued to promote management optimization and upgrading, and made strategic adjustments to the organizational structure. By streamlining management levels and eliminating functional overlap, the decision-making chain was shortened and project response speed was improved. The new organizational structure not only enhances the innovative vitality of the management team, but also further optimizes the rapid response mechanism oriented to customer needs, which will help further reduce annual operating costs.

During the reporting period, Yongda Electric continued to deepen its market layout, adhered to the dual-driven model of "regional operation + industry operation" and "channel sales", strengthened market development in key regions and increased penetration into new industries. Externally, by actively expanding the agent and dealer network, optimizing the channel structure, increasing market coverage, and further consolidating its dominant position in traditional industries such as steel, chemicals, and coal. Internally, Yongda Electric optimizes the sales management system, improves incentive policies, implements an all-employee sales mechanism, fully mobilizes internal resources, and forms a synergy for market development. Through the above measures, the company's market competitiveness has been significantly improved and its customer structure has become more diversified, laying a solid foundation for future performance growth.

At the same time, Yongda Electric always adheres to the development concept of "quality first", strictly implements the ISO quality management system, and implements refined management and control of the entire process from raw material procurement, production technology to finished product inspection to ensure stable and reliable product performance and continuous improvement of customer satisfaction. In terms of technological innovation, the company continues to increase investment in research and development, optimize the performance of core products, promote intelligent and energy-saving upgrades, and maintain its technological leadership in the industry. At the same time, Yongda Electric actively promotes standardized production, optimizes process flows, improves product consistency and yield rate, provides customers with higher-quality solutions, and assists the high-quality development of the industry. In the future, Yongda Electric will continue to seize the major opportunities presented by the 20th anniversary of the implementation of the Northeast Revitalization Strategy, deeply explore the Northeast market, develop new customer resources, strengthen the national sales network, enhance brand influence, and further expand market share.

2. Analysis of core competitiveness

Steady development of traditional main business

The company has made intensive efforts in the field of traditional intelligent permanent magnet switches, making the company better than its peers in key technical indicators, and has a rich product series and complete specifications. Yongda Electric, a wholly-owned subsidiary of the company, cooperates with advantageous companies in the permanent magnet switch industry chain and upstream and downstream industries to expand sales channels. It has been working in the steel, chemical, coal and other industries for many years and has cultivated a group of highly loyal industry customers. Yongda Electric insists on consolidating original customer resources and actively taking measures to develop customers in new industries. Currently, sales areas have spread all over the country.

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

In terms of intellectual property holding and transformation: Yongda Electric applied for 1 new invention patent and 6 new utility model patents in the first half of 2025, and passed the quality management system, environmental management system, and occupational health and safety management system certifications. Our main permanent magnet circuit breakers and contactor products all use the patented permanent magnet operating mechanism and the company's multiple patented technologies. Compared with the traditional spring mechanism circuit breakers and contactor products, the products have fewer parts, simple structure, high reliability, maintenance-free, low power consumption, long life, etc., and can work stably for a long time in extremely harsh environments.

In terms of cultural construction, Yongda Electric has always adhered to the core values of "Honesty, Trust, Cooperation, and Innovation" and the mission of "Leading Permanent Magnetic Switch Technology and Creating National Electrical Products". With "the mechanism inspires people, the culture shapes people, the feelings warm people, and the career unites people", it closely integrates cultural construction with corporate management and employee development.

In terms of talent echelon construction, Yongda Electric has 1 young and middle-aged professional and technical talent with outstanding contributions in Jilin Province, 1 top-notch young and middle-aged talent with outstanding contributions in Jilin City, 16 senior engineers or above, and 16 intermediate engineers. This has formed a professional R&D team with rich industry experience and technical reserves. It focuses on the R&D and innovation of permanent magnet switch products. Through technological innovation and upgrading, it continues to enrich the company's product categories, improve product performance parameters, expand product functions, and enhance maintenance convenience.

Strong brand influence in the field of dental medical services

(1) Have high brand awareness

After years of steady development, the "Delun Dental" brand has established high brand awareness and good reputation in Guangzhou and Foshan. During the reporting period, Delun Medical changed from a "Guangfo chain" to a "four-city chain", and its brand awareness will be further improved. By building a wider service network, building a complete dental medical service system, cultivating an efficient professional team, and relying on advanced medical technology and digital means to provide customers with excellent dental medical services, the company ensures that Delun Medical's dental medical services are both excellent in scale and quality. (2) Advanced medical technology and equipment

In the field of technology, Delun Medical always pays close attention to the cutting-edge technology of oral clinical treatment, adheres to the principle of "based on the cutting-edge of science and technology", and vigorously promotes and applies advanced clinical technology. The introduction of international and domestic cutting-edge oral medical or auxiliary equipment, as well as new oral medical materials, provides solid technical support for Delun Medical to continuously improve the quality of medical services.

After more than ten years of innovative research and development, Delun Medical has continuously improved various dental diagnosis and treatment technologies to achieve safe and comfortable diagnosis and treatment results. As of the end of the reporting period, Delun Medical has held more than 60 utility model patent certificates and invention patent certificates for oral devices, mastered many technologies such as digital comfortable dental implants, and provided professional, advanced, and internationally-aligned oral health services to millions of customers.

(3) Professional medical team

Delun Medical adheres to strict talent selection standards and has gathered a group of talents with outstanding technical capabilities in the dental field. As of the end of the reporting period, Delun Medical has established a large medical team consisting of more than 200 practicing physicians and more than 420 nursing staff. With solid professional theoretical foundation and rich clinical treatment experience, Delun Medical's service quality has won high praise and trust from dental patients.

(4) Excellent service experience

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

With the service concept of "service once, care for a lifetime", Delun Medical provides both basic diagnosis and treatment services and mid-to-high-end diagnosis and treatment services, and has established a "three-in-one" service system of "whole family, whole mouth, and whole life cycle" to continuously expand the company's service scope and fully meet the needs of oral patients. During the more than ten years since its establishment, Delun Dental has continued to improve in infection prevention and control management, patent technology applications, user service experience optimization, exploration of cutting-edge diagnosis and treatment concepts, and team building of medical experts. It has always focused on bringing users a comfortable and secure diagnosis and treatment experience, and strives to create high-quality star-level diagnosis and treatment services.

(5) Complete physician training system

Delun Medical has a sound physician training system to ensure a stable supply and sustainable development of medical talents. Delun Medical attaches great importance to the cultivation and training of professional medical talents. Through the establishment of Delun Academy, it has upgraded the training work to the company's infrastructure level and established a complete training and communication system. After years of system construction and mechanism optimization, Delun Medical has formed a multi-level talent training mechanism. By continuously improving doctors' professional skills and knowledge levels, it ensures that patients enjoy high-quality diagnosis, treatment and nursing services, thereby directly improving the overall quality of medical services.

(6) Excellent medical quality

Delun Medical adheres to the development vision of "becoming the most trusted century-old dental brand" and adheres to the medical principles of "professional rigor and excellence". By building a comprehensive and standardized dental medical quality control system and a five-ring management system with three-dimensional thinking as the core, Delun Medical implements strict quality control and continuous improvement measures, and maintains persistent execution efforts, striving to achieve refined management. As one of the medical institutions in Guangdong that has received ISO9001 quality management system certification, Delun Medical's service quality is well received by patients.

3. Main business analysis

Overview

Please refer to the relevant content of "1. Main businesses engaged in by the company during the reporting period".

Year-on-year changes in major financial data

Unit: Yuan This reporting period Same period last year Year-on-year increase or decrease Reasons for changes

Affected by the market economic environment, the company's operating income during the reporting period was 313,635,948.22 382,010,234.10 -17.90%

Oral medical business declines

Operating costs 178,274,250.68 206,067,242.04 -13.49% Sales expenses decreased with the decrease in operating income during the reporting period 76,940,756.43 89,747,327.44 -14.27% Management expenses such as business promotion expenses and employee salaries decreased during the reporting period 68,770,906.66 74,914,155.33 -8.20% Financial expenses such as employee salaries and office expenses decreased during the reporting period 20,646,355.58 22,665,084.92 -8.91% Borrowing interest and handling fees decreased during the reporting period

Income tax expense 2,543,284.59 1,379,875.03 84.31% R&D investment due to increase in taxable income during the reporting period compared with the previous period 7,966,580.46 3,605,476.51 120.96% Increase in R&D expenses during the reporting period

Cash generated from operating activities During the reporting period, the company’s dental medical business declined, and operations

-27,589,789.01 6,999,820.53 -494.15%

Net Flows Decrease in Cash Inflow from Activities

Cash generated from investing activities

-2,551,228.72 -4,822,018.74 47.09% The company’s investment activities expenses decreased during the reporting period

Net flow

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Cash generated from financing activities During the reporting period, the company did not repay any borrowings.

-6,566,110.68 -17,999,967.02 63.52%

Net flow to repay part of the loan

Affected by the decline in the company's dental medical business, net operating cash and cash equivalents

-36,706,921.74 -15,822,130.24 -132.00% Cash flow decreased significantly compared with the same period, resulting in an increase in cash and

The net increase in cash equivalents decreased significantly

There are significant changes in the company's profit composition or profit sources during the reporting period

□Applicable Not applicable

There were no major changes in the company's profit composition or profit sources during the reporting period.

Operating income composition

Unit: Yuan This reporting period Same period last year

Year-on-year increase or decrease

Amount % of operating income Amount % of operating income

Total operating income 313,635,948.22 100% 382,010,234.10 100% -17.90% Industry

Electrical switch industry 24,112,875.19 7.69% 31,771,416.07 8.32% -24.11% Medical dental industry 288,484,549.17 91.98% 349,200,294.17 91.41% -17.39% Leasing business industry 1,038,523.86 0.33% 1,038,523.86 0.27% 0.00% by product

Industrial switch products 24,112,875.19 7.69% 31,771,416.07 8.32% -24.11%Medical dental services 288,484,549.17 91.98% 349,200,294.17 91.41% -17.39%Others 1,038,523.86 0.33% 1,038,523.86 0.27% 0.00% by region

Domestic 313,635,948.22 100.00% 382,010,234.10 100.00% -17.90% Industries, products or regions accounting for more than 10% of the company's operating revenue or operating profit

Applicable □Not applicable

Unit: Yuan

Operating income compared to the previous year Operating costs compared to the previous year Gross profit margin compared to the previous year’s operating income Operating costs Gross profit margin

Increase/decrease in the same period of the year Increase/decrease in the same period of the year Increase/decrease in the same period by industry

Electrical switch industry 24,112,875.19 14,782,582.40 38.69% -24.11% -28.06% 3.37% Medical dental industry 288,484,549.17 162,667,415.28 43.61% -17.39% -11.84% -3.55% Leasing business industry 1,038,523.86 824,253.00 20.63% 0.00% -17.65% 17.01% By product

Industrial switch products 24,112,875.19 14,782,582.40 38.69% -24.11% -28.06% 3.37%Medical dental services 288,484,549.17 162,667,415.28 43.61% -17.39% -11.84% -3.55% Others 1,038,523.86 824,253.00 20.63% 0.00% -17.65% 17.01% By region

Domestic 313,635,948.22 178,274,250.68 43.16% -17.90% -13.49% -2.90% If the statistical caliber of the company’s main business data is adjusted during the reporting period, the company’s main business data for the most recent period will be adjusted based on the caliber at the end of the reporting period.

□Applicable Not applicable

4. Analysis of non-main business

Applicable □Not applicable

Unit: Yuan

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Account for total profit Whether there is an amount Explanation of reasons for formation

Proportion Sustainability The company received the "China Banking Regulatory Commission" on October 22, 2014.

China Banking Regulatory Commission’s Reply on the Equity Change of Fushun Bank”, agreeing to the public

The company received a 9.28% stake in Fushun Bank on October 30, 2014.

Completed the equity transfer procedure on 11 September and became the largest shareholder of Fushun Bank. Fushun

On December 29, 2020, the bank completed a registered capital of RMB 2,445.5 million.

The industrial and commercial registration procedures were changed from RMB 3,070,497,100 to RMB 3,070,497,100. This capital increase

After that, the company's 227 million shares of Fushun Bank remained unchanged, with a shareholding ratio of

Example changed from 9.28% to 7.39%; Fushun on April 27, 2023

Investment income 4,349,700.10 -13.56% is the result of the bank completing the change of registered capital from RMB 3,070,497,100 to

3,397,387,200 industrial and commercial procedures, the company holds Fushun Bank 22,700

The equity of 10,000 shares remains unchanged, and the shareholding ratio changes to 6.68%; the company remains Fushun

The largest shareholder of the bank. According to the 2014 Board of Directors of Fushun Bank Corporation

and the resolution of the general meeting of shareholders, the company obtained a director from the board of directors of Fushun Bank

Membership and the right to participate in decision-making on the financial and operating policies of Fushun Bank

power and has a significant impact on Fushun Bank. Therefore, the company’s investment in Fushun Bank

Capital is accounted for using the equity method.

Non-operating income 129,009.74 -0.40% No non-operating expenses 2,550,185.05 -7.95% Mainly medical insurance settlement refunds, late fees, etc. No

5. Analysis of assets and liabilities

Major changes in asset composition

Unit: Yuan End of the reporting period End of the previous year

Proportion of total assets Proportion of total assets Increase or decrease in proportion Explanation of significant changes Amount

Example Example

Monetary funds 111,862,603.68 7.74% 147,693,180.87 9.86% -2.12% No major changes occurred Accounts receivable 27,438,643.26 1.90% 39,169,433.88 2.62% -0.72% No major changes occurred in contract assets No major changes in inventory 53,276,633.14 3.69% 50,753,348.55 3.39% 0.30% No major changes in investment real estate 30,554,831.40 2.12% 31,241,592.24 2.09% 0.03% No major changes in long-term equity investments 479,164,621.92 33.17% 476,317,660.06 31.81% 1.36% No major changes occurred Fixed assets 156,077,277.45 10.81% 160,462,952.57 10.72% 0.09% No major changes occurred Construction in progress No major changes in right-of-use assets 156,468,239.55 10.83% 166,620,254.74 11.13% -0.30% No major changes in short-term borrowings 191,428,594.44 13.25% 191,588,304.03 12.79% 0.46% No major changes in contract liabilities 117,196,215.14 8.11% 124,737,128.05 8.33% -0.22% No major changes in long-term borrowings No major changes in lease liabilities 138,659,506.36 9.60% 151,095,010.40 10.09% -0.49% No major changes have occurred

Major overseas assets

□Applicable Not applicable

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Assets and liabilities measured at fair value

Applicable □Not applicable

Unit: Yuan This period’s fair calculation This period’s current period

Accumulation included in equity Output in current period Others

Item Beginning balance Change in value Provision less Purchase Closing balance Change in fair value Sales amount Change

Profit and loss value amount

financial assets

Other rights

Yitong Tool Investment 11,000,000.00 -68,540,650.00 11,000,000.00 capital

Total of the above 11,000,000.00 -68,540,650.00 11,000,000.00Financial liabilities 0.00 0.00Other changes

Whether there are any significant changes in the measurement attributes of the company's main assets during the reporting period

□Yes No

Restrictions on asset rights as of the end of the reporting period

Item Book value as of June 30, 2025 Reason for restriction

Monetary funds 16,998,718.23 time deposits and litigation frozen

Other receivables - dividends receivable 22,700,000.00 Litigation frozen

Other equity instrument investments 11,000,000.00 The aforementioned other equity instrument investments are used for company borrowings as collateral for long-term equity investments 479,164,621.92 Litigation frozen

Fixed assets 93,084,400.69 The aforementioned fixed assets are used as mortgages for company loans or as counter-guarantees. Investment properties 30,554,831.40 The aforementioned investment properties are used as mortgages for company loans. Intangible assets 28,723,763.19 The aforementioned intangible assets are used as mortgages for company loans. Total 682,226,335.43

6. Investment status analysis

Overall situation

□Applicable Not applicable

Major equity investments obtained during the reporting period

□Applicable Not applicable

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Major non-equity investments ongoing during the reporting period

□Applicable Not applicable

Financial asset investment

(1) Securities investment situation

□Applicable Not applicable

The company had no securities investments during the reporting period.

(2) Derivatives investment situation

□Applicable Not applicable

The company had no derivative investments during the reporting period.

Usage of raised funds

□Applicable Not applicable

The company has no use of raised funds during the reporting period.

7. Sale of major assets and equity

Sale of major assets

□Applicable Not applicable

The company did not sell any major assets during the reporting period.

Sale of major equity interests

□Applicable Not applicable

8. Analysis of major holding and participating companies

Applicable □Not applicable

Information about major subsidiaries and joint-stock companies that affect the company's net profit by more than 10%

Unit: yuan Company name Company type Main business Registered capital Total assets Net assets Operating income Operating profit Net profit Jilin Yongda

Switch production 300,000,0 517,811,4 387,699,6 24,112,87 3,571,994 3,306,881 Electrical switches Subsidiary

and sales 00 92.81 08.01 5.19 .54 .10 Co., Ltd.

Zhiyu Medical Medical Investment - -

50,000,00 646,451,2 275,748,5 288,484,5

Investment Co., Ltd. Subsidiary Capital, Dental 17,407,72 22,112,18

0 31.85 23.92 49.17

Company Medical Services 7.09 8.83

absorb and store

Fushun Bank

Payment and distribution 3,397,387 141,302,1 8,301,507 693,813,9 71,554,44 65,115,25 Co., Ltd. Joint stock company

Loans and banks,189 15,215.12,717.15 18.12 8.00 6.41Company

Industry business

Beijing Rongyu Technology Development 60,000,00 64,900,39 - 1,038,523 - -

Subsidiaries

Technology Co., Ltd. Development and technology 0 6.58 35,426,30 .86 4,263,419 4,264,319

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd. Company Consulting and Planning 8.82 .70 .71 Computer Network

Internet, rental

Office space

Acquisition and disposal of subsidiaries during the reporting period

□Applicable Not applicable

Description of major holding and joint-stock companies

9. Structured entities controlled by the company

□Applicable Not applicable

10. Risks faced by the company and countermeasures

Policy risks

In recent years, the state has introduced various regulatory policies to support the development of the dental medical industry. The "Healthy Oral Action Plan (2019-2025)" released in 2019 pointed out that the oral health system should be improved, oral health service capabilities should be improved, oral health management should be based on the whole population and the whole life cycle, and oral health problems of different groups should be classified and guided. The Fifth Plenary Session of the 18th Central Committee of the Communist Party of China clearly proposed to promote the construction of a healthy China, starting from the "five-in-one" overall layout and the "four comprehensives" strategic layout, emphasizing that the "Healthy China 2030" planning outline is the action plan for promoting the construction of a healthy China in the next 15 years. The country has successively introduced a series of policies and systems to promote the development of the comprehensive health industry. The company will strengthen its understanding of policy trends and adjust strategies in real time to cope with the uncertainty and impact of medical reform policies.

Medical risks

In clinical medicine, due to the influence of many factors such as limitations in medical cognition, individual differences in patients, different disease conditions, differences in doctor levels, and hospital conditions, various types of diagnosis and treatment behaviors objectively have risks of varying degrees, and medical accidents and errors cannot be completely eliminated. In the process of providing medical services to customers in the oral medical service industry, on the one hand, the doctor's diagnosis and treatment process must rely on the doctor's professional judgment. Judgment errors may affect the treatment effect, leading to unsuccessful treatment and less than expected treatment results. On the other hand, due to the limitations of medical knowledge, individual differences, medical conditions, diagnosis and treatment equipment, disease conditions and many other factors, various types of diagnosis and treatment behaviors objectively have risks of varying degrees. In response to medical risks, the company will strictly implement the national and industry diagnosis and treatment guidelines, operating specifications and nursing specifications, continuously improve the medical quality control system, strengthen the professional skills training of the physician team, improve the diagnosis, treatment and nursing standards of medical staff, conscientiously perform notification obligations and necessary procedures, strengthen and improve doctor-patient communication, and effectively improve the level of medical quality control.

Market competition and risk of brain drain

With the rapid expansion of the market size of the oral medical industry, the huge market potential has attracted a large influx of capital and practitioners. The number of private chain dental institutions and individual clinics continues to grow, market competition in the dental medical service industry intensifies, and there is a risk of dilution of market share in the industry. At the same time, the company's oral medical service business has reduced the comprehensive unit price per customer, and has increased efforts in advertising, marketing activities, and channel expansion.

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Investment may lead to an increase in operating costs, thereby squeezing profit margins to a certain extent. In the future, the company will continue to promote cost reduction and efficiency improvement while expanding markets outside the Guangfo region to tap incremental space.

Due to the particularity of the oral medical service industry, doctors and other professional and technical talents are the core elements to maintain market competitiveness. In the operation process of the oral medical service industry, doctors play an important role in attracting customers and providing medical services. In the future, the company will continue to improve its talent reserve and team building to avoid brain drain or insufficient talent reserve.

Others

(1) Matters related to the Jin Haitang case

Regarding the case of Jin Haitang Asset Management Co., Ltd. suing Zuo Jiahua, the company, and Yin Hongwei for other contract disputes, the company has filed lawsuits on July 31, 2020, August 7, 2020, May 7, 2021, September 10, 2022, October 29, 2022, July 7, 2023, December 21, 2023, January 31, 2024, February 22, 2024, March 16, 2024, March 26, 2024, On June 18, 2024, and June 29, 2024, the "Announcement on the Progress of the Receipt of the "Notice of Response" and Related Legal Documents and the Freezing of Part of the Company's Bank Accounts" was disclosed on the cninfo.com (announcement number: 2020-052), "Announcement on the freezing of equity interests in participating companies" (Announcement No.: 2020-053), "Announcement on the receipt of the first-instance "Civil Judgment" and preparation of appeal" (Announcement No.: 202 1-021), "Announcement on the receipt of the civil judgment from the Shanghai Higher People's Court" (Announcement No.: 2022-048), "Announcement on the progress of litigation matters" (Announcement No.: 2022-059), "Announcement on the receipt of the civil judgment from the Shanghai Higher People's Court" (Announcement No.: 2023-027), "Informative announcement about the judicial auction of the equity interests of the participating companies" (Announcement No.: 2023-053), "Progress Announcement on the Judicial Auction of the Equity of the Participating Company" (Announcement Number: 2024-001), "Informative Announcement on the Second Judicial Auction of the Equity of the Participating Company" (Announcement Number: 2024-003), "Progress Announcement on the Second Judicial Auction of the Equity of the Participating Company" (Announcement Number: 2024-004), "Informative Announcement on the Judicial Sale of the Equity of the Participating Company" (Announcement Number: 2024- 005), "Announcement on the progress of the judicial sale of equity interests in participating companies" (Announcement No.: 2024-025), "Announcement on the receipt of the "Execution Ruling" (Announcement No.: 2024-027).

As of the disclosure date of this report, the Shanghai Financial Court has ruled to terminate the execution procedures applied for by Jin Haitang Asset Management Co., Ltd. The company will continue to maintain communication with the applicant for execution and the Shanghai Financial Court, keep abreast of the follow-up progress of relevant matters, and promptly perform information disclosure obligations in accordance with relevant laws and regulations.

The company reminds investors to pay attention to investment risks and invest rationally.

(2) Matters related to the seizure and freezing of the equity and assets of some of the company’s subsidiaries

The company will disclose information in the designated information media Cinchao Information on July 14, 2023, July 19, 2023, August 31, 2023, October 31, 2023, and November 29, 2023 respectively. The website disclosed the "Announcement on the Frozen Bank Accounts of the Company and its Subsidiaries and the Unfreezing of Some Bank Accounts of the Company" (Announcement No.: 2023-028), and the "Announcement on the Receipt of the "Execution Notice"" (Announcement No.: 2023-028).

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

No.: 2023-032), "Announcement on the seizure and freezing of the equity and assets of some of the company's subsidiaries" (Announcement No.: 2023-036), "Announcement on the progress of the freezing of some bank accounts of the company and its subsidiaries" (Announcement No.: 2023-048).

On November 28, 2023, the company and its subsidiary Yongda Electric submitted an application for enforcement objection to the excessive seizure to the Beijing No. 1 Intermediate People's Court, requesting to lift the freeze on the company's equity in Zhiyu Medical and Wantai Zhonglian, and the freeze on Yongda Electric's bank account. According to the "Execution Ruling" [(2023) Jing01 Zhiyi No. 711] and the "Execution Ruling" [(2023) Jing01 Zhiyi No. 712] issued by the Beijing No. 1 Intermediate People's Court, the freezing of Wantai Zhonglian's equity held by the company did not constitute an effective freeze and had no corresponding legal effect; it rejected the objections raised by the company and Yongda Electric.

As of the disclosure date of this report, due to loan disputes with Zhejiang Zheshang Asset Management Co., Ltd. and Wenzhou Bank Co., Ltd., the company's assets have been seized and frozen as follows: The equity of the company's wholly-owned subsidiary Zhiyu Medical Investment Co., Ltd. was frozen by the Beijing No. 1 Intermediate People's Court, with the frozen equity amount of 50 million yuan, frozen The period is 1097 days; the real estate of the company's wholly-owned subsidiary Yongda Electric located at No. 98 Yingbin Road, Chuanying District, Jilin City (warrant number: Ji (2018) Jilin City Real Estate No. 0104786, No. 0104795, No. 0104788) was sealed by the Beijing No. 1 Intermediate People's Court for a period of 3 years. As of the end of this reporting period, the frozen bank balances of the company and its subsidiaries totaled 1,998,718.23 yuan, accounting for 0.54% of the company's most recent audited net assets; of which, the amount that had been judicially transferred totaled 4,144,318.12 yuan, accounting for 1.11% of the company's most recent audited net assets.

At present, the company is still actively communicating and negotiating with Zhejiang Zheshang Asset Management Co., Ltd. and Bank of Wenzhou Co., Ltd. to explore the feasibility of extension, batch repayment, and financing replacement to properly resolve the seizure and freezing of the above-mentioned assets and accounts.

(3) Matters regarding possible changes in company control

The company disclosed "About possible changes in the company's control" on cninfo.com on July 5, 2023, August 9, 2023, August 22, 2023, May 23, 2024, July 2, 2024, September 28, 2024, and October 25, 2024 respectively. "Updated Indicative Announcement" (Announcement No.: 2023-026), "Announcement on the Progress of Possible Changes in the Company's Control" (Announcement No.: 2023-033), "Announcement on Beijing Shoutuo Ronghui Investment Co., Ltd.'s Receipt of the "Notice of Case Acceptance"" (Announcement No.: 2023- 034), "Announcement on the receipt of the "Notification Letter" from the largest shareholder" (Announcement No.: 2024-021), "Announcement on the application for substantive merger and bankruptcy liquidation of Beijing Shoutuo Ronghui Investment Co., Ltd. and its concerted parties" (Announcement No.: 2024-02 8), "Announcement on the receipt of the "Civil Judgment" by the largest shareholder's executive partner" (Announcement No.: 2024-028), "Announcement on the receipt of the "Civil Appeal" by the largest shareholder's executive partner" (Announcement No.: 2024-037). On August 4, 2023, Huiyin Aofeng sent a "Letter on Terminating the Cooperation Agreement" to Beijing Shoutuo Ronghui. Later, Beijing Shoutuo Ronghui filed a lawsuit with the People's Court of Nansha District, Guangzhou City, requesting to confirm that the "Letter on Terminating the Cooperation Agreement" sent by Huiyin Aofeng to Beijing Shouting Ronghui was invalid.

In May 2024, the company's largest shareholder Huiyin Rifeng sent a "Notification Letter" to the company, and the Shanghai Pudong Development Bank Guangzhou Branch has become the single client of Huiyin Rifeng Limited Partner Ping An Huitong Guangzhou Huiyin Aofeng No. 7 Special Asset Management Plan.

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

In June 2024, the company received a "Notice" from Beijing Shoutuo Ronghui. The administrator of Zhongzhi Enterprise Group Co., Ltd. stated that 248 companies including Zhongzhi Group, including Beijing Shoutuo Ronghui and Qingdao Xinhui, were highly related and had highly mixed legal personalities. , on the grounds that the cost of distinguishing the assets of 248 companies including Zhongzhi Group was too high, and separate bankruptcy and liquidation would seriously damage the fair settlement interests of all creditors, an application was made to the Beijing No. 1 Intermediate People's Court for substantive merger and bankruptcy liquidation of 248 companies including Zhongzhi Group.

On September 27, 2024, the company received the (2023) Guangdong 0115 Minchu No. 10080 "Civil Judgment" issued by the Nansha District People's Court of Guangzhou City from the largest shareholder Huiyin Rifeng, ruling to reject all litigation claims of Beijing Shoutuo Ronghui Investment Co., Ltd. Beijing Shoutuo Ronghui was dissatisfied with the (2023) Guangdong 0115 Minchu No. 10080 civil judgment issued by the Guangzhou Nansha District People's Court and appealed to the Guangzhou Intermediate People's Court.

On May 8, 2025, the company disclosed the "Announcement on the Progress of the Largest Shareholder's Executive Partner's Receipt of the "Civil Judgment" and the Planned Change of Control of the Company" (Announcement Number: 2025-012) and the "Simplified Equity Change Report" on the cninfo.com, according to Guangzhou Nansha District People's Court (2023) Guangdong 0115 According to the Civil Judgment No. 10080 of the Republic of China and the Civil Judgment No. 29751 of the Guangzhou Intermediate People's Court (2024) Guangdong 01 Minzhong, the cooperation agreement signed by Beijing Shoituo Ronghui and Huiyin Aofeng has been terminated, and Mr. Xie Zhikun should no longer be recognized as the actual controller of the listed company.

At present, the company has not received the "Detailed Equity Change Report" submitted by the information disclosure obligor. In the future, the company will continue to urge the information disclosure obligors to complete the preparation of the "Detailed Equity Change Report" as soon as possible. After receiving the "Detailed Equity Change Report" and other corresponding documents that comply with laws, regulations and regulatory requirements, the company will fulfill its disclosure obligations in accordance with the requirements of relevant laws and regulations.

The company reminds investors to pay attention to investment risks and invest rationally.

In the future, the company will continue to adhere to strict risk control management and scientific investment decisions, and operate in strict accordance with the "Company Law", "Securities Law" and various rules and regulations issued by the China Securities Regulatory Commission and the Shenzhen Stock Exchange. At the same time, we pay close attention to market dynamics, strengthen internal management and risk management, and actively explore new business models and growth points to ensure the company's steady development.

11. Formulation and implementation of market value management system and valuation improvement plan

Whether the company has formulated a market value management system.

□Yes No

Whether the company has disclosed plans to increase its valuation.

□Yes No

12. Implementation of the “Double Improvement of Quality and Return” action plan

Has the company disclosed an announcement on the “Dual Improvement of Quality and Return” action plan?

□Yes No

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Section 4 Corporate Governance, Environment and Society

1. Changes in directors, supervisors and senior managers of the company

□Applicable Not applicable

There were no changes in the company’s directors, supervisors and senior managers during the reporting period. For details, please refer to the 2024 annual report.

2. Profit distribution and conversion of capital reserve funds into share capital during the reporting period

□Applicable Not applicable

The company plans not to distribute cash dividends, give away bonus shares, or convert public reserve funds into share capital in the first half of the year.

3. Implementation of the company’s equity incentive plan, employee stock ownership plan or other employee incentive measures

□Applicable Not applicable

The company has no equity incentive plan, employee stock ownership plan or other employee incentive measures and their implementation during the reporting period.

4. Environmental information disclosure

Whether listed companies and their major subsidiaries are included in the list of companies that disclose environmental information in accordance with the law

□Yes No

5. Social Responsibility

The company attaches great importance to and actively assumes social and public responsibilities. While focusing on "product safety, environmental protection, and safe production", through strict control over the production process, environmental protection, and hazard identification, the company has effectively improved product quality, ensured production safety, achieved energy conservation and consumption reduction, and enhanced industry competitiveness. In response to potential risks in daily operations, the company has taken a series of measures in energy conservation and emission reduction, environmental protection, safety management, employment of disabled people, and social welfare undertakings.

Energy conservation and emission reduction: Actively introduce advanced technology, improve equipment and processes, and gradually phase out high energy-consuming equipment.
Environmental protection: Implement strict control over the disposal of medical waste and wastewater, and continue to carry out environmental protection publicity activities.
Safety management: Standardize safe operations, install complete fire protection and explosion-proof facilities, formulate emergency plans and conduct regular drills.
Employment of disabled people: Reasonably arrange simple jobs, provide assistance objects, provide complete labor protection tools, and provide reasonable salary and welfare guarantees.
Protection of employee rights and interests: The company has established a labor union and an employee home. The employee membership rate has reached more than 95%. It has set up employee libraries, maternal and child rooms, etc., and regularly organizes job skills training, fire safety training, and special anti-gang and anti-evil combat training. It pays attention to employees with family difficulties, regularly organizes warmth, and fully protects the rights and interests of employees.
Actively participate in social welfare undertakings: focus on creating social value, focus on social responsibilities by actively participating in social welfare activities, devote yourself to public welfare and charity, and strive to create harmonious public relations. To the best of our ability, we provide support in education, culture, science, health, poverty alleviation and other areas where the company is located. During the reporting period, Delun Medical, the company's holding company, won the title of "Model Cooperation Unit for Supporting the Military and Prioritizing Affiliates" and launched a special campaign of "Caring for Veterans and Public Welfare Dental Care".

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Section 5 Important Matters

Commitments made by the company’s actual controller, shareholders, related parties, acquirers, the company and other relevant parties that have been fulfilled during the reporting period and have been overdue and unfulfilled as of the end of the reporting period

□Applicable Not applicable

During the reporting period of the company, there were no commitments made by the company's actual controller, shareholders, related parties, acquirers, the company and other relevant parties that were fully fulfilled during the reporting period and that were overdue and unfulfilled as of the end of the reporting period.

2. Non-operating capital occupation of listed companies by controlling shareholders and other related parties

□Applicable Not applicable

During the company's reporting period, there was no non-operational occupation of funds by the controlling shareholder or other related parties of the listed company.

3. Illegal external guarantees

□Applicable Not applicable

The company had no illegal external guarantees during the reporting period.

4. Appointment and dismissal of accounting firms

Has the semi-annual financial report been audited?

□Yes No

The company's semi-annual report has not been audited.

5. Explanation of the Board of Directors and the Board of Supervisors on the accounting firm’s “non-standard audit report” for this reporting period

□Applicable Not applicable

6. Explanation of the Board of Directors on the “Non-standard Audit Report” of the previous year

Applicable □Not applicable

Zhonghua Accounting Firm (Special General Partnership) issued an unqualified audit report with an emphasis on matters paragraph on the company's 2024 financial report on April 25, 2025.

(1) The main content involved in the emphasis paragraph

Zhonghua Accounting Firm (Special General Partnership) reminds users of financial statements to pay attention to As mentioned in Note 14.1 of the financial statements, the Company's parent company and Note 18.8 Actual Controller Matters, due to the execution of the largest shareholder of Haochen Medical, Guangzhou Huiyin Rifeng Investment Partnership (Limited Partnership) (hereinafter referred to as "Huiyin Rifeng") The business partners, Guangzhou Huiyin Aofeng Equity Investment Fund Management Co., Ltd. (hereinafter referred to as "Huiyin Aofeng") and Beijing Shoutuo Ronghui Investment Co., Ltd. (hereinafter referred to as "Beijing Shoutuo Ronghui") have a company control dispute and have entered the litigation stage. As of the date of this report, as the relevant litigation cases have not yet been concluded, the actual controller of Haochen Medical has not changed. If the cooperation agreement signed by Huiyin Rifeng's executive partner Huiyin Aofeng and Beijing Shoutuo Ronghui is effectively terminated in accordance with the law (including the situation of being terminated by an effective judgment of the competent judicial authority, the termination is unanimously confirmed by both parties, etc.), the actual controller of Haochen Medical may change. The contents of this paragraph do not affect the published audit opinion.

(2) Description of changes and handling of matters involved

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

At present, the company has not received the "Detailed Equity Change Report" submitted by the information disclosure obligor. The company will continue to urge the information disclosure obligor to complete the preparation of the "Detailed Equity Change Report" as soon as possible. After receiving the "Detailed Equity Change Report" and other corresponding documents that comply with laws, regulations and regulatory requirements, the company will fulfill its disclosure obligations in accordance with the requirements of relevant laws and regulations.

7. Matters related to bankruptcy and reorganization

□Applicable Not applicable

The company had no bankruptcy or reorganization related matters during the reporting period.

8. Litigation matters

Major litigation and arbitration matters

Applicable □Not applicable

Litigation (Arbitration) Amount involved Whether a Litigation (Arbitration) Litigation (Arbitration) Trial Litigation (Arbitration) Judgment

Disclosure date Basic information on disclosure index (10,000 yuan) Estimated liabilities (disclosure) progress Processing results and impact Implementation status

Corporate and Subsidiary Department

For details, please refer to Juchao Capital Company and Zhejiang Branch bank accounts, public

Xunwang announced that the assets of Zhejiang Province are currently under execution. Zhiyu Medical held by the company

In 2023, "About the stage of receipt of management shares, the company's medical equity was frozen,

13,524.55 No Execution stage July 18 Execution notice > Co., Ltd. notarization Sub-assets frozen Yongda Electric is located in Jilin

Announcement of Japan" (the public debt document case was closed and sealed. Yingbin, Chuanying District, Lin City

Report No.: Room No. 98, Main Road

2023-032) Real estate seized

For details, please refer to the announcement of Jinhaitang Assets on Juchao Information Network

"About Receipt Management Co., Ltd. Current Shanghai Financial

At present, the Shanghai Financial Law 2023 Shanghai Senior Department and the Zuo Family Court have finally ruled

36,229.84 Yes Execution stage The court has ruled to terminate this execution. On July 7, People’s Court Minhua and Yin Hong concluded this execution process.

The execution procedure for the first time is the grandeur of the ruling and the order of the group.

Announcement" (announcement of contract disputes)

No.: 2023-027)

For details, please refer to the announcement on Juchao Information Network. The company and Beijing ruled in favor of us and the money has been returned.

"About the receipt of arbitration request from Shengyuan Tong Chuangke, the public price is 94,574.86 yuan, 2022

Beijing Arbitration Commission Technology Co., Ltd. 7,637.7 No Enforcement stage The company has applied for compulsory follow-up to identify the property line June 17

The dispute over the equity transfer of the committee’s ruling has been appealed and the company will apply for the date.

"Announcement" (public dispute, execution suspended, please resume execution)

Report No.: 2022-026) For details, please see Juchao Capital. Shenzhen has not yet been discovered.

Xunwang Announcement Company has a partnership with Shenzhen Tomet Technology

Subsequently, the property line will be identified in 2023. "About receiving <Tomet Technology Co., Ltd. has other

8,100 No Execution stage After the request is made, the company will apply for an execution ruling on December 30> Limited liability company with financial resources available for execution.

Please resume the implementation of the announcement of the date" (public dispute case property, currently has been

Report No.: Suspended

2023-054) Other litigation matters

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd. Applicable □Not applicable

Litigation (Arbitration) Litigation (Arbitration) Litigation (Arbitration) Amount involved Whether a pre-litigation (arbitration) trial result and judgment execution date Disclosure date Basic information on disclosure index (10,000 yuan) Liability calculation progress

The impact is not reached in other situations

Major litigation targets

100.49 -- -- -- -- -- --accurate lawsuit

pieces

9. Punishment and Rectification

□Applicable Not applicable

There were no penalties or rectifications during the company's reporting period.

Integrity status of the company, its controlling shareholders and actual controllers □Applicable Not applicable

11. Major related transactions

Related transactions related to daily operations

□Applicable Not applicable

The company had no related transactions related to daily operations during the reporting period.

Related transactions arising from asset or equity acquisition and sale

□Applicable Not applicable

The company had no related transactions involving acquisition or sale of assets or equity during the reporting period.

Related transactions related to joint external investment

□Applicable Not applicable

The company had no related transactions involving joint external investments during the reporting period.

Related credit and debt transactions

□Applicable Not applicable

The company had no related creditor's rights or debts during the reporting period.

Dealings with related financial companies

□Applicable Not applicable

There are no deposits, loans, credit or other financial business between the company and its related financial companies and related parties.

Dealings between financial companies controlled by the company and related parties □Applicable Not applicable

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

There are no deposits, loans, credit or other financial business between the financial companies controlled by the company and related parties.

Other major related transactions

□Applicable Not applicable

The company had no other major related transactions during the reporting period.

12. Major contracts and their performance

Custody, contracting and leasing matters

(1) Custody situation

□Applicable Not applicable

There was no custody situation during the company's reporting period.

(2) Contracting situation

□Applicable Not applicable

There was no contracting situation during the reporting period of the company.

(3) Leasing situation

□Applicable Not applicable

There was no leasing situation during the company's reporting period.

Major guarantee

Applicable □Not applicable

Unit: RMB 10,000 External guarantees provided by the company and its subsidiaries (excluding guarantees to subsidiaries)

Guarantee amount Counter guarantee

Is the collateral related to the guarantee? Amount of guarantee actually issued. Actual guarantee. Guarantee type situation. Whether it has been fulfilled.

(For example, guarantee period, name of related party, announcement disclosure, date of birth, insured amount type (if completed, yes), guarantee disclosure date, yes)

The company’s guarantees for subsidiaries

Guarantee amount Counter guarantee

Is the collateral related to the guarantee? Amount of guarantee actually issued. Actual guarantee. Guarantee type situation. Whether it has been fulfilled.

(For example, guarantee period, name of related party, announcement disclosure, date of birth, insured amount type (if any after completion of the transaction) Guarantee

Revealed date (yes)

Jilinyong

2025 2025

Da Electric is jointly and severally liable

April 26 7,790 June 19 7,790 3 years No No The switch has any warranty

day day

Ltd.

Approval of subsidiaries during the reporting period

The total amount of the company's guarantees is 7,790. The total actual amount of guarantees is 7,790 (B1). Total (B2)

Approved at the end of the reporting period

7,790 7,790 Guarantee limit for subsidiaries Total actual guarantee balance

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Total (B3) (B4)

Guarantees provided by subsidiaries to subsidiaries

Guarantee amount Counter guarantee

Is the collateral related to the guarantee? Amount of guarantee actually issued. Actual guarantee. Guarantee type situation. Whether it has been fulfilled.

(For example, guarantee period, name of related party, announcement disclosure, date of birth, insured amount type (if any after completion of the transaction) Guarantee

Exposed date: Yes) Jilin Yong

2025 2025

Da Electric is jointly and severally liable

April 26 7,790 June 19 7,790 3 years No No The switch has any warranty

day day

Ltd.

Approval of subsidiaries during the reporting period

The total amount of the company's guarantees is 7,790. The total actual amount of guarantees is 7,790 (C1). Total (C2)

Approved at the end of the reporting period

Guarantee limit for subsidiaries 7,790 Total actual guarantee balance 7,790 Total (C3) (C4)

The total amount of company guarantees (i.e. the total of the first three major items)

Approval of guarantees during the reporting period Actual guarantees during the reporting period

Total quota 15,580 Total amount incurred 15,580 (A1+B1+C1) (A2+B2+C2)

Actual guarantees approved at the end of the reporting period

Total guarantee limit 15,580 Total balance 15,580 (A3+B3+C3) (A4+B4+C4)

The actual total guarantee amount (i.e. A4+B4+C4) accounts for the company’s net capital

41.79% production ratio

Among them:

Provide guarantees for shareholders, actual controllers and their related parties

The balance (D)

Directly or indirectly, for those whose asset-liability ratio exceeds 70%

The balance of debt guarantee provided by the insured party (E)

The amount of the total guarantee exceeding 50% of the net assets (F) 0The total amount of the above three guarantees (D+E+F) 0For unexpired guarantee contracts, guarantee liabilities occurred during the reporting period

There may be any evidence indicating the possibility of being jointly and severally liable for repayment. Not applicable

Description of the situation (if any)

Explanation of providing external guarantees in violation of prescribed procedures (such as

Not applicable

Yes)

Specific instructions for using composite guarantees

Not applicable

Entrusted financial management

□Applicable Not applicable

The company did not have entrusted financial management during the reporting period.

Other major contracts

□Applicable Not applicable

The company had no other major contracts during the reporting period.

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

13. Description of other major matters

Applicable □Not applicable

The "Announcement on Uncovered Losses Reaching One-third of the Total Paid-In Share Capital" was disclosed on April 26, 2025 (Announcement No.: 2025-007). For details, please see the relevant announcements disclosed on the Juchao Information Network (www.cninfo.com.cn) and China Securities Journal, Shanghai Securities News, and Securities Times.

On May 8, 2025, the "Announcement on the Progress of the Receipt of the Civil Judgment by the Executive Partner of the Largest Shareholder and the Planned Change of Control of the Company" (announcement number: 2025-012) was disclosed. For details, please see the relevant announcements disclosed by Juchao Information Network (www.cninfo.com.cn) and China Securities Journal, Shanghai Securities News, and Securities Times.

14. Major events of the company’s subsidiaries

Applicable □Not applicable

The "Announcement on the Wholly-Owned Subsidiary's Plan to Apply for a Bank Loan Extension and the Company and its Subsidiaries Provide Guarantees" (Announcement No.: 2025-008) was disclosed on April 26, 2025. For details, please see the relevant announcements disclosed on the Juchao Information Network (www.cninfo.com.cn) and China Securities Journal, Shanghai Securities News, and Securities Times.

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Section 6 Share changes and shareholder status

1. Changes in shares

Changes in shares

Unit: Before the change in share capital Increase or decrease in this change (+, -) After this change, transfer of reserve fund

Quantity Proportion Issuance of new shares Bonus shares Others Subtotal Quantity Proportion

1. Limited

Conditional shares 24,750 0.00% 0 0 0 0 0 24,750 0.00% shares

Country

0 0.00% 0 0 0 0 0 0 0.00% family holdings

Country

There is a legal person holding 0 0.00% 0 0 0 0 0 0 0.00% shares

Other domestic investors hold 24,750 0.00% 0 0 0 0 0 24,750 0.00% shares

its

Medium: Domestic 0 0.00% 0 0 0 0 0 0 0.00% legal person shareholding

within the territory

Natural persons hold 24,750 0.00% 0 0 0 0 0 24,750 0.00% shares

outside

0 0.00% 0 0 0 0 0 0 0.00% capital holding

its

Medium: Overseas 0 0.00% 0 0 0 0 0 0 0.00% legal person shareholding

overseas

Natural persons hold 0 0.00% 0 0 0 0 0 0 0.00% shares

2. Unlimited

839,975, 839,975,

Conditional shares 100.00% 0 0 0 0 0 100.00%

250 250

portion

People

839,975, 839,975,

RMB Ordinary 100.00% 0 0 0 0 0 100.00%

250 250

Environment

0 0.00% 0 0 0 0 0 0 0.00% foreign-invested shares listed in China

Environment

Externally listed 0 0.00% 0 0 0 0 0 0 0.00% foreign-invested shares

Its 0 0.00% 0 0 0 0 0 0 0.00%

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

him

Shares 840,000, 840,000,

100.00% 0 0 0 0 0 100.00% Total 000 000 Reasons for share changes

□Applicable Not applicable

Approval status of share changes

□Applicable Not applicable

Transfer status of changes in shares

□Applicable Not applicable

Implementation progress of share buybacks

□Applicable Not applicable

Implementation progress of using centralized bidding method to reduce and repurchase shares

□Applicable Not applicable

The impact of share changes on financial indicators such as basic earnings per share and diluted earnings per share in the most recent year and period, net assets per share attributable to the company's common shareholders □Applicable Not applicable

Other content that the company deems necessary or required to be disclosed by securities regulatory authorities

□Applicable Not applicable

Changes in restricted shares

□Applicable Not applicable

2. Securities issuance and listing

□Applicable Not applicable

3. Number of shareholders and shareholding status of the company

Unit: Total number of ordinary shareholders at the end of the reporting period Total number of preference shareholders with restored voting rights at the end of the reporting period

48,616 0 Number Number (if any) (see Note 8)

Shareholdings of shareholders holding more than 5% of the shares or the top 10 shareholders (excluding shares lent through refinancing) during the reporting period Limited holdings Unlimited holdings Pledge, marking or freezing

Shareholding ratio Shareholding at the end of the reporting period

Name of shareholder Nature of shareholder Increase or decrease Changes Conditions for sale Number of shares Status of shares Number

Situation Number of Shares Quantity Guangzhou Huiyin

Rifeng Investment

non-state within territory

Partnership 23.81% 200,000,000 0 0 200,000,000 Not applicable 0

Have legal person

(Limited

Guy)

Shaanxi Province

international trust stocks

limited company

Division - Shaanxi Others 3.84% 32,263,200 0 0 32,263,200 Not applicable 0 vote·Xinxin

Xiangrong No. 78

Securities investment

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Pooled funds

trust plan

Qingdao Xinhui

Joint investment management Domestic non-state

1.79% 15,060,966 0 0 15,060,966 Pledge 15,060,966 Co., Ltd. Publicly owned legal person

Division

Nature within the territory

Wang Cunbin 1.65% 13,859,080 0 0 13,859,080 Not applicable 0

people

BARCLA YS

Overseas legal person 0.87% 7,284,800 6331886 0 7,284,800 Not applicable 0 BANK PLC

MORGAN

STANLEY &

CO. Overseas legal person 0.79% 6,611,257 5590630 0 6,611,257 Not applicable 0 INTERNATI

ONAL PLC.

Nature within the territory

Liu Songnan 0.66% 5,517,100 3987100 0 5,517,100 Not applicable 0 people

Nature within the territory

Ji Changjiang 0.65% 5,418,000 4939500 0 5,418,000 Not applicable 0 people

Nature within the territory

Jia Senmao 0.62% 5,203,400 0 0 5,203,400 Not applicable 0 people

Nature within the territory

Xie Shiye 0.51% 4,304,700 0 0 4,304,700 Not applicable 0

people

Strategic investors or general legal persons

Became top 10 due to placement of new shares

None

The situation of shareholders (if any) (see

See note 3)

The above-mentioned shareholder related relationship or a

The company does not know whether there is any related relationship among the top ten shareholders, nor whether they are persons acting in concert.

instructions for action

On May 8, 2025, the company disclosed on cninfo.com "About the civil judgment received by the largest shareholder's executive affairs partner"

Decision> and Announcement on the Progress of the Planned Change of Control of the Company" (Announcement No.: 2025-012), "Simple Form Equity Change Report" The above-mentioned shareholders are involved in entrustment/entrustment

Letter", based on the Guangzhou Nansha District People's Court (2023) Guangdong 0115 Minchu No. 10080 Civil Judgment and Guangzhou Intermediate Voting Rights and Waiver of Voting Rights

The judgment results of the People's Court (2024) Guangdong 01 Minzhong No. 29751 Civil Judgment, explanation of the signing situation of Beijing Shoituo Ronghui and Huiyin Aofeng

The cooperation agreement with the Company has been terminated, and Mr. Xie Zhikun should no longer be recognized as the actual controller of the listed company. Huiyin Aofeng passed

Huiyin Rifeng indirectly controls the voting rights corresponding to 23.81% of the shares of the listed company.

Buybacks exist among the top 10 shareholders

Special instructions for special accounts (if any) None

(See note 11)

Shareholdings of the top 10 shareholders without sales restrictions (excluding shares lent through refinancing and shares locked by executives)

Type of shares Name of shareholder Number of shares without selling restrictions held at the end of the reporting period

Type of shares Quantity Guangzhou Huiyin Rifeng Investment Partnership RMB 200,000,00

200,000,000

Enterprise (limited partnership) common stock 0Shaanxi International Trust Co., Ltd.

Co., Ltd.-Shaanxi Guotou·Xinxin RMB General

32,263,200 32,263,200 Xiangrong No. 78 Securities Investment Collection Stock Exchange

Fund Trust Plan

Qingdao Xinhuihe Investment Management Co., Ltd.

15,060,966 15,060,966 Co., Ltd. common stock

RMB general

Wang Cunbin 13,859,080 13,859,080 shares

RMB general

BARCLA YS BANK PLC 7,284,800 7,284,800

common stock

MORGAN STANLEY & CO. RMB General

6,611,257 6,611,257 INTERNATIONAL PLC. General shares

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

RMB general

Liu Songnan 5,517,100 5,517,100 shares

RMB general

Ji Changjiang 5,418,000 5,418,000 common shares

RMB general

Jia Senmao 5,203,400 5,203,400 common shares

RMB general

Xie Shiye 4,304,700 4,304,700

common stock

Top 10 shareholders with no sales limit

between, and top 10 unlimited

The company does not know whether there is a related relationship between the top ten shareholders and the top ten shareholders, nor whether they are persons acting in concert.

relationship or consistency between

description of action

Top 10 common shareholders participate

Description of margin trading and securities lending business None

(if any) (see note 4)

The situation of shareholders holding more than 5% of the shares, the top 10 shareholders and the top 10 shareholders of unrestricted tradable shares participating in the refinancing business and lending shares

□Applicable Not applicable

The top 10 shareholders and the top 10 shareholders of unrestricted tradable shares have changed from the previous period due to refinancing lending/returning.

□Applicable Not applicable

Whether the company's top 10 ordinary shareholders and the top 10 unrestricted ordinary shareholders conducted agreed repurchase transactions during the reporting period

□Yes No

The company's top 10 common shareholders and the top 10 common shareholders without selling restrictions did not conduct agreed repurchase transactions during the reporting period.

4. Changes in shareholdings of directors, supervisors and senior managers

□Applicable Not applicable

The shareholdings of the company's directors, supervisors and senior managers did not change during the reporting period. For details, please refer to the 2024 annual report.

5. Changes in controlling shareholders or actual controllers

Changes in controlling shareholders during the reporting period

□Applicable Not applicable

The company's controlling shareholder did not change during the reporting period.

Changes in actual controller during the reporting period

Applicable □Not applicable

Name of original actual controller Xie Zhikun

According to the "Simplified Equity Change Report" provided by the information disclosure obligor, Beijing Shoutuo Ronghui: "After the completion of this equity change, Mr. Xie Zhikun will no longer be recognized as the actual controller of the listed company."

As of now, the actual controller of the company has not been finalized. For the specific changes, the name of the new actual controller can be found in the relevant announcements disclosed by the company later. The company will continue to urge the information disclosure obligors to complete the preparation of the "Detailed Equity Change Report" as soon as possible. After receiving the "Detailed Equity Change Report" and other corresponding documents that comply with laws, regulations and regulatory requirements, the company will fulfill its disclosure obligations in accordance with the requirements of relevant laws and regulations.

Change date May 08, 2025

For details, please refer to the announcement of cninfo.com.cn "Announcement on the progress of the largest shareholder's executive affairs partner receiving the designated website query index to the "Civil Judgment" and the planned change of the company's control" (Announcement No.: 2025-012), "Simplified Equity Change Report"

The full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd. will be disclosed on the designated website on May 8, 2025.

6. Relevant information on preference shares

□Applicable Not applicable

There were no preferred shares in the company during the reporting period.

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Section 7 Bond-related situations □Applicable Not applicable

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Section 8 Financial Report

1. Audit report

Has the semi-annual report been audited?

□Yes No

The company's semi-annual financial report has not been audited.

2. Financial statements

The unit of statements in the financial notes is: Yuan

Consolidated balance sheet

Prepared by: Haochen Medical Technology Co., Ltd.

June 30, 2025

Unit: Yuan

Item Ending balance Beginning balance

Current assets:

Monetary funds 111,862,603.68 147,693,180.87 Settlement reserves

Loan funds

trading financial assets

Derivative financial assets

Notes receivable 4,443,525.52 9,041,164.44 Accounts receivable 27,438,643.26 39,169,433.88 Accounts receivable financing

Prepayments 17,400,007.01 6,954,032.08 Premiums receivable

Reinsurance accounts receivable

Receivable reinsurance contract reserves

Other receivables 41,792,999.65 40,326,226.96 Including: interest receivable

Dividends receivable 22,700,000.00 22,700,000.00 Financial assets purchased under resale agreements

Inventory 53,276,633.14 50,753,348.55

Among them: data resources

contract assets

Assets held for sale

Non-current assets due within one year

Other current assets 2,260,855.71 2,485,124.07 Total current assets 258,475,267.97 296,422,510.85

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Non-current assets:

Grant loans and advances

debt investment

Other debt investments

long-term receivables

Long-term equity investment 479,164,621.92 476,317,660.06 Other equity instrument investment 11,000,000.00 11,000,000.00 Other non-current financial assets

Investment real estate 30,554,831.40 31,241,592.24 Fixed assets 156,077,277.45 160,462,952.57 Construction in progress

productive biological assets

oil and gas assets

Right-of-use assets 156,468,239.55 166,620,254.74 Intangible assets 47,447,594.30 48,294,719.84

Among them: data resources

development expenditure

Among them: data resources

Goodwill 199,672,759.15 199,672,759.15 Long-term deferred expenses 58,609,821.67 60,127,111.92 Deferred income tax assets 46,936,439.40 47,324,082.17 Other non-current assets

Total non-current assets 1,185,931,584.84 1,201,061,132.69 Total assets 1,444,406,852.81 1,497,483,643.54 Current liabilities:

Short-term borrowings 191,428,594.44 191,588,304.03 Borrowings from the central bank

borrowing funds

Trading financial liabilities

Derivative financial liabilities

Notes payable

Accounts payable 64,597,303.90 60,297,291.97 Advance payments

Contract liabilities 117,196,215.14 124,737,128.05 Financial assets sold and repurchased

Taking deposits and placing deposits with other banks

Agent for buying and selling securities

Agent underwriting securities funds

Employee benefits payable 27,046,201.78 31,784,754.19 Taxes payable 2,196,584.85 6,953,260.67 Other payables 341,208,248.12 332,863,567.48

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Including: interest payable 78,447,928.18 69,657,936.53

Dividends payable 50,000.00

Handling fees and commissions payable

Reinsurance accounts payable

Liabilities held for sale

Non-current liabilities due within one year 136,657,653.28 134,470,301.80 Other current liabilities 1,354,242.24 4,382,216.99 Total current liabilities 881,685,043.75 887,076,825.18 Non-current liabilities:

insurance contract reserves

long term borrowing

bonds payable

Among them: preferred shares

perpetual bond

Lease liabilities 138,659,506.36 151,095,010.40 Long-term payables

Long-term employee benefits payable

Estimated liabilities

Deferred income 8,438,190.41 8,661,684.77 Deferred income tax liabilities 7,223,730.91 7,602,828.98 Other non-current liabilities

Total non-current liabilities 154,321,427.68 167,359,524.15 Total liabilities 1,036,006,471.43 1,054,436,349.33 Owners’ equity:

Share capital 840,000,000.00 840,000,000.00 Other equity instruments

Among them: preferred shares

perpetual bond

Capital reserve 21,685,838.28 21,685,838.28 less: treasury shares

Other comprehensive income -50,158,199.09 -48,655,667.52Special reserve

Surplus reserve 40,813,718.28 40,813,718.28 General risk reserve

Undistributed profits -479,559,780.00 -455,808,714.88 Total owners’ equity attributable to the parent company 372,781,577.47 398,035,174.16 Minority shareholders’ equity 35,618,803.91 45,012,120.05 Total owners’ equity 408,400,381.38 443,047,294.21 Total liabilities and owners’ equity 1,444,406,852.81 1,497,483,643.54 Legal representative: Lu Lu Person in charge of accounting work: Deng Qiang Person in charge of accounting department: Wang Yanxiao

Balance sheet of the parent company

Unit: Yuan

Item Ending balance Beginning balance

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Current assets:

Monetary funds 2,649.68 1,680.49Trading financial assets

Derivative financial assets

Notes receivable

Accounts receivable

Receivables Financing

advance payment

Other receivables 22,880,649.39 22,866,727.04 Including: interest receivable

Dividends receivable 22,700,000.00 22,700,000.00 Inventory 4,549,491.18 4,549,491.18

Among them: data resources

contract assets

Assets held for sale

Non-current assets due within one year

Other current assets 1,876,335.74 1,797,954.57 Total current assets 29,309,125.99 29,215,853.28 Non-current assets:

debt investment

Other debt investments

long-term receivables

Long-term equity investment 1,256,296,181.88 1,253,449,220.02 Other equity instrument investments 11,000,000.00 11,000,000.00 Other non-current financial assets

investment real estate

Fixed assets 67,250.26 67,620.67 Construction in progress

productive biological assets

oil and gas assets

right-of-use assets

intangible assets

Among them: data resources

development expenditure

Among them: data resources

goodwill

Long-term deferred expenses

Deferred income tax assets 22,396,861.70 22,390,096.41 Other non-current assets

Total non-current assets 1,289,760,293.84 1,286,906,937.10 Total assets 1,319,069,419.83 1,316,122,790.38

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Current liabilities:

Short-term borrowings 113,528,594.44 113,558,470.70 Trading financial liabilities

Derivative financial liabilities

Notes payable

Accounts payable 23,395,229.72 23,395,229.72 Advance payments

Contract liabilities 5,146,386.73 5,146,386.73 Employee benefits payable 1,152,739.19 1,164,540.81 Taxes payable 5,040.00 5,365.24 Other payables 616,506,763.22 610,343,573.00 including: interest payable

Dividends payable

Liabilities held for sale

Non-current liabilities due within one year 95,745,681.88 95,745,681.88 Other current liabilities 669,030.27 669,030.27 Total current liabilities 856,149,465.45 850,028,278.35 Non-current liabilities:

long term borrowing

bonds payable

Among them: preferred shares

perpetual bond

Lease liability

long-term payables

Long-term employee benefits payable

Estimated liabilities

Deferred income 4,982,417.14 5,120,583.76 Deferred income tax liabilities

Other non-current liabilities

Total non-current liabilities 4,982,417.14 5,120,583.76 Total liabilities 861,131,882.59 855,148,862.11 Owners’ equity:

Share capital 840,000,000.00 840,000,000.00 Other equity instruments

Among them: preferred shares

perpetual bond

capital reserve

Less: treasury shares

Other comprehensive income -50,158,473.98 -48,655,735.74Special reserves

Surplus reserve 40,813,718.28 40,813,718.28 Undistributed profits -372,717,707.06 -371,184,054.27 Total owners’ equity 457,937,537.24 460,973,928.27

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Total liabilities and owners’ equity 1,319,069,419.83 1,316,122,790.38

Consolidated income statement

Unit: Yuan

Project Half-year 2025 Half-year 2024

Total operating income 313,635,948.22 382,010,234.10 Including: operating income 313,635,948.22 382,010,234.10 Interest income

Premiums earned

Fee and commission income

Total operating costs 353,745,281.85 398,227,590.97 Including: operating costs 178,274,250.68 206,067,242.04 Interest expenses

Handling fees and commission expenses

surrender deposit

Net compensation expenses

Net withdrawal of insurance liability reserves

policy dividend payout

Reinsurance cost

Taxes and surcharges 1,146,432.04 1,228,304.73 Sales expenses 76,940,756.43 89,747,327.44 Management expenses 68,770,906.66 74,914,155.33 Research and development expenses 7,966,580.46 3,605,476.51Financial expenses 20,646,355.58 22,665,084.92Including: Interest expenses 20,256,561.25 21,454,310.59

Interest income 333,837.89 897,501.49 plus: other income 2,835,597.49 1,817,867.61 Investment income (losses are filled in with "-"

4,349,700.10 16,737,122.44 columns)

Of which: for associates and joint ventures

4,349,700.10 16,737,122.44 Enterprise investment income

Measured at amortized cost

Income from derecognition of financial assets

Exchange gains (losses are filled in with "-"

column)

Net exposure hedging gains (losses expressed as “—

"Fill in the column)

Gains from changes in fair value (losses calculated as

Fill in the column with "—" sign)

Credit impairment losses (losses are preceded by “—”

2,596,096.74 1,849,323.45 (please fill in the list)

Asset impairment losses (losses are represented by “—”

(Fill in the number)

Income from asset disposal (loss indicated by “—” 678,017.94

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

(Fill in the number)

3. Operating profit (loss should be filled in with “—”

-29,649,921.36 4,186,956.63 columns)

Add: non-operating income 129,009.74 165,728.27

Less: Non-operating expenses 2,550,185.05 166,708.68

4. Total profit (total loss is marked with “—”

-32,071,096.67 4,185,976.22 fill in the column)

Less: Income tax expense 2,543,284.59 1,379,875.03

5. Net profit (net loss is filled in with "-"

-34,614,381.26 2,806,101.19 columns)

(1) Classification by business continuity

Net profit from continuing operations (net loss divided by

-34,614,381.26 2,806,101.19 (Fill in “—”)

Net profit from discontinued operations (net loss equal to

Fill in the column with "—" sign)

(2) Classification according to ownership ownership

Net profit attributable to shareholders of the parent company

-23,751,065.12 553,485.18 (Net loss is listed with "—")

Profit and loss of minority shareholders (net loss is represented by “—

-10,863,316.14 2,252,616.01 "Fill in the number)

Net after-tax amount of other comprehensive income -1,502,531.57 2,010,575.34 Other comprehensive income attributable to owners of the parent company

-1,502,531.57 2,010,575.34 net amount after tax

(1) Others that cannot be reclassified into profit or loss

Comprehensive income

Remeasure changes in defined benefit plans

Others that cannot be transferred to profit or loss under the equity method

Comprehensive income

Fair value of other equity instrument investments

change

Fair value of the company’s own credit risk

change

5.Others

(2) Other comprehensive items that will be reclassified into profit or loss

-1,502,531.57 2,010,575.34 combined income

Other comprehensive items that can be transferred to profits and losses under the equity method

-1,502,738.24 2,010,540.35 combined income

Changes in fair value of other debt investments
Financial assets are reclassified into other comprehensive

Amount of combined income

Credit impairment provisions for other debt investments
Cash flow hedging reserve
Translation difference of foreign currency financial statements 206.67 34.99 7. Others

Other comprehensive income attributable to minority shareholders

net of tax

Total comprehensive income -36,116,912.83 4,816,676.53 Total comprehensive income attributable to owners of the parent company

-25,253,596.69 2,564,060.52 amount

Total comprehensive income attributable to minority shareholders -10,863,316.14 2,252,616.01

8. Earnings per share:

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

(1) Basic earnings per share -0.0283 0.0007

(2) Diluted earnings per share -0.0283 0.0007 If a business merger under the same control occurs in this period, the net profit realized by the merged party before the merger is: yuan, and the net profit realized by the merged party in the previous period is: yuan.

Legal representative: Lu Lu Person in charge of accounting work: Deng Qiang Head of accounting department: Wang Yanxiao

Income statement of the parent company

Unit: Yuan

Project Half-year 2025 Half-year 2024

Operating income 0.00 0.00 minus: operating cost 0.00 0.00 taxes and surcharges

selling expenses

Management expenses 1,802,565.80 2,447,530.58 Research and development expenses

Financial expenses 14,199,059.48 14,434,837.71 Including: interest expenses 14,196,859.83 14,431,600.75

Interest income 1.70 14.95 plus: other income 139,318.22 139,310.74 investment income (losses are filled in with "-"

14,349,700.10 26,737,122.44 columns)

Of which: for associates and joint ventures

4,349,700.10 16,737,122.44 Investment income from the industry

Money measured at amortized cost

Gains from derecognition of financial assets (losses are represented by “—”

(Fill in the number)

Net exposure hedging gains (losses expressed as “—

"Fill in the column)

Gains from changes in fair value (losses calculated as

Fill in the column with "—" sign)

Credit impairment losses (losses are preceded by “—”

-27,061.12 -32,895.47 (fill in the numbers)

Asset impairment losses (losses are represented by “—”

(Fill in the number)

Gains from asset disposals (losses are marked with “—”

(Fill in the number)

2. Operating profit (loss should be filled in with “—”

-1,539,668.08 9,961,169.42 columns)

Add: non-operating income

Less: Non-operating expenses 750.00 1,739.72

3. Total profit (total loss is marked with “—”

-1,540,418.08 9,959,429.70 fill in the column)

Less: Income tax expense -6,765.29 -8,223.87

4. Net profit (net loss is filled in with "—"

-1,533,652.79 9,967,653.57 columns)

(1) Net profit from continuing operations (net loss divided by

-1,533,652.79 9,967,653.57 (Fill in “—”)

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

(2) Net profit from discontinued operations (net loss is listed with “—”)

Net after-tax amount of other comprehensive income -1,502,738.24 2,010,540.35

(1) Other comprehensive income that cannot be reclassified into profit or loss

Remeasure the changes in defined benefit plan
Other comprehensive income that cannot be transferred to profit or loss under the equity method
Changes in fair value of other equity instrument investments
Changes in the fair value of the company’s own credit risk

5.Others

(2) Other comprehensive items that will be reclassified into profit or loss

-1,502,738.24 2,010,540.35 combined income

Other comprehensive items that can be transferred to profits and losses under the equity method

-1,502,738.24 2,010,540.35 combined income

Changes in fair value of other debt investments
The amount of financial assets reclassified and included in other comprehensive income
Credit impairment provisions for other debt investments 5. Cash flow hedging reserves
Translation differences of foreign currency financial statements

7.Others

Total comprehensive income -3,036,391.03 11,978,193.92

7. Earnings per share:

(1) Basic earnings per share

(2) Diluted earnings per share

Consolidated cash flow statement

Unit: Yuan

Project Half-year 2025 Half-year 2024

1. Cash flow generated from operating activities:

Cash received from sales of goods and provision of services 314,418,542.07 376,015,931.87 Net increase in customer deposits and interbank deposits

Net increase in borrowing from the central bank

The net increase in funds borrowed from other financial institutions is the cash obtained from premiums received from the original insurance contract.

Net cash received from reinsurance business

Net increase in policyholders’ savings and investment funds

Net increase in cash borrowing funds collected from interest, handling fees and commissions

Net increase in repurchase business funds

Net cash received from buying and selling securities on behalf of agents

Tax returns received 2,376,818.04 1,476,827.91 Other cash received related to operating activities 2,487,426.25 2,238,294.82 Subtotal of cash inflows from operating activities 319,282,786.36 379,731,054.60 Cash paid for purchasing goods and receiving services 138,603,596.41 148,781,105.29

Net increase in loans and advances to customers

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Net increase in deposits with central banks and inter-banks

Cash used to pay compensation from the original insurance contract

Net increase in lending funds

Cash payments for interest, fees and commissions

Cash payment for policy dividends

Cash paid to and for employees 150,399,324.24 152,070,280.26 Various taxes and fees paid 7,938,136.46 8,567,043.80

Other cash payments related to operating activities 49,931,518.26 63,312,804.72 Subtotal cash outflow from operating activities 346,872,575.37 372,731,234.07 Net cash flow generated from operating activities -27,589,789.01 6,999,820.53

2. Cash flow generated from investing activities:

Recover cash received on investment

Cash received from investment income

Disposal of fixed assets, intangible assets and other long-term

Net cash received from period assets

Received from disposal of subsidiaries and other business units

net cash

Other cash received related to investing activities

Subtotal of cash inflows from investing activities

Purchase and construction of fixed assets, intangible assets and other long-term

2,551,228.72 4,822,018.74 Cash paid for assets

Cash paid for investments

Net increase in mortgage loans

Obtain payment from subsidiaries and other business units

net cash

Other cash payments related to investing activities

Subtotal of cash outflows from investing activities 2,551,228.72 4,822,018.74 Net cash flow generated from investing activities -2,551,228.72 -4,822,018.74

3. Cash flow generated from financing activities:

Cash received from investment 3,430,000.00 0.00 Including: Income from investment by subsidiaries from minority shareholders

3,430,000.00 0.00 in cash

Obtain cash received from borrowing money

Other cash received related to financing activities

Subtotal of cash inflows from financing activities 3,430,000.00 0.00 Cash paid to repay debts 9,100,000.00

Distribution of dividends, profits or repayment of interest payments

9,709,711.07 8,568,921.46 cash

Including: shares paid by subsidiaries to minority shareholders

Profit, profit

Payment of other cash related to financing activities 286,399.61 331,045.56 Subtotal of cash outflows from financing activities 9,996,110.68 17,999,967.02 Net cash flow generated from financing activities -6,566,110.68 -17,999,967.02

4. The impact of exchange rate changes on cash and cash equivalents

206.67 34.99Impact

Net increase in cash and cash equivalents -36,706,921.74 -15,822,130.24

Add: Balance of cash and cash equivalents at the beginning of the period 131,570,807.19 141,916,655.64

Balance of cash and cash equivalents at the end of the period 94,863,885.45 126,094,525.40
Cash flow statement of the parent company

Unit: Yuan

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Project Half-year 2025 Half-year 2024

1. Cash flow generated from operating activities:

Cash received from selling goods and providing services

Tax refund received 1,220.70 7,797.34

Other cash received related to operating activities 4,719,157.94 9,186,768.89 Subtotal of cash inflows from operating activities 4,720,378.64 9,194,566.23 Cash paid for purchasing goods and receiving services 4,000.00 Cash paid to and for employees 251,588.89 205,024.25 taxes paid

Other cash payments related to operating activities 14,467,826.12 13,509,678.64 Subtotal cash outflow from operating activities 14,719,415.01 13,718,702.89 Net cash flow generated from operating activities -9,999,036.37 -4,524,136.66

2. Cash flow generated from investing activities:

Recover cash received on investment

Cash received from investment income 10,000,000.00 10,000,000.00

Disposal of fixed assets, intangible assets and other long-term

Net cash received from period assets

Received from disposal of subsidiaries and other business units

net cash

Other cash received related to investing activities

Subtotal of cash inflows from investing activities 10,000,000.00 10,000,000.00

Purchase and construction of fixed assets, intangible assets and other long-term

Cash paid for future assets

Cash paid for investments

Obtain payment from subsidiaries and other business units

net cash

Other cash payments related to investing activities

Subtotal of cash outflows from investing activities

Net cash flow generated from investing activities 10,000,000.00 10,000,000.00

3. Cash flow generated from financing activities:

Absorbing cash received from investments

Obtain cash received from borrowing money

Other cash received related to financing activities

Subtotal of cash inflows from financing activities

Cash paid to repay debt

Distribution of dividends, profits or repayment of interest payments

5,483,875.00 cash

Other cash payments related to financing activities

Subtotal of cash outflows from financing activities 5,483,875.00 Net cash flow generated from financing activities -5,483,875.00

4. The impact of exchange rate changes on cash and cash equivalents

influence

Net increase in cash and cash equivalents 963.63 -8,011.66

Add: Balance of cash and cash equivalents at the beginning of the period 202.64 8,912.22

Balance of cash and cash equivalents at the end of the period 1,166.27 900.56
Consolidated statement of changes in owners’ equity

Amount of current period

Unit: Yuan

Project Half Year 2025

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Less equity attributable to owners of the parent company

Other equity instruments Part 1 There is a decrease and there is no amount

He who specializes in making money

: shares

Equity Preferred shares Perpetual bonds Others Capital reserves Comprehensive receipts Reserves Reserves Risks Reserved profits Other subtotal Owners’ equity Equity joint venture profit

Benefit plan

840 21, 40, 398 45, 443

48,455

,00 685 813 ,03 012 ,04

1. Previous year period 0.0 0.0 0.0 0.0 655 0.0 0.0 ,80 0.0

0,0 ,83 ,71 5,1 ,12 7, balance at the end of 2nd 0 0 0 0 ,66 0 0 8,7 0

8.2 8.2 74. 0.0 94.

7.5 14.

00 8 8 16 5 21

2 88

Add: Will 0.0 0.0Policy change 0 0

Previous 0.0 0.0 period error correction 0 0

its 0.0 0.0his 0 0

840 21, 40, 398 45, 443

48,455

,00 685 813 ,03 012 ,04

2. Current year 0.0 0.0 0.0 0.0 655 0.0 0.0 ,80

0,0 ,83 ,71 5,1 ,12 7,2 Beginning balance 0 0 0 0 ,66 0 0 8,7

8.2 8.2 74. 0.0 94.

7.5 14.

00 8 8 16 5 21 2 88

3. Added in this issue - -

23, 25, 34, minus changes 1,5 9,3

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 751 253 646 (reduced to 02, 93,

0 0 0 0 0 0 0 0 0 ,06 ,59 ,91 Fill in “—” 531 316

5.1 6.6 2.8 columns) .57 .14

2 9 3 - - - - -

23, 25, 10, 36,

1,5

(1) Comprehensive 751 253 863 116

02,

Total income ,06 ,59 ,31 ,91 5.1 6.6 6.1 2.8 .57

2 9 4 3

3,4 3,4

(2) All

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 30, 30, input and minus

0 0 0 0 0 0 0 0 0 0 0 0 000 000

less capital

.00 .00

3,4 3,4 1. owner

0.0 30, 30, average investment

0 000 000 shares

.00 .00 2． Other rights

0.0 0.0 Yield Instrument Holding

0 0 person invests capital

3． Share branch

Payment is included in the equity of all 0.0 0.0 0 0 amount

0.0 0.0 4． Others

0 0

(3) Profit 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 - -

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Allocation 0 0 0 0 0 0 0 0 0 0 0 0 1,9 1,9 60, 60, 000 000

.00 .00 1. Withdrawal of surplus 0.0 0.0 0.0 0.0 Surplus reserve 0 0 0 0 2. Withdrawal 0.0 0.0 General risk reserve 0 0

- 1. for all 1,9 1,9

0.0

Distribution to shareholders (or shareholders) 000 000 .00 .00

0.0 0.0 4． Others

0 0

(4) All

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 Equity Internal

0 0 0 0 0 0 0 0 0 0 0 0 0 0

carry forward

1． capital company

0.0 0.0 points converted into capital

0 0 (or share capital)

surplus public

0.0 0.0 points converted into capital

0 0 (or share capital)

3． Surplus share 0.0 0.0 reserve to make up for losses 0 0 4. Settings subject to

Changes in profit plan 0.0 0.0 amount carried forward and retained 0 0 income

Other comprehensive

0.0 0.0 Total income carried forward

0 0Retained earnings

0.0 0.0 6. Others

0 0

(5) Special projects 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 Reserves 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1. Withdraw 0.0 in this period 0.0 takes 0 0 2. Use 0.0 0.0 in this period 0 0

0.0 0.0

(6) Others

0 0 - -

840 21, 40, 372 35, 408 50, 479

,00 685 813 ,78 618 ,40

4. This period 0.0 0.0 0.0 0.0 158 0.0 0.0 ,55 0.0

0,0 ,83 ,71 1,5 ,80 0,3 balance at the end of 0 0 0 0 ,19 0 0 9,7 0

8.2 8.2 77. 3.9 81. 9.0 80.

00 8 8 47 1 38

9 00

Amount of previous year

Unit: Yuan

Project 2024 half year

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Less equity attributable to owners of the parent company

Other equity instruments Part 1 There is a decrease and there is no amount

He who specializes in making money

: shares

Equity Preferred Shares Perpetual Bonds Others Capital Reserves Treasury Shares Comprehensive Income Reserves Reserves Risk Reserve Profit Other Subtotal Owners’ Equity Equity Joint Provision

840 21, 40, 432 32, 465

51,418

,00 685 813 ,78 358 ,14

1. Previous year period 597,11

0,0 ,83 ,71 4,0 ,92 Balance at the end of 2,9 ,70 7,8

8.2 8.2 31. 8.9 59.

8.4 17.

00 8 8 08 1 99

1 07

Add: yes

Changes in accounting policies

before

period error correction

its

him

840 21, 40, 432 32, 465

51,418

,00 685 813 ,78 358 ,14

2. Current year 0.0 0.0 0.0 0.0 597 0.0 0.0 ,11

0,0 ,83 ,71 4,0 ,92 2,9 Beginning balance 0 0 0 0 ,70 0 0 7,8

8.2 8.2 31. 8.9 59.

8.4 17.

00 8 8 08 1 99

1 07

3. Added in this issue

2,0 553 2,5 2,2 4,8 minus changes

0.0 0.0 0.0 0.0 0.0 0.0 10, 0.0 0.0 0.0 ,48 64, 52, 16, (reduce to

0 0 0 0 0 0 575 0 0 0 5.2 060 615 676 Fill in the “—” sign

.34 0 .54 .98 .52 columns)

2,0 553 2,5 2,2 4,8

(1) Comprehensive 10, ,48 64, 52, 16, total income 575 5.2 060 615 676

.34 0 .54 .98 .52

(2) All

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 input and minus

0 0 0 0 0 0 0 0 0 0 0 0 0 0

less capital

1． owner

0.0 0.0 input ordinary

0 0 shares

Other rights

0.0 0.0 Yield Instrument Holding

0 0 person invests capital

3． Share branch

Payment is included in the equity of all 0.0 0.0 0 0 amount

0.0 0.0 4． Others

0 0

(3) Profit 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0Distribution 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1. Withdrawal profit 0.0 0.0 0.0 0.0 Surplus reserve 0 0 0 0

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Extract a 0.0 0.0 General risk reserve 0 0 3. to all

0.0 0.0 (or stock

0 0 East) allocation

0.0 0.0 4． Others

0 0

(4) All

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 Equity Internal

0 0 0 0 0 0 0 0 0 0 0 0 0 0

carry forward

1． capital company

0.0 0.0 points converted into capital

0 0 (or share capital)

surplus public

0.0 0.0 points converted into capital

0 0 (or share capital)

3． Surplus share 0.0 0.0 reserve to make up for losses 0 0 4. Settings subject to

Changes in profit plan 0.0 0.0 amount carried forward and retained 0 0 income

Other comprehensive

0.0 0.0 Total income carried forward

0 0Retained earnings

0.0 0.0 6. Others

0 0

(5) Special projects 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 Reserves 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1. Withdraw 0.0 in this period 0.0 takes 0 0 2. Use 0.0 0.0 in this period 0 0

0.0 0.0

(6) Others

0 0 - -

840 21, 40, 435 34, 469 49, 417

,00 685 813 ,34 611 ,95

4. This period 0.0 0.0 0.0 0.0 587 0.0 0.0 ,56

0,0 ,83 ,71 8,0 ,54 9.Balance at the end of 6th 0 0 0 0 ,13 0 0 4,3

8.2 8.2 91. 4.8 36. 3.0 31.

00 8 8 62 9 51

7 87

Statement of changes in owner’s equity of the parent company

Amount of current period

Unit: Yuan

2025 half year

Other equity instruments All less: Others Undivided

Project Capital Special Surplus Owner's Equity Priority Perpetual Inventory Comprehensive Distribution Others

Other public reserves, reserves, equity joint ventures, bonds, shares, profits

plan

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

840,0 40,81 460,9

1. Previous year period 48,65 371,1

00,00 0.00 0.00 0.00 0.00 0.00 0.00 3,718 0.00 73,92 Ending balance 5,735 84,05

0.00 .28 8.27 .74 4.27

Add: yes

0.00 meter policy change

before

0.00 issue error correction

its

0.00 him

840,0 40,81 460,9

2. Current period 48,65 371,1

00,00 0.00 0.00 0.00 0.00 0.00 0.00 3,718 0.00 73,92Initial balance 5,735 84,05

0.00 .28 8.27

.74 4.27

3. Added in this issue

- -Minus change amount

1,502 1,533 3,036 (reduced by 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

,738. ,652. ,391. Fill in the “—” sign

24 79 03 columns)

(1) Comprehensive 1,502 1,533 3,036

0.00

Total income ,738. ,652. ,391.

24 79 03

(2) All

0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 less capital

1． owner

Common 0.00 shares invested

Other rights

beneficial instruments held

investors invest capital

3． Share branch

Payment is included in all

0.00 stake in gold

4． Others 0.00

(3) Profit

0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00Distribution

1． Withdraw profit

0.00 0.00 0.00 0.00 surplus reserve

to all

Distribution to the shareholder (or shareholder of 0.00)

3． Others 0.00

(4) All

Internal equity of shareholders 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Carry forward

1． capital company

Convert accumulated capital to increase capital 0.00 (or share capital)

Surplus public 0.00

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Convert accumulated assets to capital

(or equity)

3． surplus public

0.00 points to make up for losses

4． Settings subject to

Changes in benefit plan

0.00 amount carried forward and retained

income

Other comprehensive

Combined earnings carried forward 0.00 retained earnings

6． Others 0.00

(5) Special projects

0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Reserve

1． This issue mentions

Take 0.00

This issue makes

0.00 used

(6) Others 0.00 - -

840,0 40,81 457,9

4. This period 50,15 372,7

00,00 0.00 0.00 0.00 0.00 0.00 0.00 3,718 0.00 37,53 Ending balance 8,473 17,70

0.00 .28 7.24

.98 7.06

Amount of previous year

Unit: yuan for the first half of 2024

Other equity instruments All less: Others Undivided

Project Capital Special Surplus Owner's Equity Priority Perpetual Inventory Comprehensive Distribution Others

Other public reserves, reserves, equity joint ventures, bonds, shares, profits

Count - -

840,0 40,81 498,3

1. Previous year period 51,59 330,8

00,00 0.00 0.00 0.00 0.00 0.00 0.00 3,718 77,87 Ending balance 7,741 38,09

0.00 .28 8.12 .64 8.52

Add: yes

0.00 meter policy change

before

0.00 issue error correction

its

0.00 him

840,0 40,81 498,3

2. Current year 51,59 330,8

00,00 0.00 0.00 0.00 0.00 0.00 0.00 3,718 77,87Initial balance 7,741 38,09

0.00 .28 8.12

.64 8.52

3. Added in this issue

Less amount of changes 2,010 9,967 11,97 (decrease is filled in with 0.00 0.00 0.00 0.00 0.00 0.00 ,540. 0.00 0.00 ,653. 8,193 “—” in column 35 57 .92)

(1) Comprehensive 2,010 9,967 11,97Total income ,540. ,653. 8,193

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

35 57 .92

(2) All

0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 less capital

1． owner

Common 0.00 shares invested

Other rights

beneficial instruments held

investors invest capital

3． Share branch

Payment is included in all

0.00 stake in gold

4． Others 0.00

(3) Profit

0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00Distribution

1． Withdraw profit

0.00 0.00 0.00 surplus reserve

to all

Distribution to the shareholder (or shareholder of 0.00)

3． Others 0.00

(4) All

Internal equity of shareholders 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Carry forward

1． capital company

Convert accumulated capital to increase capital 0.00 (or share capital)

surplus public

Convert accumulated capital to increase capital 0.00 (or share capital)

3． surplus public

0.00 points to make up for losses

4． Settings subject to

Changes in benefit plan

0.00 amount carried forward and retained

income

Other comprehensive

Combined earnings carried forward 0.00 retained earnings

6． Others 0.00

(5) Special projects

0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Reserve

1． This issue mentions

Take 0.00

This issue makes

0.00 used

(6) Others 0.00

840,0 - 40,81 - 510,3

4. This period 0.00 0.00 0.00 0.00 0.00 0.00

00,00 49,58 3,718 320,8 56,07

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Closing balance 0.00 7,201 .28 70,44 2.04

.29 4.95

3. Basic situation of the company

Company registered address, organizational form, headquarters address and registered capital

(1) Registered address: No. 98, Yingbin Road, Chuanying District, Jilin City

(2) Organizational form: joint stock limited company (listed)

(3) Office address: Room 1810, 18th Floor, Bank of East Asia Building, Century Fortune Center, No. 5 Guanghua Road, Chaoyang District, Beijing

(4) Registered capital: 840 million yuan

Company establishment status

Haochen Medical Technology Co., Ltd. (formerly known as "Jilin Yongda Group Co., Ltd." and "Rongyu Group Co., Ltd.") (referred to as "the Company" or "the Company", the same below) was formerly known as Jilin Yongda Group Co., Ltd., and was founded by the natural person Lu Yong Xiang, Lu Yang, Lu Lan, Lan Xiuzhen, Lu Yongkai, Lu Yuzhen and Li Xiangwen jointly invested and established it. On November 6, 1998, it obtained the "Enterprise Legal Person Business License" No. 2202142420088 issued by the Jilin Municipal Administration for Industry and Commerce. The company's registered capital is RMB 60 million, of which: natural person Lu Yongxiang invested RMB 24 million, with an investment ratio of 40.00%; natural person Lu Yang invested RMB 12 million, with an investment ratio of 20.00%; natural person Lu Lan invested RMB 12 million, with an investment ratio of 20.00% , the natural person Lan Xiuzhen invested 6 million yuan, the investment ratio is 10.00%, the natural person Lu Yongkai invested 3 million yuan, the investment ratio is 5.00%, the natural person Lu Yuzhen invested 1.5 million yuan, the investment ratio is 2.50%, the natural person Li Xiangwen invested 1.5 million yuan, the investment ratio is 2.50%.

On October 26, 2007, the company's shareholders' meeting resolved to apply for an increase in registered capital by RMB 2.5 million. The increased registered capital was paid in full by the new shareholder, Ma Liming, a natural person. After the capital increase, the company's registered capital was changed to RMB 62.5 million, of which: natural person Lu Yongxiang invested RMB 24 million, with an investment ratio of 38.40%, natural person Lu Yang invested RMB 12 million, with an investment ratio of 19.20%, natural person Lu Lan invested RMB 12 million, with an investment ratio of 19.20%, and natural person Lan Xiuzhen invested RMB 12 million, with an investment ratio of 19.20%. The natural person Lv Yongkai invested 3 million yuan, with an investment ratio of 9.60%. The natural person Lv Yuzhen invested 1.5 million yuan, with an investment ratio of 2.40%. The natural person Li Xiangwen invested 1.5 million yuan, with an investment ratio of 2.40%. The natural person Ma Liming invested 2.5 million yuan, with an investment ratio of 4.00%. Subsequently, the company's shareholders Lu Yongkai, Li Xiangwen, and Lu Yuzhen respectively transferred their 4.40% equity, 2.16% equity, and 2.22% equity in Yongda Company to shareholder Lu Yongxiang. After this equity transfer, the company The registered capital of the company is still 62.5 million yuan, of which the natural person Lu Yongxiang invested 29.4875 million yuan, with an investment ratio of 47.18%, and the natural person Lu Yang invested 12 million yuan, with an investment ratio of 19.20%. The natural person Lu Lan invested 12 million yuan, with an investment ratio of 19.20%. The natural person Lan Xiuzhen invested 6 million yuan, with an investment ratio of 9.60%. The natural person Lu Yongkai invested 250,000 yuan, with an investment ratio of 0.40%. Natural person Lu Yuzhen invested 112,500 yuan, with an investment ratio of 0.18%. Natural person Li Xiangwen invested 150,000 yuan, with an investment ratio of 0.24%. Natural person Ma Liming invested 2.5 million yuan, with an investment ratio of 4.00%.

On January 23, 2008, the company's shareholders meeting resolved to apply for the establishment of a joint-stock company. The company's net assets as of December 31, 2007 were RMB 107,135,771.25, which was converted into a total of 107,000,000 shares at a ratio of 1:0.9987327, with a face value of RMB 1 per share, and the remaining net assets of RMB 135,771.25 were converted into capital reserves. After the change, the company's share capital was RMB 107 million, and it obtained the "Enterprise Legal Person Business License" No. 220214000001024 issued by the Jilin Municipal Administration for Industry and Commerce.

On June 18, 2008, the company's shareholders meeting resolved to apply for an increase in registered capital of RMB 5 million, which will be paid by Jilin Junhe Enterprise Management Co., Ltd. in the form of monetary funds. After the capital increase, the registered capital of the company is 112 million yuan, of which the natural person Lu Yongxiang invested 50.4826 million yuan, with an investment ratio of 45.08%; the natural person Lu Yang invested 20.5444 million yuan, with an investment ratio of 18.34%; the natural person Lu Lan invested 20.5444 million yuan, with an investment ratio of 18.34%. 18.34%; natural person Lan Xiuzhen invested 10.272 million yuan, with an investment ratio of 9.17%; natural person Ma Liming invested 4.280 million yuan, with an investment ratio of 3.82%; natural person Lu Yongkai invested 428,000 yuan, with an investment ratio of 3.82%;

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

The capital ratio is 0.38%; the natural person Li Xiangwen invested 256,800 yuan, the investment ratio is 0.23%; the natural person Lu Yuzhen invested 192,600 yuan, the investment ratio is 0.17%; Jilin Junhe Enterprise Management Co., Ltd. invested 5 million yuan, the investment ratio is 4.47%.

On September 15, 2011, according to the China Securities Regulatory Commission's "Reply on the Approval of the Initial Public Offering of Jilin Yongda Group Co., Ltd." (CSRC License [2011] No. 1470), the company publicly issued 38 million new shares and was listed on the Shenzhen Stock Exchange on October 18, 2011, with the stock code 002622. After the public issuance of new shares, the company's registered capital was 150 million yuan, and on October 18, 2011, it obtained the "Enterprise Legal Person Business License" with registration number 220214000001024 issued by the Jilin Municipal Administration for Industry and Commerce, and the unified social credit code is 912202016051690282.

According to the company's 2014 profit distribution plan, the company used capital reserves to increase share capital in 2015, with an increase in share capital of RMB 270 million. After this transfer, the company's share capital was changed to RMB 420 million.

According to the company's profit distribution plan for 2015, the company used capital reserves to increase share capital in 2016, with an increase in share capital of RMB 420 million. After this transfer, the company's share capital was changed to RMB 840 million.

The 17th extraordinary meeting of the company's third board of directors and the fifth extraordinary general meeting of shareholders in 2016 reviewed and approved the "Proposal on the Proposal to Change the Company's Name and Securities Abbreviation." On November 4, 2016, the company was renamed "Rongyu Group Co., Ltd." On November 8, 2016, the company's securities abbreviation was changed to "Rongyu Group".

The company held the 19th extraordinary meeting of the fifth board of directors on November 7, 2022, and reviewed and approved the "Proposal on the Proposed Change of the Company's Name, Securities Abbreviation and Business Scope", and agreed that the company would change the company's name, securities abbreviation and business scope. On December 12, 2022, the company officially changed its name to "Haochen Medical Technology Co., Ltd.", and the company's securities abbreviation was changed to "Haochen Medical".

Company business scope

Technical services, technology development, technology consulting, technology exchange, technology transfer, technology promotion; hospital management; information consulting services (excluding licensed information consulting services); information technology consulting services; engineering and technology research and experimental development; software development; medical research and experimental development; new material technology promotion services; digital technology services; software outsourcing services; health consulting services (excluding diagnosis and treatment services); business training (excluding education training, vocational skills training and other training that require a license); business management; business management consulting; supply Supply chain management services; engaging in investment activities with own funds; manufacturing of distribution switch control equipment; manufacturing of power transmission and distribution and control equipment; research and development of distribution switch control equipment; manufacturing of mechanical and electrical equipment; sales of distribution switch control equipment; manufacturing of electrical instruments and meters; manufacturing of industrial automatic control system devices; manufacturing of metal structures; sales of chemical products (excluding licensed chemical products); sales of construction engineering machinery; sales of building materials; sales of building decoration materials; sales of communication equipment; wholesale of hardware products; sales of machinery and equipment; wholesale of automobile spare parts.

The company’s business period

The company's business period: November 6, 1998 to no fixed period

Approval date of this financial report

August 28, 2025

Consolidation scope of financial statements during the reporting period

Serial number Subsidiary Half-year 2025 Year 2024 1 Jilin Yongda Electrical Switch Co., Ltd. Merger Merger 2 Beijing Rongyu Technology Co., Ltd. Merger Merger

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

3 Rongyu Huatong Leasing (Tianjin) Co., Ltd. Merge Merge 4 Beijing Luluba Technology Co., Ltd. Merge Merge 5 Beijing Ruichi Anxin Technology Co., Ltd. Merge Merge 6 Zhiyu Medical Investment Co., Ltd. Merge Merge 7 Guangdong Delun Medical Group Co., Ltd. Merge Merge 8 Guangzhou Delun Dental Clinic Co., Ltd. Merger Merge 9 Guangzhou Kaituo Baoye Delun Dental Clinic Co., Ltd. Merge Merge 10 Guangzhou Kaituo Binjiang Delun Dental Clinic Co., Ltd. Merged Merged 11 Foshan Shunde Delun Dental Hospital Co., Ltd. Merged Merged 12 Guangzhou Delun Yueken Dental Clinic Co., Ltd. Merged Merged 13 Guangzhou Delun Yuebao Dental Clinic Co., Ltd. Merged Merged 14 Guangzhou Delun Litai Dental Clinic Co., Ltd. Merged Merged 15 Guangzhou Delun Gaosheng Dental Clinic Co., Ltd. Merged Merged 16 Guangzhou Delun District Zhuang Dental Clinic Co., Ltd. Merged Merged 17 Guangzhou Delun Shixi Dental Clinic Co., Ltd. Merged Merged 18 Guangzhou Delun Huadi Dental Clinic Co., Ltd. Merged Merged 19 Guangzhou Delun Chigang Dental Clinic Co., Ltd. Merged Merged 20 Guangzhou Delun Sanyuanli Dental Clinic Co., Ltd. Merged Merged 21 Guangzhou Delun Xiancun Dental Clinic Co., Ltd. Merged Merged 22 Guangzhou Delun Jingxi Dental Clinic Co., Ltd. Merge Merge 23 Guangzhou Delun Huiqiao Dental Clinic Co., Ltd. Merge Merge 24 Guangzhou Delun Changshou Road Dental Clinic Co., Ltd. Merge Merge 25 Guangzhou Delun Ximenkou Dental Clinic Co., Ltd. Merge Merge 26 Guangzhou Delun Xintang Dental Clinic Co., Ltd. Merge Merge 27 Foshan Delun Wanyi Dental Clinic Co., Ltd. Merge Merge 28 Guangzhou Delun Wanbo Dental Clinic Co., Ltd. Merge Merge 29 Guangzhou Delun Yusan Dental Clinic Co., Ltd. Merged Merged 30 Guangzhou Delun Jinbo Dental Clinic Co., Ltd. Merged Merged 31 Foshan Shunde Ronggui Delun Dental Clinic Co., Ltd. Merged Merged 32 Guangzhou Delun Fengya Dental Clinic Co., Ltd. Merged Merged 33 Guangzhou Delun Yida Dental Clinic Co., Ltd. Merged Merged 34 Guangzhou Delun Zhengsheng Dental Clinic Co., Ltd. Merged Merged 35 Foshan Nanhai Kangyi Delun Dental Clinic Co., Ltd. Merged Merged 36 Foshan Nanhai Guida Delun Dental Clinic Co., Ltd. Merged Merged 37 Jilin Chenda Trading Co., Ltd. Merged Merged 38 Zhiyu (Hong Kong) International Co., Ltd. Merged Merged 39 Beijing Chenjiu Technology Co., Ltd. Merged Merged 40 Zhaoqing Delun Medical Management Co., Ltd. Merged (Note 1) Not merged 41 Huizhou Haochendelun Medical Investment Co., Ltd. Consolidated (Note 2) Not consolidated Note 1: The above-mentioned subsidiaries were invested and established by the company in 2025 and have been included in the scope of consolidated statements since the date of establishment.

Note 2: The above-mentioned subsidiaries were invested and established by the company in 2025 and have been included in the scope of consolidated statements since the date of establishment.

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

4. Basis for preparation of financial statements

Basics of preparation

The company prepares financial statements on the basis of going concern, based on actual transactions and events, and in accordance with the "Accounting Standards for Business Enterprises - Basic Standards" and various specific accounting standards, application guides for the Accounting Standards for Business Enterprises, interpretations of the Accounting Standards for Business Enterprises and other relevant regulations promulgated by the Ministry of Finance (hereinafter collectively referred to as the "Accounting Standards for Business Enterprises"), as well as the disclosure provisions of the China Securities Regulatory Commission's "Information Disclosure and Preparation Rules No. 15 of Companies that Offer Securities to the Public - General Provisions for Financial Reports".

Continued operations

According to the Company's assessment, within 12 months from the end of this reporting period, the Company's ability to continue operating is good, and there are no factors that would cause significant doubts about the Company's ability to continue operating.

5. Important accounting policies and accounting estimates

Specific accounting policies and accounting estimation tips:

None

Statement on compliance with corporate accounting standards

The financial statements prepared by the company comply with the requirements of the Accounting Standards for Business Enterprises and truly and completely reflect the company's financial status, operating results, cash flow and other relevant information during the reporting period.

Accounting period

The accounting period begins on January 1 and ends on December 31 of the Gregorian calendar.

Business cycle

The company uses 12 months as an operating cycle and uses it as the liquidity classification standard for assets and liabilities.

Accounting standard currency

The accounting standard currency is RMB.

Determination method and selection basis of importance standards

Applicable □Not applicable

Project Materiality Criteria

The company will make bad debt provision for important single accounts receivable that exceed 5% of the total accounts receivable.

Recognized as important accounts receivable.

The company will make provision for bad debt provisions for its important individual other receivables if the amount of individual other receivables exceeds 10% of the total amount of other receivables.

Other receivables are identified as important other receivables.

The company combines important contract liabilities with a single aging of more than 1 year and an amount of more than 3 million yuan and a combined aging of more than 1 year.

Same liabilities are identified as important contract liabilities with an aging of more than 1 year.

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

The company considers the amount of other payables individually aged over 1 year to be greater than the amount of other important other payables aged over 1 year or overdue.

3% of the total amount was identified as important other payables aged more than 1 year.

The company's total assets/total income exceed 15% of the group's total assets/total income as important non-wholly owned subsidiaries

The subsidiaries are determined as important non-wholly owned subsidiaries.

Accounting treatment methods for business combinations under the same control and those not under the same control

 Business combination under common control

If the enterprises participating in the merger are ultimately controlled by the same party or the same parties before and after the merger and the control is not temporary, it is deemed to be a business merger under the same control.

If the merging party issues equity securities as the merger consideration, the share of the book value of the merged party's owner's equity in the ultimate controlling party's consolidated financial statements on the merger date shall be used as the initial investment cost of the long-term equity investment. The total face value of the shares issued is regarded as share capital. The difference between the initial investment cost of the long-term equity investment and the total face value of the shares issued is adjusted to the capital reserve; if the capital reserve is insufficient for offset, the retained earnings are adjusted.

The merging party's intermediary fees such as auditing, legal services, evaluation and consulting, and other related management expenses incurred by the business merger shall be included in the current profit and loss when incurred.  Business combination not under common control

If the parties involved in the merger are not ultimately controlled by the same party or the same parties before and after the merger, it is deemed to be a business merger not under the same control.

For a business combination achieved by the purchaser through an exchange transaction, the merger cost shall be the fair value of the assets paid by the purchaser, liabilities incurred or assumed, and equity securities issued by the purchaser to obtain control of the purchased party on the purchase date. The intermediary fees such as auditing, legal services, evaluation consulting and other related management expenses incurred by the buyer for the business merger shall be included in the current profit and loss when incurred; the transaction costs of equity securities or debt securities issued by the buyer as consideration for the merger shall be included in the initial recognition amount of the equity securities or debt securities.

The purchaser's merger costs and the identifiable net assets obtained by the purchaser in the merger are measured at fair value on the purchase date. The difference between the merger cost and the fair value of the acquiree's identifiable net assets obtained in the merger on the purchase date is recognized as goodwill; the difference between the merger cost and the fair value of the acquiree's identifiable net assets obtained in the merger is included in the current profit and loss.

 Being able to exercise control over investee units that are not under common control due to additional investment or other reasons

When preparing individual financial statements, the sum of the book value of the original equity investment plus the new investment cost will be used as the initial investment cost to be accounted for using the cost method. Other comprehensive income recognized due to equity method accounting for equity investments held before the acquisition date will be accounted for on the same basis as the investee's direct disposal of relevant assets or liabilities when disposing of the investment. If the equity investment held before the purchase date is accounted for in accordance with the relevant provisions of the "Accounting Standards for Business Enterprises No. 22 - Recognition and Measurement of Financial Instruments", the cumulative fair value changes originally included in other comprehensive income will be transferred to the current profit and loss when the cost method is used.

In the consolidated financial statements, the equity of the purchased party held before the purchase date is remeasured according to the fair value of the equity on the purchase date, and the difference between the fair value and its book value is included in the investment income of the current period; if the equity of the purchased party held before the purchase date involves other comprehensive income under equity method accounting, the other comprehensive income related to it shall be converted into the current period income on the purchase date.

Judgment standards for control and preparation methods of consolidated financial statements

 Scope

The consolidation scope of the consolidated financial statements includes the company and its subsidiaries. The scope of consolidation in consolidated financial statements is determined on the basis of control.

 Basis for control

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

If the investor has power over the investee, enjoys variable returns by participating in the investee's relevant activities, and has the ability to use its power over the investee to affect the amount of its returns, the investor is deemed to control the investee. Relevant activities are activities that have a significant impact on the return of the investee.

 Decision makers and agents

The agent only exercises decision-making power on behalf of the principal responsible person and does not control the investee. If an investor entrusts the decision-making power of the investee's relevant activities to an agent, the investor shall regard the decision-making power as being directly held by itself.

When determining whether a decision-maker is an agent, the company comprehensively considers the relationship between the decision-maker and the investee and other investors.

If there is a single party with substantial rights to unconditionally remove the decision-maker, the decision-maker is an agent.
In situations other than 1), comprehensive consideration shall be given to the decision-maker's judgment on the scope of decision-making power of the investee, the substantive rights enjoyed by other parties, the salary level of the decision-maker, the risk of variable returns borne by the decision-maker due to holding other interests in the investee, and other relevant factors.

 Investment entities

When the following conditions are met at the same time, it is regarded as an investment entity:

The company aims to provide investment management services to investors and obtains funds from one or more investors;
The company’s sole business purpose is to provide returns to investors through capital appreciation, investment income, or both;
The company considers and evaluates the performance of almost all investments based on fair value.

Investment entities usually meet all of the following characteristics:

Own more than one investment;
Have more than one investor;
The investor is not a related party of the entity;
Its owner's equity exists in the form of equity or similar equity.

If the parent company is an investment entity, the parent company will only include the subsidiaries (if any) that provide related services for its investment activities into the scope of consolidation and prepare consolidated financial statements; other subsidiaries will not be consolidated, and the parent company's investments in other subsidiaries will be measured at fair value and their changes will be included in the current profits and losses.

If the parent company of an investment entity is not an investment entity itself, all entities it controls, including those indirectly controlled through the investment entity, will be included in the scope of the consolidated financial statements.

 Merger process

If the accounting policies or accounting periods adopted by a subsidiary are inconsistent with the Company's, necessary adjustments shall be made to the subsidiary's financial statements in accordance with the Company's accounting policies or accounting periods; or the subsidiary shall be required to prepare separate financial statements in accordance with the Company's accounting policies or accounting periods.

The consolidated balance sheet, consolidated income statement, consolidated cash flow statement and consolidated statement of changes in owners' (shareholders' equity) are based on the balance sheet, income statement, cash flow statement and statement of changes in owners' (shareholders') equity of the company and its subsidiaries respectively, and are prepared by the company after offsetting the impact of internal transactions between the company and its subsidiaries and between subsidiaries on the consolidated balance sheet, consolidated income statement, consolidated cash flow statement and consolidated statement of changes in owners' (shareholders') equity. Unrealized internal transaction gains and losses arising from the company's sale of assets to subsidiaries are fully offset against "net profits attributable to owners of the parent company". Unrealized internal transaction profits and losses arising from the sale of assets by a subsidiary to the Company are offset and allocated between "net profits attributable to owners of the parent company" and "minority shareholders' profits and losses" in accordance with the Company's distribution ratio to the subsidiary. Unrealized internal transaction profits and losses arising from the sale of assets between subsidiaries shall be allocated and offset between "net profits attributable to owners of the parent company" and "minority shareholders' profits and losses" in accordance with the company's distribution ratio to the selling subsidiary.

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

The share of the subsidiary's owner's equity that does not belong to the company, as minority shareholders' equity, is listed as "minority shareholders' equity" under the owner's equity item in the consolidated balance sheet. The share of minority shareholders' equity in the current period's net profits and losses of a subsidiary is listed as "minority shareholders' profits and losses" under the net profit item in the consolidated income statement. The share of the subsidiary's current comprehensive income that is attributable to minority shareholders' equity is listed under the item "total comprehensive income attributable to minority shareholders" in the consolidated income statement. If there are minority shareholders, the "Minority Shareholders' Equity" column will be added to the consolidated statement of changes in owners' equity to reflect the changes in minority shareholders' equity. If the current losses shared by the minority shareholders of a subsidiary exceed the minority shareholders' share of the opening owner's equity of the subsidiary, the balance shall still be offset against the minority shareholders' equity.

If the company adds subsidiaries and businesses during the reporting period due to the merger of enterprises under the same control, when preparing the consolidated balance sheet, the opening balance of the consolidated balance sheet will be adjusted; when preparing the consolidated income statement, the income, expenses and profits of the subsidiaries and business combination from the beginning of the current period to the end of the reporting period will be included Consolidated income statement; when preparing the cash flow statement, the cash flow of the subsidiary and the business combination from the beginning of the current period to the end of the reporting period is included in the consolidated cash flow statement; at the same time, relevant items in the comparative statement are adjusted, and the post-merger reporting entity is deemed to have existed since the time when the ultimate controlling party began to control.

For subsidiaries and businesses added due to business mergers or other methods not under common control, when preparing the consolidated balance sheet, the opening balance of the consolidated balance sheet will not be adjusted; when preparing the consolidated income statement, the income, expenses, and profits from the date of acquisition of the subsidiary and business to the end of the reporting period will be included in the consolidated income statement; when preparing the consolidated cash flow statement, the cash flow from the date of acquisition of the subsidiary to the end of the reporting period will be included in the consolidated cash flow statement.

The company disposes of subsidiaries and businesses during the reporting period. When preparing the consolidated balance sheet, the opening balance of the consolidated balance sheet will not be adjusted; when preparing the consolidated income statement, the income, expenses and profits of the subsidiary and the business from the beginning of the period to the date of disposal will be included in the consolidated income statement; when preparing the consolidated cash flow statement, the cash flow of the subsidiary and the business from the beginning of the period to the date of disposal will be included in the consolidated cash flow statement.

 Special transaction accounting

Purchase equity in a subsidiary owned by minority shareholders of the subsidiary

In the consolidated financial statements, the capital reserve (capital premium or equity premium) is adjusted for the difference between the newly acquired long-term equity investment due to the purchase of minority equity and the share of the subsidiary's net assets calculated continuously from the date of purchase or merger based on the new shareholding ratio. If the capital reserve is insufficient for offset, the retained earnings are adjusted. 2) Dispose of long-term equity investments in subsidiaries without losing control

If a long-term equity investment in a subsidiary is partially disposed of without losing control, in the consolidated financial statements, the difference between the disposal price and the share of the subsidiary's net assets continuously calculated from the date of purchase or merger should be adjusted in the consolidated financial statements. If the capital reserve is insufficient to offset, the retained earnings will be adjusted.

When the control over the investee is lost due to disposal of part of the equity investment or other reasons, the treatment of the remaining equity

When preparing consolidated financial statements, the remaining equity is remeasured according to its fair value on the date when control is lost. The difference between the sum of the consideration obtained for disposing of the equity and the fair value of the remaining equity, minus the share of the original subsidiary's net assets calculated continuously from the date of purchase or merger based on the original shareholding ratio, shall be included in the investment income for the period when control is lost, and goodwill shall be offset at the same time. Other comprehensive income related to the equity investment in the original subsidiary will be converted into current investment income when control is lost.

The enterprise disposes the equity investment in the subsidiary step by step through multiple transactions until it loses control, and the multiple transactions belong to a package deal

If the various transactions involving the disposal of equity investments in a subsidiary until the loss of control belong to a package of transactions, each transaction shall be accounted for as a transaction in which the subsidiary is disposed of and control is lost; however, the difference between the price of each disposal and the share of the net assets of the subsidiary corresponding to the disposal investment before the loss of control shall be recognized as other comprehensive income in the consolidated financial statements, and shall be transferred to the profits and losses of the current period when control is lost.

The principles for judging whether various transactions from the step-by-step disposal of equity to the loss of control belong to a package deal are as follows:

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

The terms, conditions and economic impact of various transactions related to the disposal of equity investments in subsidiaries meet one or more of the following circumstances, which usually indicates that multiple transactions are a package deal:

 The transactions were entered into simultaneously or with consideration of their effects on each other;

 These transactions as a whole can achieve a complete business result;

 The occurrence of one transaction depends on the occurrence of at least one other transaction;

 A transaction is uneconomical on its own but is economical when considered together with other transactions.

Classification of joint arrangements and accounting treatment of joint operations

 Classification of joint arrangements

Joint arrangements are divided into joint operations and joint ventures.

 Accounting treatment of joint operating parties

The joint venture party shall confirm the following items related to its interest share in the joint operation, and conduct accounting treatment in accordance with the relevant accounting standards for enterprises: 1) Confirm the assets held individually, and confirm the assets held jointly according to its share;

Recognize the liabilities borne individually and recognize the liabilities borne jointly according to their shares;
Recognize the income generated from the sale of its share of joint operating output;
Recognize the income generated by the joint operation from the sale of output according to its share;
Recognize the expenses incurred individually, and recognize the expenses incurred by joint operations according to their share.

When a joint venture invests or sells assets, etc. (except those assets that constitute a business) to a joint operation, before the assets, etc. are sold by the joint operation to a third party, only the portion of the profits and losses arising from the transaction that are attributable to the other participants in the joint operation is recognized. If the assets invested or sold suffer an asset impairment loss that complies with the "Accounting Standards for Business Enterprises No. 8 - Asset Impairment" and other provisions, the joint venture party shall fully recognize the loss.

When a joint venture party purchases assets, etc. from a joint operation (except where the assets constitute a business), before selling the assets, etc. to a third party, only the portion of the profits and losses arising from the transaction that are attributable to other participants in the joint operation will be recognized. If the purchased assets suffer asset impairment losses that comply with the provisions of "Accounting Standards for Business Enterprises No. 8 - Asset Impairment" and other provisions, the joint venture party shall recognize this part of the loss according to its share.

If a participant who does not enjoy joint control over a joint operation owns the assets related to the joint operation and assumes the liabilities related to the joint operation, the accounting treatment shall be carried out according to the above method; otherwise, the accounting treatment shall be carried out in accordance with the provisions of the relevant accounting standards for enterprises.

Determination standards for cash and cash equivalents

The cash listed in the cash flow statement refers to cash on hand and deposits that can be used for payment at any time. Cash equivalents refer to investments with a short holding period (generally due within three months from the date of purchase), high liquidity, easy conversion into known amounts of cash and a small risk of value changes.

Foreign currency business and foreign currency statement conversion

 Foreign currency business

For foreign currency business, the foreign currency amount is converted into RMB and recorded in RMB based on the spot exchange rate on the date of business occurrence.

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

On the balance sheet date, foreign currency monetary items are converted into RMB using the spot exchange rate on the balance sheet date. The resulting translation differences are directly included in the current profit and loss, except for the exchange differences arising from foreign currency borrowings for the purchase, construction or production of assets that meet the capitalization conditions, which are treated according to the capitalization principle. Foreign currency non-monetary items measured at historical cost are translated on the balance sheet date using the spot exchange rate on the date of the transaction.

 Translation of foreign currency financial statements

The assets and liability items in the balance sheet prepared in non-accounting functional currency are converted into the accounting functional currency using the spot exchange rate on the balance sheet date. Except for the undistributed profit items, other items in the owner's equity are converted using the spot exchange rate at the time of occurrence. Income and expense items in the income statement prepared in a non-accounting functional currency are converted into the accounting functional currency using the spot exchange rate on the date of transaction. The translation difference of foreign currency statements arising from the above translation shall be accounted for in other comprehensive income. The cash flows of each item in the cash flow statement prepared in a non-accounting functional currency are converted into the accounting functional currency using the spot exchange rate on the date when the cash flow occurs. The impact of exchange rate changes on cash is presented separately in the cash flow statement.

Financial instruments

 Recognition and derecognition of financial instruments

When the company becomes a party to a financial instrument contract, it recognizes a financial asset or financial liability.

For the purchase or sale of financial assets in a conventional way, the company recognizes the assets to be received and the liabilities to be assumed on the transaction date, or derecognizes the sold assets on the transaction date, and simultaneously recognizes the disposal gains or losses and the receivables that should be collected from the buyer.

Financial assets shall be derecognized if they meet one of the following conditions:

The contractual right to receive cash flows from the financial asset terminates;
The financial asset has been transferred, and the company has transferred almost all risks and rewards of ownership of the financial asset;
The financial asset has been transferred, and the Company has neither transferred nor retained substantially all risks and rewards of ownership of the financial asset. However, the Company has not retained control of the financial asset.

If the current obligation of a financial liability (or part thereof) has been discharged, the Company shall terminate the recognition of the financial liability (or part thereof).

 Classification of financial assets

According to the business model of managing financial assets and the contractual cash flow characteristics of financial assets, financial assets are divided into the following three categories:

Financial assets measured at amortized cost;
Financial assets measured at fair value with changes included in other comprehensive income;
Financial assets measured at fair value with changes included in current profits and losses.
Financial assets measured at amortized cost

If a financial asset meets the following conditions at the same time, the Company will classify it as a financial asset measured at amortized cost:

①The company’s business model for managing this financial asset is aimed at collecting contractual cash flows.

②The contractual terms of the financial asset stipulate that the cash flow generated on a specific date is only the payment of principal and interest based on the outstanding principal amount. When notes receivable and accounts receivable meet the above conditions at the same time, the company will classify them as financial assets measured at fair value and whose changes are included in other comprehensive income, and list them as receivable financing in the statements.

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Financial assets measured at fair value with changes included in other comprehensive income (debt instrument investments)

If a financial asset meets the following conditions at the same time, the Company will classify it as a financial asset measured at fair value with changes included in other comprehensive income:

① The company’s business model for managing the financial assets aims at both collecting contractual cash flows and selling the financial assets.

②The contractual terms of the financial asset stipulate that the cash flow generated on a specific date is only the payment of principal and interest based on the outstanding principal amount.

Financial assets measured at fair value and changes included in current profits and losses

Financial assets other than financial assets that are classified as measured at amortized cost in accordance with item 1) of this article and financial assets (debt instrument investments) classified as measured at fair value with changes included in other comprehensive income in accordance with item 2) of this article, the Company classifies them as financial assets measured at fair value with changes included in current profits and losses.

At the time of initial recognition, the company may designate non-trading equity instrument investments as financial assets measured at fair value with changes included in other comprehensive income (non-trading equity instrument investments), and recognize dividend income in accordance with regulations. This designation, once made, cannot be revoked. If the contingent consideration recognized by the Company in a business combination not under common control constitutes a financial asset, the financial asset is classified as a financial asset measured at fair value with changes included in current profits and losses.

 Classification of financial liabilities

In addition to the following items, the Company classifies financial liabilities as financial liabilities measured at amortized cost:

Financial liabilities measured at fair value through profit or loss for the current period, including trading financial liabilities (including derivatives that are financial liabilities) and financial liabilities designated as measured at fair value through profit or loss for the current period.
The transfer of financial assets does not meet the conditions for derecognition or the financial liabilities formed by continuing to be involved in the transferred financial assets.
Financial guarantee contracts that do not fall under the circumstances of item 1) or 2) of this article, and loan commitments for loans at lower than market interest rates that do not fall under the circumstances of item 1) of this article.

In a business combination not under common control, if the contingent consideration recognized by the Company as the purchaser forms a financial liability, the financial liability shall be accounted for at fair value through profit and loss of the current period.

At the time of initial recognition, in order to provide more relevant accounting information, the company can designate financial liabilities as financial liabilities measured at fair value and whose changes are included in current profits and losses. This designation meets one of the following conditions:

Can eliminate or significantly reduce accounting mismatch;
According to the enterprise risk management or investment strategies stated in formal written documents, manage and perform performance evaluation of financial liability portfolios or financial assets and financial liability portfolios based on fair value, and report to key management personnel on this basis within the company.

This designation, once made, cannot be revoked.

 Embedded derivatives

Embedded derivatives refer to derivatives embedded in non-derivative instruments (ie, the host contract).

If the main contract included in a mixed contract is an asset regulated by the Standards for the Recognition and Measurement of Financial Instruments, the Company will apply the relevant provisions of the Standards on the classification of financial assets to the mixed contract as a whole.

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

If the main contract included in the hybrid contract is not an asset regulated by the financial instrument recognition and measurement standards, and meets the following conditions at the same time, the company will separate the embedded derivatives from the hybrid contract and treat them as separate derivatives:

The economic characteristics and risks of embedded derivatives are not closely related to the economic characteristics and risks of the host contract.
A separate instrument with the same terms as an embedded derivative meets the definition of a derivative.
The mixed contract is not measured at fair value and its changes are included in the current profit and loss for accounting treatment.

 Reclassification of financial instruments

When the Company changes its business model for managing financial assets, it reclassifies all affected related financial assets. The Company is not allowed to reclassify any financial liabilities.

The company reclassifies financial assets and adopts the prospective application method for relevant accounting treatment from the reclassification date. The reclassification date refers to the first day of the first reporting period after the change in the business model that causes the company to reclassify financial assets.

 Measurement of financial instruments

Initial measurement

The company initially recognizes financial assets or financial liabilities and measures them at fair value. For financial assets and financial liabilities measured at fair value and whose changes are included in the current profit and loss, the relevant transaction costs are directly included in the current profit and loss; for other types of financial assets or financial liabilities, the relevant transaction costs should be included in the initial recognition amount.

Subsequent measurement

After initial recognition, the Company conducts subsequent measurement of different types of financial assets at amortized cost, at fair value with changes included in other comprehensive income, or at fair value with changes included in current profits and losses.

After initial recognition, the Company will conduct subsequent measurement of different types of financial liabilities at amortized cost, at fair value with changes included in current profits and losses, or by other appropriate methods.

The amortized cost of a financial asset or financial liability is determined by adjusting the initial recognition amount of the financial asset or financial liability as follows:

①Deduct the repaid principal.

② Add or subtract the accumulated amortization amount formed by amortizing the difference between the initial recognition amount and the maturity amount using the effective interest method.

③ Deduct accumulated loss provisions (only applicable to financial assets).

The Company recognizes interest income based on the actual interest rate method. Interest income is calculated and determined based on the book balance of the financial asset multiplied by the actual interest rate, except for the following circumstances: ① For purchased or originated financial assets that have incurred credit impairment, the company determines its interest income based on the amortized cost of the financial asset and the credit-adjusted actual interest rate from the initial recognition.

② For purchased or originated financial assets that have not been credit-impaired but have become credit-impaired in the subsequent period, the Company will calculate and determine its interest income based on the amortized cost and actual interest rate of the financial asset in the subsequent period. If the company uses the actual interest rate method to calculate interest income on the amortized cost of financial assets in accordance with the above policies, if the financial instrument no longer has credit impairment due to its credit risk improvement in the subsequent period, and this improvement can be objectively linked to an event that occurs after the application of the above policies (such as the credit rating of the debtor being raised), the company will calculate and determine interest income based on the actual interest rate multiplied by the book balance of the financial asset.

 Impairment of financial instruments

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Impairment items

Based on expected credit losses, the company performs impairment accounting on the following items and recognizes loss provisions:

① Financial assets classified as measured at amortized cost and financial assets classified as measured at fair value with changes included in other comprehensive income.

②Lease receivables.

③Loan commitment and financial guarantee contract.

The expected credit loss model is not applicable to other financial assets measured at fair value held by the Company, including financial assets measured at fair value with changes included in current profits and losses, financial assets designated as measured at fair value with changes included in other comprehensive income (non-trading equity instrument investments), and derivative financial assets.

Recognition and measurement of impairment provisions

Except for purchased or originated financial assets that are credit-impaired and financial assets that always measure loss provisions at an amount equivalent to the expected credit losses throughout the entire duration, the company evaluates at each balance sheet date whether the credit risk of relevant financial instruments has increased significantly since initial recognition, and measures its loss provisions, recognizes expected credit losses and changes in them according to the following circumstances:

If the credit risk of the financial instrument has not increased significantly since initial recognition and is in the first stage, the company will measure its loss provision at an amount equivalent to the expected credit loss of the financial instrument in the next 12 months. Regardless of whether the company's basis for assessing credit losses is a single financial instrument or a combination of financial instruments, the resulting increase or reversal of the loss provision will be included in the current profit and loss as an impairment loss or gain.

If the credit risk of the financial instrument has increased significantly since initial recognition and is in the second stage, the company will measure its loss provision based on an amount equivalent to the expected credit losses during the entire duration of the financial instrument. Regardless of whether the company's basis for assessing credit losses is a single financial instrument or a combination of financial instruments, the resulting increase or reversal of loss provisions is included in the current profit and loss as impairment losses or gains.

For financial assets that have been credit-impaired and are in the third stage, the company will only recognize the cumulative changes in expected credit losses during the entire duration since initial recognition as loss provisions on the balance sheet date. On each balance sheet date, the company will include the change in expected credit losses during the entire duration as impairment losses or gains into the current profits and losses. Even if the expected credit losses during the entire duration determined on the balance sheet date are less than the amount of expected credit losses reflected in the estimated cash flows at the time of initial recognition, the company will recognize favorable changes in expected credit losses as impairment gains.

For financial assets (debt instrument investments) classified as measured at fair value and whose changes are included in other comprehensive income, the company recognizes its loss provisions in other comprehensive income and includes impairment losses or gains in current profits and losses, and the book value of the financial assets listed in the balance sheet should not be reduced.

The Company has measured loss provisions in the previous accounting period at an amount equivalent to the expected credit losses for the entire duration of the financial instrument. However, on the current balance sheet date, if the financial instrument no longer has a significant increase in credit risk since initial recognition, the Company will measure the loss provisions for the financial instrument at an amount equivalent to the expected credit losses within the next 12 months on the current balance sheet date. The resulting reversal amount of the loss provisions shall be included in the current profit and loss as impairment gain.

When the Company is unable to obtain sufficient evidence of a significant increase in credit risk at a reasonable cost at the individual instrument level, the Company assesses whether the credit risk has significantly increased on a portfolio basis.

For various financial instruments subject to the provisions on impairment of financial instruments under this policy, the Company determines their credit losses according to the following methods:

① For financial assets, credit loss is the present value of the difference between the contractual cash flow received by the company and the expected cash flow received.

② For lease receivables, credit loss is the present value of the difference between the contractual cash flow that the company should receive and the cash flow that is expected to be received.

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

③ For undrawn loan commitments, credit losses should be the present value of the difference between the contractual cash flows that the company should receive and the cash flows that are expected to be collected if the loan commitment holder draws on the corresponding loan.

④ For financial guarantee contracts, credit losses shall be the present value of the difference between the expected payment amount that the company will pay to the contract holder for the credit losses incurred by the contract holder, minus the amount that the company expects to collect from the contract holder, debtor or any other party.

⑤ For financial assets that have been credit-impaired on the balance sheet date but were not purchased or originated from credit-impairment, the credit loss is the difference between the book balance of the financial asset and the present value of the estimated future cash flows discounted at the original effective interest rate.

Credit risk increases significantly

The Company determines whether the credit risk of a financial instrument has increased significantly by comparing the default probability within the expected duration of the financial instrument determined at initial recognition with the default probability within the estimated duration of the instrument determined at the balance sheet date. Except for special circumstances, the Company uses the change in default risk in the next 12 months as a reasonable estimate of the change in default risk during the entire duration to determine whether credit risk has increased significantly since initial recognition.

If the Company determines that a financial instrument only has low credit risk on the balance sheet date, it can be assumed that the credit risk of the financial instrument has not increased significantly since initial recognition. Generally, if the financial instrument is overdue for more than 30 days, the Company considers that the credit risk of the financial instrument has increased significantly, unless there is conclusive evidence that the credit risk of the financial instrument has not increased significantly since the initial recognition.

Impairment of notes receivable and accounts receivable

For notes receivable and accounts receivable, regardless of whether there is a significant financing component, the company measures loss provisions based on expected credit losses throughout the duration. When individual notes receivable and accounts receivable cannot assess expected credit losses at a reasonable cost, the company divides notes receivable and accounts receivable into several combinations based on credit risk characteristics, and calculates expected credit losses on a combination basis. If there is objective evidence that a certain note receivable and account receivable has suffered credit impairment, the company will make a provision for bad debts and recognize expected credit losses for the note receivable and account receivable individually. For notes receivable and accounts receivable divided into portfolios, the Company refers to historical credit loss experience, combined with current conditions and predictions of future economic conditions, and calculates expected credit losses through default risk exposure and expected credit loss rate throughout the duration. For accounts receivable grouped by aging, the aging is calculated from the date of confirmation.

Notes receivable and accounts receivable portfolio:

Combination name Determine the combination basis

Notes Receivable Portfolio 1 Bank Acceptance Bill The acceptor is a bank with low credit risk

Notes receivable portfolio 2 Commercial acceptance bill According to the credit risk classification of the acceptor, it is the same as the "accounts receivable" portfolio Accounts receivable portfolio 3 Aging portfolio

Accounts receivable portfolio 4 Amounts due from related parties

Impairment of other receivables

Recognize and measure impairment as described in III.10.(7)2).

When it is impossible to assess expected credit losses for a single item of other receivables at a reasonable cost, the company divides other receivables into several combinations based on credit risk characteristics, and calculates expected credit losses on the basis of the combinations. The basis for determining the combinations is as follows:

Combination name Determine the combination basis

Other receivables portfolio 1 Employee insurance

Other receivables combination 2 Deposit, margin

Other receivables portfolio 3 Accounts from non-related parties

Other receivables portfolio 4 Accounts with related parties

 Gains and losses

The Company will include the gains or losses of financial assets or financial liabilities measured at fair value into current profits and losses, unless the financial assets or financial liabilities fall into one of the following situations:

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

It is part of the hedging relationship stipulated in "Accounting Standards for Business Enterprises No. 24 - Hedge Accounting".
It is an investment in non-trading equity instruments, and the company designates it as a financial asset measured at fair value with changes included in other comprehensive income.
It is a financial liability designated as measured at fair value and its changes are included in the current profit and loss. Changes in the fair value of this liability caused by changes in the company's own credit risk should be included in other comprehensive income.
It is a financial asset (debt instrument investment) classified as measured at fair value with changes included in other comprehensive income, and changes in fair value other than impairment losses or gains and exchange gains and losses are included in other comprehensive income.

The company can recognize dividend income and include it in the current profit and loss only when the following conditions are met at the same time:

The company’s right to receive dividends has been established;
The economic benefits related to dividends are likely to flow into the company;
The amount of dividends can be measured reliably.

Gains or losses arising from financial assets that are measured at amortized cost and are not part of any hedging relationship are included in the current profits and losses when they are derecognized, reclassified in accordance with this item, amortized according to the effective interest method, or impairment is recognized. If the Company reclassifies a financial asset measured at amortized cost to a financial asset measured at fair value and whose changes are included in current profits and losses, it shall be measured according to the fair value of the asset on the reclassification date. The difference between the original book value and the fair value is included in the current profit and loss. If a financial asset measured at amortized cost is reclassified into a financial asset measured at fair value with changes included in other comprehensive income, it shall be measured according to the fair value of the financial asset on the reclassification date. The difference between the original book value and the fair value is included in other comprehensive income. Gains or losses arising from financial liabilities that are measured at amortized cost and are not part of any hedging relationship are included in the profit or loss of the current period when derecognized or are included in the profit or loss of the relevant period when amortized according to the effective interest method.

For the company that designates financial liabilities as financial liabilities measured at fair value and whose changes are included in current profits and losses, the gains or losses arising from the financial liabilities are handled in accordance with the following provisions:

The amount of change in the fair value of the financial liability caused by changes in the company's own credit risk is included in other comprehensive income;
Other changes in the fair value of the financial liability are included in the current profits and losses.

If handling the impact of changes in the financial liability's own credit risk in accordance with the provisions of paragraph 1) of this article will cause or expand the accounting mismatch in profit and loss, the company will include all gains or losses from the financial liability (including the amount affected by the change in the company's own credit risk) into the current profit and loss. When the financial liability is derecognised, the accumulated gains or losses previously included in other comprehensive income should be transferred out of other comprehensive income and included in retained earnings.

If the company designates non-trading equity instrument investments as financial assets measured at fair value and whose changes are included in other comprehensive income, when the financial assets are derecognised, the accumulated gains or losses previously included in other comprehensive income will be transferred out from other comprehensive income and included in retained earnings.

All gains or losses arising from financial assets classified as fair value through other comprehensive income (investments in debt instruments), except for impairment losses or gains and exchange gains and losses, are included in other comprehensive income until the financial asset is derecognised or reclassified. However, the interest on this financial asset calculated using the actual interest rate method is included in the current profit and loss. When the financial asset is derecognised, the accumulated gains or losses previously included in other comprehensive income should be transferred out of other comprehensive income and included in the current profit and loss. If the company reclassifies the financial asset into other categories of financial assets, it will transfer out the accumulated gains or losses previously included in other comprehensive income, adjust the fair value of the financial asset on the reclassification date, and use the adjusted amount as the new book value.

 Report presentation

The company will classify financial assets measured at fair value with changes included in current profits and losses, and list them in the "trading financial assets" account. Non-current financial assets that mature more than one year from the balance sheet date and are expected to be held for more than one year and are measured at fair value and whose changes are included in current profits and losses are listed in the "other non-current financial assets" account.

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

The company will classify long-term debt investment measured at amortized cost and list it in the "debt investment" account. Long-term debt investments due within one year from the balance sheet date are listed in the "non-current assets due within one year" account. Debt investments due within one year measured at amortized cost purchased by the Company are listed in the "other current assets" account.

The company will classify long-term debt investments measured at fair value with changes included in other comprehensive income, and list them in the "other debt investments" account. The closing book value of long-term debt investments due within one year from the balance sheet date is listed in the "non-current assets due within one year" account. Debt investments that are due within one year and are measured at fair value and whose changes are included in other comprehensive income purchased by the company are listed in the "other current assets" account.

The Company will list non-trading equity instrument investments designated as measured at fair value and whose changes are included in other comprehensive income in the "Other Equity Instrument Investments" account.

The trading financial liabilities undertaken by the Company, as well as the financial liabilities held by the Company that are directly designated as measured at fair value and whose changes are included in the current profit and loss, are listed in the "Trading financial liabilities" account.

 Equity instruments

Equity instruments are contracts that evidence ownership of a residual interest in the company's assets after deducting all liabilities. The company's issuance (including refinancing), repurchase, sale or cancellation of equity instruments is treated as a change in equity, and transaction costs related to equity transactions are deducted from equity. The Company does not recognize changes in the fair value of equity instruments. The company's distribution to equity instrument holders is treated as profit distribution, and stock dividends issued do not affect the total owner's equity.

Notes receivable

 Determination method and accounting treatment method of expected credit loss of notes receivable

For details, see V. 11. Financial Instruments

Accounts receivable

 Determination method and accounting treatment method of expected credit loss of accounts receivable

For details, see V. 11. Financial Instruments

Accounts receivable financing

When notes receivable and accounts receivable meet the following conditions at the same time, the company will classify them as financial assets measured at fair value with changes included in other comprehensive income. For specific accounting treatment methods, see V. 11. Financial instruments, which will be listed as receivable financing in the statement:

 Contractual cash flows are payments of principal and interest based on the outstanding principal amount;

 The Company's business model for managing notes receivable and accounts receivable is both aimed at collecting contractual cash flows and selling them.

Other receivables

Determination method and accounting treatment method of expected credit losses of other receivables

 Determination method and accounting treatment method of expected credit losses of other receivables

For details, see V. 11. Financial Instruments

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Contract assets

 Recognition methods and standards for contract assets

The Company and its subsidiaries present contract assets or contract liabilities in the balance sheet based on the relationship between performance obligations and customer payments.

The Company and its subsidiaries present the right to receive consideration from customers that is unconditional (i.e., dependent only on the passage of time) as receivables and the right to receive consideration for goods transferred to customers that is dependent on factors other than the passage of time as contract assets.

 Determination method and accounting treatment method of expected credit loss of contract assets

For details, see V. 11. Financial Instruments

Inventory

 Category of inventory

Inventories include raw materials, work in progress, goods in stock, etc., and are stated at the lower of cost and net realizable value.

 Valuation method for issued inventory

The cost of inventory when it is issued is calculated according to the weighted average method. The cost of finished goods and work in progress includes raw materials, direct labor and manufacturing expenses allocated according to a certain method under normal production capacity. Recycling materials include low-value consumables and packaging materials.

 Basis for determining the net realizable value of different categories of inventories

If the inventory cost is higher than its net realizable value, a provision for inventory depreciation is made and included in the current profit and loss. Net realizable value refers to the estimated selling price of inventory in daily activities minus the estimated costs to be incurred upon completion, estimated sales expenses and related taxes. The company determines the net realizable value of inventories based on the conclusive evidence obtained and considers the purpose of holding inventories, the impact of events after the balance sheet date and other factors.

For materials held for production, if the net realizable value of the finished product produced is higher than the cost, the material is still measured at cost; if the decline in material prices indicates that the net realizable value of the finished product is lower than the cost, the material is measured at the net realizable value.

The net realizable value of inventories held for the execution of sales contracts or labor contracts is calculated based on the contract price. If the quantity of inventory held is greater than the quantity ordered in the sales contract, the net realizable value of the excess inventory is calculated based on the general sales price.

 Inventory inventory system

The inventory inventory system adopts the perpetual inventory system.

 Amortization method for low-value consumables and packaging

The cost of low-value consumables is calculated using the one-time write-off method when used.

The cost of packaging is calculated using the one-time write-off method when it is collected.

 Recognition standards and accrual methods for inventory depreciation provisions

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Assets held for sale

 Recognition criteria and accounting treatment methods for non-current assets or disposal groups classified as held for sale

Non-current assets or disposal groups that meet the following conditions simultaneously are recognized as assets held for sale:

According to the practice of selling such assets or disposal groups in similar transactions, they can be sold immediately under the current conditions;
The sale is very likely to occur, that is, the company has made a resolution on a sale plan and obtained a firm purchase commitment, and the sale is expected to be completed within one year. Relevant regulations require the company's relevant authorities or regulatory authorities to obtain approval before sale, and the approval has been obtained.

A firm purchase commitment refers to a legally binding purchase agreement signed between the company and other parties. The agreement contains important terms such as transaction price, time and sufficiently severe penalties for breach of contract, making the possibility of major adjustments or cancellation of the agreement extremely small.

 Measurement of non-current assets or disposal groups held for sale

When the company initially measures or re-measures non-current assets or disposal groups held for sale on the balance sheet date, if its book value is higher than the net amount of fair value minus selling expenses, the book value will be written down to the net amount of fair value minus selling expenses. The amount of the write-down is recognized as asset impairment loss and included in the current profit and loss, and at the same time, provision for impairment of assets held for sale is made.

For non-current assets or disposal groups that are classified as held for sale on the acquisition date, the company will compare the initial measurement amount and the net amount of fair value less selling expenses if it is not classified as held for sale during initial measurement, and measure the lower of the two. Except for non-current assets or disposal groups acquired in company mergers, the difference arising from the initial measurement amount of non-current assets or disposal groups using the net amount after the fair value minus selling expenses is included in the current profit and loss.

When the company remeasures the disposal group held for sale on the balance sheet date, it first measures the book value of the assets and liabilities in the disposal group in accordance with relevant accounting standards, and then performs accounting treatment in accordance with the provisions of the previous paragraph.

For the amount of asset impairment loss recognized by the disposal group held for sale, the book value of the goodwill in the disposal group will first be deducted, and then the book value of the non-current assets in the disposal group will be deducted in proportion according to the proportion of the book value of each non-current asset measured under the applicable standards in the disposal group.

If the net amount of the fair value of non-current assets held for sale less selling expenses increases on subsequent balance sheet dates, the previously written-down amount will be restored and reversed within the amount of asset impairment losses recognized after being classified as held-for-sale, and the reversed amount will be included in the current profit and loss. Impairment losses on assets recognized before they are classified as held for sale cannot be reversed.

If the net amount of the fair value of the disposal group held for sale less selling expenses increases on the subsequent balance sheet date, the previously written-down amount will be restored and reversed within the amount of asset impairment losses recognized for non-current assets that are classified as held-for-sale according to the measurement provisions of applicable standards, and the reversed amount will be included in the current profit and loss. The book value of goodwill that has been deducted, as well as the asset impairment losses recognized before the non-current assets are classified as held for sale according to the measurement requirements of applicable standards, shall not be reversed.

The subsequent reversal amount of asset impairment losses recognized by the disposal group held for sale shall be increased proportionally to the book value of the non-current assets in the disposal group based on the proportion of the book value of each non-current asset measured under applicable standards except goodwill.

No depreciation or amortization is provided for non-current assets held for sale or non-current assets in the disposal group, and interest and other expenses on liabilities in the disposal group held for sale continue to be recognized.

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

When a non-current asset or disposal group is no longer classified as a held-for-sale category because it no longer meets the conditions for classification into the held-for-sale category or the non-current asset is removed from the held-for-sale disposal group, it shall be measured according to the lower of the following two:

The book value before being classified as held for sale, adjusted for the depreciation, amortization or impairment that would have been recognized had it not been classified as held for sale;
Recoverable amount.

When the company terminates the recognition of non-current assets or disposal groups held for sale, the unrecognized gains or losses will be included in the current profits and losses.

 Recognition standards and presentation methods for discontinued operations

Discontinued operations refer to an individually distinguishable component that meets one of the following conditions, and the component has been disposed of or classified as held for sale: 1) The component represents an independent major business or a separate major operating region;

The component is part of a related plan to dispose of an independent main business or a separate main operating area; 3) The component is a subsidiary acquired specifically for resale.

The profit and loss from continuing operations and the profit and loss from discontinued operations are presented separately in the income statement. For discontinued operations reported in the current period, the company will re-present the information originally presented as profits and losses from continuing operations as profits and losses from discontinued operations in the comparable accounting period in the current financial statements. If the discontinued operations no longer meet the conditions for classification into held-for-sale categories, the company will re-present the information originally presented as profits and losses from discontinued operations as profits and losses from continuing operations in the comparable accounting period in the current financial statements.

Debt investment
Other debt investments
Long-term receivables
Long-term equity investment

 Judgment criteria for joint control and significant influence

Shared control over an arrangement in accordance with relevant agreements, and the relevant activities of the arrangement must be decided with the unanimous consent of the parties sharing control rights, is deemed to be joint control. If a combination of two or more parties can collectively control an arrangement, it will not be regarded as joint control.

If the investor has the power to participate in decision-making on the financial and operating policies of the investee but is unable to control or jointly control the formulation of these policies with other parties, it is deemed to have significant influence on the investee.

 Initial investment cost determination

For long-term equity investments formed by business combinations, the initial investment cost shall be recognized in accordance with the relevant contents of this note "3.5 Accounting treatment methods for business combinations under the same control and not under the same control"; except for long-term equity investments formed by business combinations, the initial investment costs of long-term equity investments obtained in other ways shall be recognized according to the following method:

For long-term equity investments obtained by paying cash, the actual purchase price paid shall be regarded as the initial investment cost. Initial investment costs include fees, taxes and other necessary expenses directly related to obtaining long-term equity investment.
For long-term equity investments obtained by issuing equity securities, the initial investment cost shall be based on the fair value of the equity securities issued. Expenses directly related to the issuance of equity securities shall be determined in accordance with the relevant provisions of "Accounting Standards for Business Enterprises No. 37 - Presentation of Financial Instruments".

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Under the premise that the non-monetary asset exchange has commercial substance and the fair value of the assets exchanged or the assets exchanged can be measured reliably, the initial investment cost of the long-term equity investment exchanged in the non-monetary asset exchange shall be based on the fair value of the assets exchanged, unless there is conclusive evidence that the fair value of the assets exchanged is more reliable; for non-monetary asset exchanges that do not meet the above premise, the book value of the assets exchanged and the relevant taxes payable shall be used as the initial investment cost of the long-term equity investment exchanged.
For long-term equity investments obtained through debt restructuring, the initial investment cost is determined based on fair value.

 Subsequent measurement and profit and loss recognition methods

Subsequent measurement using cost method

The long-term equity investment that the company can control over the invested unit is accounted for using the cost method, and the long-term equity investment is valued according to the initial investment cost. Additional or withdrawn investments adjust the cost of long-term equity investments. Cash dividends or profits declared by the investee to be distributed shall be recognized as investment income for the current period.

Subsequent measurement of equity method

The company uses the equity method to account for its long-term equity investments in associates and joint ventures. If the initial investment cost of the long-term equity investment is greater than the fair value share of the investee's identifiable net assets at the time of investment, the initial investment cost of the long-term equity investment will not be adjusted; if the initial investment cost of the long-term equity investment is less than the fair value share of the investee's identifiable net assets at the time of investment, the difference will be included in the current profit and loss, and the cost of the long-term equity investment will be adjusted at the same time.

When accounting using the equity method, after the investor obtains the long-term equity investment, it shall recognize investment income and other comprehensive income respectively according to its share of the net profit or loss and other comprehensive income realized by the invested unit, and at the same time adjust the book value of the long-term equity investment; The portion of profits or cash dividends that are reported to be distributed is calculated and the book value of the long-term equity investment is reduced accordingly; for other changes in the owner's equity of the invested unit other than net profit and loss, other comprehensive income and profit distribution, the investor adjusts the book value of the long-term equity investment and includes it in the owner's equity. When an investor confirms its share of the investee's net profits and losses, it shall adjust and confirm the net profit of the investee based on the fair value of the investee's identifiable net assets at the time of acquisition of the investment. If the accounting policies and accounting periods adopted by the invested unit are inconsistent with those of the investor, the financial statements of the invested unit shall be adjusted in accordance with the accounting policies and accounting periods of the investor, and investment income and other comprehensive income shall be recognized accordingly.

The investor recognizes the net loss incurred by the invested unit to the extent that the book value of the long-term equity investment and other long-term interests that essentially constitute the net investment in the invested unit are reduced to zero, unless the investor has the obligation to bear additional losses. If the invested unit realizes net profits in the future, the investor will resume recognition of the income sharing amount after its income sharing amount makes up for the unrecognized loss sharing amount.

When an investor calculates and confirms that it should enjoy or share the net profits and losses of the investee, the unrealized internal transaction profits and losses that occur with associates and joint ventures are calculated and attributed to the investor in proportion to their share, and are offset, and investment income is recognized on this basis. If the unrealized internal transaction losses between the investor and the investee are asset impairment losses in accordance with the relevant provisions of "Accounting Standards for Business Enterprises No. 8 - Asset Impairment" and other relevant provisions, the full amount shall be recognized.

Part of an investor's equity investment in an associated enterprise is indirectly held through venture capital institutions, mutual funds, trust companies or similar entities including investment-linked insurance funds. Regardless of whether the above entities have a significant impact on this part of the investment, the investor will, in accordance with the relevant provisions of the financial instrument policy, choose to measure the indirectly held investment at fair value through profit and loss, and use the equity method to account for the remaining part. (Note: When describing this policy, you should understand whether the company's relevant policies are consistent with the template policy)

Treatment that can exert significant influence on the investee or implement joint control due to additional investment or other reasons but does not constitute control

The sum of the fair value of the originally held equity investment and the new investment cost determined in accordance with the "Accounting Standards for Business Enterprises No. 22 - Recognition and Measurement of Financial Instruments" shall be regarded as the initial investment cost calculated according to the equity method. The equity investment originally held is designated as a non-trading investment at fair value through other comprehensive income.

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

For investments in tradable equity instruments, the difference between their fair value and book value, as well as the cumulative changes in fair value originally included in other comprehensive income, are transferred to retained earnings when accounting is changed to the equity method.

Disposal of partial equity

If the joint control or significant influence on the invested unit is lost due to the disposal of part of the equity investment or other reasons, the remaining equity after disposal shall be accounted according to the policy of "Financial Instruments" in this note, and the difference between its fair value and the book value on the date of loss of joint control or significant influence shall be included in the current profit and loss. Other comprehensive income recognized as a result of the original equity investment being accounted for using the equity method will be accounted for on the same basis as if the investee directly disposed of relevant assets or liabilities when the equity method is terminated.

If the control over the invested unit is lost due to the disposal of part of the equity investment or other reasons, when preparing individual financial statements, if the remaining equity after the disposal can jointly control or exert significant influence on the invested unit, it shall be accounted for according to the equity method, and the remaining equity shall be deemed to have been adopted from the time of acquisition. Adjustments will be made to equity method accounting; if the remaining equity after disposal cannot jointly control or exert significant influence on the invested unit, accounting treatment will be carried out in accordance with the relevant policies of "Financial Instruments" in this note, and the difference between its fair value and book value on the date of loss of control shall be included in the current profit and loss. When preparing consolidated financial statements, follow the relevant content of this note "Preparation Method of Consolidated Financial Statements".

Treatment of all or part of equity investments in associates or joint ventures classified as assets held for sale

Equity investments in associates or joint ventures that are classified as assets held for sale are listed at the lower of the book value and the fair value minus disposal costs. The amount of the fair value minus the disposal costs that is lower than the original book value is recognized as an asset impairment loss. For remaining equity investments that are not classified as assets held for sale, the equity method is used for accounting treatment. If an equity investment in an associate or joint venture that has been classified as held for sale no longer meets the classification conditions for assets held for sale, it will be retrospectively adjusted using the equity method from the date it is classified as an asset held for sale. The financial statements during the period classified as held for sale are adjusted accordingly.

Disposal of long-term equity investments

When a long-term equity investment is disposed of, the difference between its book value and the actual price obtained shall be included in the current profit and loss. When disposing of a long-term equity investment accounted for using the equity method, the same basis as the investee's direct disposal of relevant assets or liabilities will be used, and the portion originally included in other comprehensive income will be accounted for in a corresponding proportion.

Investment real estate

Investment real estate measurement model

Cost method measurement

Depreciation or amortization method

Investment real estate includes land use rights that are held for rent and are ready to be transferred after appreciation in value, as well as leased buildings, which are initially measured at actual cost. Subsequent expenditures related to investment real estate will be included in the cost of investment real estate when the relevant economic benefits are likely to flow into the company and its cost can be measured reliably; otherwise, they will be included in the current profit and loss when incurred.

The Company adopts the cost model for subsequent measurement of all investment real estate, and provides depreciation or amortization for buildings and land use rights based on their estimated useful lives and net residual value rates. The estimated service life, net residual value rate and annual depreciation (amortization) rate of investment properties are as follows:

Category Estimated service life (years) Estimated net residual value rate (%) Annual depreciation (amortization) rate (%) Houses and buildings 30 5.00 3.17

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Fixed assets

(1) Confirmation conditions

Fixed assets refer to tangible assets held for the production of goods, provision of labor services, leasing or operation and management, and with a useful life of more than one accounting year. Fixed assets can only be recognized if they meet the following conditions at the same time:

The economic benefits related to the fixed asset are likely to flow into the enterprise;
The cost of the fixed asset can be measured reliably.

(2) Depreciation method

Category Depreciation method Depreciation period Residual value rate Annual depreciation rate Houses and buildings Year-average method 20-30 5.00 3.17-4.75

Special equipment Average age method 5-10 5.00 9.50-19.00

Machinery and equipment Average age method 10 5.00 9.50

Transportation equipment Average age method 5 5.00 19.00

Office and other equipment Average age method 5 5.00 19.00

Projects under construction

Construction in progress is measured based on actual costs incurred. Actual costs include construction costs, other necessary expenses incurred to bring the project under construction to its intended usable state, and borrowing costs that meet the capitalization conditions incurred before the asset reaches its intended usable state. When the construction in progress reaches the intended usable state, it will be transferred to fixed assets and depreciation will be accrued from the next month.

Borrowing costs

Borrowing costs incurred that are directly attributable to the purchase and construction of fixed assets that require a considerable period of time to reach the intended usable state shall be capitalized and included in the cost of the asset when the asset expenditures and borrowing costs have been incurred and the purchase and construction activities necessary to bring the asset to the intended usable state have begun. Capitalization stops when the assets purchased and constructed reach the intended usable condition, and the borrowing costs incurred thereafter are included in the current profits and losses. If the asset acquisition and construction activities are interrupted abnormally and the interruption lasts for more than 3 months, the capitalization of borrowing costs will be suspended until the asset acquisition and construction activities restart.

During the capitalization period, the amount of interest that should be capitalized on special borrowings (referring to the amount borrowed specifically for the purpose of purchasing, constructing or producing assets that meet the capitalization conditions) is determined based on the interest expenses actually incurred on the special borrowings in the current period, minus the interest income from depositing unused borrowed funds in banks or investment income from temporary investments; for general borrowings, the interest amount that should be capitalized is calculated and determined based on the weighted average of asset disbursements that exceed the part of the accumulated asset disbursements that exceed the special borrowing multiplied by the capitalization rate of the occupied general borrowings. The capitalization rate is calculated and determined based on the weighted average interest rate of general borrowings.

If there is a discount or premium on the loan, the amount of discount or premium that should be amortized in each accounting period shall be determined according to the actual interest rate method, and the interest amount of each period shall be adjusted.

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Biological assets
Oil and gas assets
Intangible assets

(1) Useful life and its basis for determination, estimation, amortization method or review procedure

Intangible assets include land use rights, software, patents and non-patented technologies. Intangible assets are measured at actual cost.

The land use rights are amortized on an average basis over a useful life of 50 years. If the price of purchased land and buildings cannot be reasonably allocated between the land use rights and the buildings, all of them shall be treated as fixed assets.

The estimated useful life and amortization method of intangible assets with limited service life are reviewed at the end of each year and appropriate adjustments are made.

(2) Scope of aggregation of R&D expenditures and related accounting treatment methods

According to the nature of internal research and development project expenditures and whether there is great uncertainty in the eventual formation of intangible assets from R&D activities, they are divided into research stage expenditures and development stage expenditures.

Expenditures in the research stage shall be included in the current profit and loss when incurred; expenditures in the development stage shall be recognized as intangible assets if they meet the following conditions:

It is technically feasible to complete the intangible asset so that it can be used or sold;
The management has the intention to complete the intangible asset and use or sell it;
Be able to prove how the intangible asset will generate economic benefits;
Have sufficient technical, financial and other resource support to complete the development of the intangible asset and have the ability to use or sell the intangible asset; 5) Expenditures attributable to the development stage of the intangible asset can be measured reliably.

Expenditures in the development phase that do not meet the above conditions are included in the current profits and losses when incurred. Development expenditures that have been included in profits and losses in the previous period will not be recognized as assets in subsequent periods. Capitalized expenditures in the development phase are listed as development expenditures on the balance sheet and are converted into intangible assets from the date the project reaches its intended usable state.

When the recoverable amount of development expenditure is lower than its carrying amount, the carrying amount is written down to the recoverable amount.

Impairment of long-term assets

Goodwill and intangible assets with indefinite useful lives that are separately presented in the financial statements shall be tested for impairment at least annually regardless of whether there is any indication of impairment. Fixed assets, intangible assets, investment real estate measured using the cost model and long-term equity investments, etc., are subject to impairment testing if there are signs of impairment on the balance sheet date. If the impairment test results show that the recoverable amount of the asset is lower than its book value, impairment provisions will be made based on the difference and included in the impairment loss. The recoverable amount is the higher of the asset's fair value less disposal costs and the present value of the asset's expected future cash flows. Asset impairment provisions are calculated and recognized on the basis of individual assets. If it is difficult to estimate the recoverable amount of an individual asset, the recoverable amount of the asset group to which the asset belongs is determined. An asset group is the smallest combination of assets that can independently generate cash inflows. Once the aforementioned asset impairment loss is recognized, it will not be reversed if the value is restored in subsequent periods.

Long-term deferred expenses

Long-term deferred expenses are expenses that have been incurred but should be borne by the current reporting period and subsequent periods with an amortization period of more than one year. Long-term deferred expenses are amortized on a straight-line basis over the expected benefit period.

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Contract liabilities

The Company presents contract assets or contract liabilities in the balance sheet based on the relationship between performance obligations and customer payments.

The Company and its subsidiaries present obligations to transfer goods to customers for consideration received or receivable from customers as contract liabilities, such as payments received by an enterprise before transferring promised goods.

Employee compensation

(1) Accounting treatment method for short-term compensation

During the accounting period when employees provide services to the company, the actual short-term compensation is recognized as a liability and included in the current profit and loss or related asset costs. Employee welfare expenses incurred shall be included in the current profit and loss or related asset costs according to the actual amount when they are actually incurred. If employee benefits are non-monetary benefits, they are measured at fair value. Social insurance premiums such as medical insurance premiums, work-related injury insurance premiums, maternity insurance premiums, and housing provident funds paid for employees, as well as labor union funds and employee education funds withdrawn in accordance with regulations, during the accounting period when employees provide services to the company, the corresponding employee salary amounts are calculated and determined based on the prescribed accrual basis and accrual ratio, and the corresponding liabilities are recognized and included in the current profit and loss or related asset costs.

When an employee provides services that increase his or her future paid absence rights, employee benefits related to accumulated paid absences are recognized and measured based on the expected increase in payment amount due to accumulated unexercised rights. Employee benefits related to non-cumulative paid absences are recognized during the accounting period in which employees are actually absent.

When the profit sharing plan meets the following conditions at the same time, the company will confirm the relevant employee benefits payable:

The current legal or constructive obligation to pay employee remuneration due to past events;
The amount of employee compensation obligations payable due to the profit sharing plan can be estimated reliably.

(2) Accounting treatment of post-employment benefits

Set up a withdrawal plan

During the accounting period when employees provide services to them, the company will recognize the deposit amount payable calculated according to the defined contribution plan as a liability and include it in the current profit and loss or related asset costs. According to the defined contribution plan, if the entire payable deposit amount is not expected to be paid within twelve months after the end of the annual reporting period in which the employee provides relevant services, the company will measure the entire payable deposit amount as the discounted amount to measure the employee benefits payable.

Defined benefit plan

The company's accounting treatment of defined benefit plans includes the following four steps:

① Based on the expected cumulative benefit unit method, use unbiased and mutually consistent actuarial assumptions to estimate relevant demographic variables and financial variables, measure the obligations arising from the defined benefit plan, and determine the vesting period of the relevant obligations. The company discounts the obligations arising from the defined benefit plan to determine the present value of the defined benefit plan obligations and the current service cost.

② If there are assets in the defined benefit plan, the company will recognize the deficit or surplus formed by the present value of the defined benefit plan obligations minus the fair value of the defined benefit plan assets as a net liability or net asset of the defined benefit plan. If there is a surplus in the defined benefit plan, the company shall measure the net assets of the defined benefit plan at the lower of the surplus of the defined benefit plan and the upper asset limit.

③ Determine the amount that should be included in the current profit and loss.

④ Determine the amount that should be included in other comprehensive income.

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

The company attributes the welfare obligations arising from the defined benefit plan to the period in which employees provide services based on the formula determined by the expected cumulative welfare unit method, and includes them in the current profits and losses or related asset costs. When an employee's service in subsequent years will result in a significantly higher level of defined benefit plan benefits than in previous years, the accumulated defined benefit plan obligations will be apportioned and recognized using the straight-line method from the period when the employee's provision of services results in the company's first defined benefit plan welfare obligation to the time when the employee's provision of services no longer results in a significant increase in the welfare obligation.

At the end of the reporting period, the company recognizes the employee compensation costs generated by the defined benefit plan as: service costs, net interest on the net liabilities or net assets of the defined benefit plan, and changes caused by re-measurement of the net liabilities or net assets of the defined benefit plan.

Under the defined benefit plan, the company recognizes past service costs as current expenses on the earliest of the following dates:

When modifying the defined benefit plan.
When the enterprise confirms relevant restructuring expenses or dismissal benefits.

The company recognizes a settlement gain or loss when settling the defined benefit plan.

(3) Accounting treatment method for dismissal benefits

If the company provides dismissal benefits to employees, the employee compensation liabilities arising from the dismissal benefits will be recognized at the earliest of the following two times, and included in the current profit and loss:

The company cannot unilaterally withdraw the dismissal benefits provided due to the labor relationship termination plan or layoff proposal.
When the company recognizes costs or expenses related to restructuring involving payment of termination benefits.

In accordance with the provisions of the dismissal plan, the company reasonably estimates and confirms the employee benefits payable arising from dismissal benefits.

(4) Accounting treatment methods for other long-term employee benefits

Other long-term employee benefits provided by the company to employees that meet the conditions of the defined contribution plan shall be handled in accordance with the relevant policies on defined contribution plans. Except for the above circumstances, the company recognizes and measures other long-term employee welfare net liabilities or net assets in accordance with the relevant policies on defined benefit plans. At the end of the reporting period, employee compensation costs arising from other long-term employee benefits are recognized as the following components:

Service cost.
Net interest on other long-term employee benefits net liabilities or net assets.
Changes caused by re-measurement of other long-term employee benefit net liabilities or net assets.

In order to simplify the relevant accounting treatment, the total net amount of the above items should be included in the current profit and loss or related asset costs.

If the level of long-term disability benefits depends on the length of the employee's service period, the company shall confirm the obligation to pay long-term disability benefits during the period during which the employee provides services; if the long-term disability benefits have nothing to do with the length of the employee's service period, the company shall confirm the obligation to pay long-term disability benefits in the current period when the event causing the employee's long-term disability occurs.

Estimated liabilities

For current obligations arising from product quality guarantees, loss-making contracts, etc., the performance of which is likely to result in an outflow of economic benefits, when the amount of the obligation can be measured reliably, is recognized as a provision. For future operating losses, no estimated liabilities are recognized.

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Estimated liabilities are initially measured based on the best estimate of the expenditure required to fulfill the relevant current obligations, and factors such as risks, uncertainties, and time value of money related to contingencies are comprehensively considered. If the time value of money has a significant impact, the best estimate is determined by discounting the relevant future cash outflows; the increase in the book value of estimated liabilities caused by the discount reduction over time is recognized as interest expense.

On the balance sheet date, the book value of estimated liabilities is reviewed and appropriately adjusted to reflect the current best estimate.

Share-based payment

 Types of share-based payments

According to the settlement method, it is divided into equity-settled share-based payment involving employees and cash-settled share-based payment involving employees.

 Determination method of fair value of equity instruments

For shares granted to employees, their fair value is measured based on the market price of the company's shares, and adjusted by taking into account the terms and conditions on which the shares are granted (excluding vesting conditions other than market conditions). For stock options granted to employees, the fair value of the options granted is estimated through an option pricing model.

 Basis for confirming the best estimate of exercisable equity instruments

On each balance sheet date during the waiting period, the company makes its best estimate based on the latest changes in the number of vested employees and other subsequent information, and corrects the number of equity instruments expected to be vested.

 Accounting treatments related to the implementation, modification, and termination of share-based payment plans

Equity-settled share-based payments involving employees, if vested immediately after grant, are included in costs and expenses and capital reserves based on the fair value of the equity instruments on the date of grant; if vesting is subject to completion of services within the waiting period or meeting specified performance conditions after grant, on each balance sheet date during the waiting period, based on the best estimate of the number of exercisable equity instruments, based on the fair value of the equity instrument on the date of grant, the services obtained in the current period are included in relevant costs or expenses and capital reserves.

Share-based payments involving employees settled in cash and exercisable immediately after grant shall be included in the relevant costs or expenses and corresponding liabilities based on the fair value of the liabilities borne by the company on the date of grant; if the vesting is subject to completion of services during the waiting period or meeting specified performance conditions after the grant, on each balance sheet date during the waiting period, based on the best estimate of the vesting situation and based on the fair value of the liabilities borne by the company, the services obtained in the current period shall be included in the relevant costs or expenses and corresponding liabilities based on the fair value of the liabilities borne by the company.

Preferred shares, perpetual bonds and other financial instruments

 Preferred shares

In accordance with the provisions of the Financial Instrument Standards, the Company classifies preferred shares as financial assets, financial liabilities or equity instruments upon initial recognition based on the terms of the contract for the issuance of preferred shares and the economic substance reflected in them rather than just the legal form, combined with the definitions of financial assets, financial liabilities and equity instruments. If the following conditions are met at the same time, the company will classify the financial instruments issued as equity instruments: (1) The financial instrument does not include the contractual obligation to deliver cash or other financial assets to other parties, or to exchange financial assets or financial liabilities with other parties under potentially adverse conditions; (2) If the financial instrument must or can be settled with the enterprise's own equity instruments in the future, if the financial instrument

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

The instrument is a non-derivative instrument and does not include the contractual obligation to deliver a variable number of its own equity instruments for settlement; if it is a derivative instrument, the financial instrument can only be settled by exchanging a fixed number of its own equity instruments for a fixed amount of cash or other financial assets.

 Perpetual bonds

Based on the contractual terms of the perpetual bonds issued and the economic essence reflected in them, combined with the definitions of financial assets, financial liabilities and equity instruments, the Company classifies these financial instruments or their components as financial assets, financial liabilities or equity instruments upon initial recognition.

The perpetual bonds issued by the company that should be classified as equity instruments are included in equity based on the actual amount received. If dividends or interest are distributed during the existence period, they will be treated as profit distribution. If the perpetual bonds are redeemed according to the terms of the contract, the equity will be offset at the redemption price.

Income

Disclose accounting policies adopted for revenue recognition and measurement by business type

General principles for revenue recognition and measurement of each business type

On the contract commencement date, the Company evaluates the contract, identifies each individual performance obligation contained in the contract, and determines whether each individual performance obligation is to be performed within a certain period of time or at a certain point in time.

When one of the following conditions is met, the performance obligation is performed within a certain period of time; otherwise, the performance obligation is performed at a certain point in time:

① When the company performs the contract, the customer obtains and consumes the economic benefits brought by the company's performance of the contract.

②Customers can control the goods or services under construction during the performance of the contract by the company.

③The goods or services produced by the company during the performance of the contract have irreplaceable uses, and the company has the right to collect payment for the cumulative performance part completed so far during the entire contract period.

For performance obligations performed within a certain period of time, the Company recognizes revenue based on the performance progress within that period of time. When the progress of contract performance cannot be reasonably determined, if the costs incurred are expected to be compensated, revenue shall be recognized based on the amount of costs incurred until the progress of contract performance can be reasonably determined.

For performance obligations fulfilled at a certain point in time, revenue is recognized at the point when the customer obtains control of the relevant goods or services. When judging whether the customer has obtained control of the goods, the company considers the following signs:

① The company has the current right to receive payment for the product, that is, the customer has the current payment obligation for the product.

②The company has transferred the legal ownership of the product to the customer, which means that the customer already has the legal ownership of the product.

③The company has physically transferred the commodity to the customer, which means that the customer has physically taken possession of the commodity.

④ The company has transferred the main risks and rewards of ownership of the commodity to the customer, that is, the customer has obtained the main risks and rewards of ownership of the commodity. ⑤The customer has accepted the product.

⑥Other indications that the customer has obtained control of the product.

Income measurement principles

The Company measures revenue based on the transaction price allocated to each individual performance obligation. The transaction price is the amount of consideration that the Company expects to be entitled to receive for transferring goods or services to the customer, excluding amounts collected on behalf of third parties and amounts expected to be returned to the customer.

If there is variable consideration in the contract, the company determines the best estimate of the variable consideration based on the expected value or the most likely amount, but the transaction price including the variable consideration shall not exceed the amount at which a significant reversal of the cumulative recognized revenue is unlikely to occur when the relevant uncertainty is eliminated.

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

If there is a significant financing component in the contract, the company determines the transaction price based on the amount payable in cash when the customer obtains control of the goods or services. The difference between the transaction price and the contract consideration is amortized using the effective interest method during the contract period. On the start date of the contract, if the Company expects that the interval between the customer obtaining control of the goods or services and the customer paying the price will not exceed one year, the significant financing component in the contract will not be considered.

If the customer pays non-cash consideration, the company determines the transaction price based on the fair value of the non-cash consideration. If the fair value of the non-cash consideration cannot be reasonably estimated, the transaction price is determined indirectly by referring to the stand-alone selling price of the goods the company promises to transfer to the customer. If the fair value of non-cash consideration changes due to reasons other than the form of consideration, it is treated as variable consideration.

If the Company pays consideration to customers (or third parties who purchase the Company's goods from customers), the consideration payable will be deducted from the transaction price, and the current revenue will be deducted at the later point between the recognition of relevant income and the payment (or commitment to pay) of the customer consideration, unless the consideration payable to the customer is for the purpose of obtaining other clearly distinguishable goods from the customer.

If the contract contains two or more performance obligations, the company will allocate the transaction price to each individual performance obligation based on the relative proportion of the stand-alone selling price of the goods promised by each individual performance obligation on the contract commencement date.

For sales with a sales return clause, when the customer obtains control of the relevant goods, the company recognizes revenue based on the amount of consideration that it is expected to be entitled to for transferring the goods to the customer, and recognizes it as an estimated liability based on the amount that is expected to be refunded due to sales return; at the same time, according to the amount expected to be returned The book value of the goods at the time of transfer, after deducting the expected costs of recovering the goods (including the value impairment of the returned goods), is recognized as an asset, that is, the return cost receivable. The book value of the transferred goods at the time of transfer is the net carry-over cost after deducting the cost of the above assets. On each balance sheet date, the company re-estimates future sales returns and re-measures the above assets and liabilities.

In accordance with contract agreements, legal regulations, etc., the Company provides quality assurance for the goods sold or assets constructed. For guarantee-type quality assurance to ensure that the goods sold meet established standards, the Company conducts accounting treatment in accordance with the "Accounting Standards for Business Enterprises No. 13 - Contingencies". For service-type quality assurance that provides a separate service to customers in addition to ensuring that the goods sold meet established standards, the company treats it as a single performance obligation and allocates part of the transaction price to the service-type quality assurance based on the relative proportion of the separate selling price of the goods and service-type quality assurance provided, and recognizes revenue when the customer obtains control of the service. When assessing whether a quality guarantee provides a separate service to customers beyond the assurance that the goods sold meet established standards, the Company considers factors such as whether the quality guarantee is a statutory requirement, the duration of the quality guarantee and the nature of the tasks to which the Company undertakes to perform.

The company has the right to independently determine the price of the goods traded, that is, the company can control the goods and other products before transferring them to customers, then the company is the main responsible person and recognizes revenue based on the total consideration received or receivable. Otherwise, the company acts as an agent and recognizes revenue based on the amount of commissions or fees that it is expected to be entitled to receive. This amount should be recognized based on the net amount of the total consideration received or receivable after deducting the price payable to other related parties, or based on the established commission amount or ratio, etc.

Similar business adopts different business models and involves different revenue recognition methods and measurement methods.

Sales of permanent magnet switches

The company sells permanent magnet switches to external parties. According to the contract, the product is shipped to the location designated by the customer. The customer receives and accepts the goods. If the payment has been recovered or the payment receipt has been obtained and the relevant economic benefits are likely to flow in, the main risks and rewards of product ownership have been transferred, and the legal ownership of the product has been transferred, the company will recognize the realization of operating income.

Sales of complete sets of high and low voltage switch equipment

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

The company sells complete sets of high- and low-voltage switch equipment. According to the contract, the products are shipped to the customer's designated location and accepted for acceptance. At the same time, the products are installed and debugged. After the installation and debugging are completed and run stably for a certain period of time, the customer issues a performance acceptance form. The payment for the goods has been recovered or the receipt of payment has been obtained and the relevant economic benefits are likely to flow in. The main risks and rewards of the ownership of the goods have been transferred, and the legal ownership of the product has been transferred. The company will then confirm the realization of operating income. 3) Dental service income is recognized according to the treatment progress during the service cycle of each business. The timing of income recognition varies according to different diagnosis and treatment projects. The specific situation is as follows:

Treatment items Diagnosis and treatment stage Revenue recognition time point General practice Not divided into stages Treatment completed

Scheme design

Completed wearing of braces

Wearing braces

Orthodontics: Traditional orthodontics are confirmed on a one-by-one basis; invisible orthodontics are on a cumulative follow-up basis

Confirmation of the proportion of braces consumed

Wearing the retainer Complete wearing the retainer

Scheme design

Complete implant placement surgery

Implant implant placement

Wearing a dental crown Complete wearing a dental crown

Similar business adopts different business models and involves different revenue recognition methods and measurement methods.

Contract costs

Contract costs are divided into contract performance costs and contract acquisition costs.

The costs incurred by the company to perform the contract are recognized as an asset as contract performance costs when the following conditions are met:

(1) The cost is directly related to a current or expected contract;

(2) This cost increases the company’s resources for fulfilling performance obligations in the future;

(3) The cost is expected to be recovered.

The incremental costs incurred by the Company to obtain the contract are expected to be recovered and are recognized as an asset as the contract acquisition cost.

Assets related to contract costs are amortized on the same basis as the revenue recognition of goods or services related to the assets; however, if the amortization period of the contract acquisition costs does not exceed one year, the company will include them in the current profits and losses when incurred.

If the book value of assets related to contract costs is higher than the difference between the following two items, the company will make impairment provisions for the excess and recognize it as asset impairment losses:

(1) The remaining consideration expected to be obtained from the transfer of goods or services related to the asset;

(2) The estimated cost to be incurred in transferring the relevant goods or services.

If the above-mentioned asset impairment provision is subsequently reversed, the book value of the asset after the reversal shall not exceed the book value of the asset on the date of reversal if no impairment provision was made.

Government subsidies

 Judgment basis and accounting treatment method for government subsidies related to assets

Government subsidies related to assets are offset against the book value of the relevant assets or recognized as deferred income. If government subsidies related to assets are recognized as deferred income, they shall be included in profits and losses in installments according to a reasonable and systematic method within the useful life of the relevant assets. Government subsidies measured according to the nominal amount are directly included in the current profit and loss.

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

If the relevant assets are sold, transferred, scrapped or damaged before the end of their useful life, the undistributed balance of relevant deferred income shall be transferred to the profits and losses of the current period of asset disposal.

 Judgment basis and accounting treatment method for government subsidies related to income

If it is used to compensate the enterprise for relevant costs, expenses or losses in the future period, it is recognized as deferred income, and during the period when the relevant costs, expenses or losses are recognized, it is included in the current profit and loss or offsets the relevant costs; if it is used to compensate the enterprise for the relevant costs, expenses or losses that have already occurred, it is directly included in the current profits and losses or offsets the relevant costs.

 Government subsidies that include both asset-related parts and income-related parts

For government subsidies that contain both asset-related parts and income-related parts, different parts should be distinguished and accounted for separately; if it is difficult to distinguish, they should be classified as a whole as income-related government subsidies.

 Accounting of government subsidies in the income statement

Government subsidies related to the daily activities of the enterprise shall be included in other income or offset relevant costs and expenses according to the economic business essence. Government subsidies that have nothing to do with the daily activities of the enterprise shall be included in non-operating income and expenses.

 Handling of government subsidy returns

If the confirmed government subsidies need to be returned, accounting treatment will be carried out in accordance with the following provisions in the current period in which they need to be returned:

If the book value of related assets is offset upon initial recognition, the book value of the assets will be adjusted;

If there is relevant deferred income, the book balance of the relevant deferred income will be offset, and the excess will be included in the current profit and loss;

If it falls under other circumstances, it will be directly included in the current profit and loss.

 Handling of policy-based preferential loan interest discounts

If the finance department allocates interest discount funds to the lending bank, and the lending bank provides loans to the enterprise at policy preferential interest rates, the accounting treatment is as follows: the actual loan amount received is used as the entry value of the loan, and the relevant borrowing costs are calculated based on the loan principal and the policy preferential interest rate.

The finance department will directly allocate interest subsidy funds to enterprises, and enterprises should use the corresponding interest subsidy to offset related borrowing costs.

Deferred income tax assets/deferred income tax liabilities

Deferred income tax assets and deferred income tax liabilities are calculated and recognized based on the difference between the tax basis of assets and liabilities and their book value (including taxable temporary differences and deductible temporary differences). Deductible losses that can be offset against taxable income in subsequent years in accordance with tax laws are deemed to be deductible temporary differences. For temporary differences arising from the initial recognition of goodwill, no corresponding deferred income tax liabilities are recognized.

Except for individual transactions (including leasing transactions in which the lessee initially recognizes lease liabilities and includes them in the right-of-use assets at the beginning of the lease period, and transactions in which estimated liabilities are recognized and included in the cost of related assets due to the disposal obligation of fixed assets, etc.), for temporary differences arising from the initial recognition of assets or liabilities in other non-business combination transactions that neither affect accounting profits nor taxable income (or deductible losses), the corresponding deferred income tax assets and liabilities are not recognized.

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Deferred tax liabilities. For the taxable temporary differences and deductible temporary differences arising from the initial recognition of assets and liabilities in the aforementioned individual transactions, the corresponding deferred income tax liabilities and deferred income tax assets are recognized respectively when the transaction occurs.

On the balance sheet date, deferred income tax assets and deferred income tax liabilities are measured according to the applicable tax rate during the period when the asset is expected to be recovered or the liability is settled. Deferred income tax assets are recognized to the extent that the company is likely to obtain taxable income that can be used to offset deductible temporary differences, deductible losses and tax credits. Deferred income tax assets and deferred income tax liabilities arising from temporary differences related to investments in subsidiaries, associates and joint ventures are recognized. However, if the company is able to control the timing of the reversal of the temporary difference and the temporary difference is likely not to be reversed in the foreseeable future, it will not be recognized.

Leasing

(1) Accounting treatment method for leasing as lessee

Initial confirmation

The Company, as the lessee, recognizes right-of-use assets and lease liabilities for leases.

Lease changes

Lease changes refer to changes in the lease scope, lease consideration, and lease term beyond the terms of the original contract, including increasing or terminating the right to use one or more leased assets, extending or shortening the lease period stipulated in the contract, etc. The effective date of the lease change refers to the date when both parties agree on the lease change.

If a lease changes and the following conditions are met at the same time, the company will account for the lease change as a separate lease:

① The lease change expands the scope of the lease by adding the right to use one or more leased assets;

② The increased consideration is equivalent to the amount of the separate price of the expanded part of the lease scope adjusted according to the conditions of the contract.

The provisions of the spin-off allocate the consideration of the modified contract and re-determine the lease term after the modification; and use the revised discount rate to discount the modified lease payment to re-measure the lease liability. When calculating the present value of lease payments after the change, the Company uses the interest rate implicit in the lease during the remaining lease period as the discount rate; if the interest rate implicit in the lease during the remaining lease period cannot be determined, the Company uses the incremental borrowing rate of the lessee on the effective date of the lease change as the discount rate. Regarding the impact of the above lease liability adjustments, the Company distinguishes the following situations for accounting treatment:

① If the change in the lease results in a reduction in the scope of the lease or a shortening of the lease period, the lessee shall reduce the book value of the right-of-use asset and include the gains or losses related to the partial or complete termination of the lease into the current profits and losses.

② If other lease changes result in the remeasurement of lease liabilities, the lessee shall adjust the book value of the right-of-use assets accordingly.

Short-term leasing and leasing of low-value assets

For short-term leases with a lease term not exceeding 12 months and low-value asset leases with a lower value when the individual leased assets are new assets, the company chooses not to recognize right-of-use assets and lease liabilities. The company will include the lease payments of short-term leases and low-value asset leases into the relevant asset costs or current profits and losses according to the straight-line method or other systematic and reasonable methods during each period of the lease term.

(2) Accounting treatment method for leasing as lessor

On the lease commencement date, the Company divides leases into finance leases and operating leases.

If a lease transfers substantially all the risks and rewards associated with ownership of the leased asset, the lessor classifies the lease as a finance lease, and leases other than finance leases as operating leases.

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Accounting treatment of operating leases

During each period during the lease term, the Company uses the straight-line method or other systematic and reasonable methods to recognize the lease receipts from operating leases as rental income.

If a rent-free period is provided, the company will distribute the total rent on a straight-line basis throughout the entire lease period without deducting the rent-free period, and the rental income shall be recognized during the rent-free period. If the company bears certain expenses of the lessee, the expenses will be deducted from the total rental income, and the remaining rental income after deduction will be distributed during the lease period. The initial direct expenses incurred by the company related to the operating lease shall be capitalized to the cost of the leased asset, and included in the current profit and loss in installments during the lease term on the same recognition basis as rental income.

For fixed assets included in operating lease assets, the Company adopts the depreciation policy for similar assets to calculate depreciation; for other operating lease assets, a systematic and reasonable method is used for amortization.

Variable lease payments obtained by the company related to operating leases that are not included in the lease receipts are included in the current profit and loss when they actually occur. If an operating lease changes, the Company will account for it as a new lease starting from the effective date of the change, and the amount of lease receipts received in advance or receivable related to the lease before the change is regarded as the amount of receipts from the new lease.

Accounting treatment of financial lease

On the lease commencement date, the Company recognizes finance lease receivables for finance leases and terminates the recognition of finance lease assets. When the Company initially measures the financial lease receivables, it takes the net lease investment as the entry value of the financial lease receivables. The net investment in a lease is the sum of the unguaranteed residual value and the present value of the lease payments that have not yet been received at the start of the lease term, discounted at the interest rate implicit in the lease.

The Company calculates and recognizes interest income in each period during the lease term based on fixed periodic interest rates. Variable lease payments obtained by the Company that are not included in the measurement of net lease investment are included in the current profit and loss when actually incurred.

Other important accounting policies and accounting estimates
Changes in important accounting policies and accounting estimates

(1) Changes in important accounting policies

□Applicable Not applicable

(2) Changes in important accounting estimates

□Applicable Not applicable

(3) Adjustments to relevant items in the financial statements at the beginning of the year when the new accounting standards are first implemented starting from 2025.

□Applicable Not applicable

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Others

6. Taxes

Main tax types and tax rates

Type of tax Tax calculation basis Tax rate

Taxable value-added amount (taxable amount is based on taxable sales

The value-added tax amount is multiplied by the applicable tax rate and deducts 3.00%, 5.00%, 6.00%, and 13.00% of the allowable deductions for the current period.

Calculation of the balance after input tax)

Urban maintenance and construction tax The amount of turnover tax payable is 7.00% (see the explanation for the subsidiary's turnover tax rate discount) Corporate income tax Taxable income 25.00% (see the explanation for the subsidiary's income tax rate) Education fee surcharge The amount of turnover tax payable is 3.00% (see the explanation for the subsidiary's turnover tax rate discount) If there are taxpayers with different corporate income tax rates, a description of the disclosure

Name of tax payer Income tax rate

Tax incentives

(1) Jilin Yongda Electric Switch Co., Ltd. (hereinafter referred to as the "Switch Company"), a subsidiary of the company, was established on January 11, 2007. It is an enterprise established in the National High-tech Zone. On October 16, 2023, the company passed the review of high-tech enterprise qualifications and re-obtained the high-tech enterprise certificate for a period of three years. Therefore, the switch company’s income tax rate in 2023, 2024 and 2025 is 15%.

The switch company has been recognized as a social welfare enterprise for the placement of persons with disabilities since December 2009. According to the Ministry of Finance and the State Administration of Taxation's "Notice on Preferential Corporate Income Tax Policies Regarding the Employment of Disabled Persons" (Caishui [2009] No. 70), the switch company's corporate income tax can be deducted 100% from the wages of employees with disabilities. According to the Ministry of Finance and the State Administration of Taxation's "Notice on Preferential Value-Added Tax Policies for Promoting the Employment of Disabled Persons" (Cai Shui [2016] No. 52), switch companies enjoy a policy of instant refund of VAT upon collection. The specific limit of VAT refundable per disabled person per month shall be determined by the tax authorities at or above the county level based on four times the monthly minimum wage standard approved by the provincial (including autonomous regions, municipalities, and cities under separate state planning, the same below) applicable to the district and county where the taxpayer is located (including county-level cities and banners, the same below).

(2) In 2023, Guangzhou Delun Dental Clinic Co., Ltd. (hereinafter referred to as "Delun Dental"), a subsidiary of the company, passed the review of high-tech enterprise qualifications and re-obtained the high-tech enterprise certificate for a period of three years. Therefore, Delun Dental’s income tax rate in 2023, 2024 and 2025 is 15%.

(3) According to the "Provisions on the Transition Policy for the Pilot Program of Replacing Business Tax with Value-Added Tax" (Annex 3 of Finance and Taxation [2016] No. 36), medical services provided by medical institutions are exempt from VAT. The 29 subsidiaries of Guangdong Delun Medical Group Co., Ltd. (hereinafter referred to as "Delun Medical"), a subsidiary of the Company, are all medical institutions, and the medical services provided by them are exempt from VAT.

(4) According to the "Announcement of the Ministry of Finance and the State Administration of Taxation on Preferential Income Tax Policies for Small and Micro Enterprises and Individual Industrial and Commercial Households" (No. 6 of 2023), and according to the "Announcement of the Ministry of Finance and the State Administration of Taxation on Relevant Tax Policies to Further Support the Development of Small and Micro Enterprises and Individual Industrial and Commercial Households" (No. 12 of 2023), from January 1, 2023 to December 31, 2027 On the same day, the annual taxable income of small and low-profit enterprises does not exceed 1 million yuan, a reduced rate of 25% is included in the taxable income, and the corporate income tax is paid at a rate of 20%.

(5) According to the "Announcement of the Ministry of Finance and the State Administration of Taxation on Tax Policies to Further Support the Development of Small and Micro Enterprises and Individual Industrial and Commercial Households" (No. 12, 2023), from January 1, 2023 to December 31, 2027, the resource tax levied on small-scale value-added tax taxpayers, small low-profit enterprises and individual industrial and commercial households will be halved

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

(excluding water resources tax), urban maintenance and construction tax, real estate tax, urban land use tax, stamp tax (excluding securities transaction stamp tax), farmland occupation tax and education surcharge, local education surcharge, Delun Medical is a small-scale taxpayer of value-added tax and can enjoy relevant tax preferential policies in 2025.

Others

7. Notes on Consolidated Financial Statement Items

Monetary funds

Unit: Yuan

Item Ending balance Beginning balance

Cash on hand 73,091.08 34,518.08 Bank deposits 95,338,824.00 120,267,981.95 Other monetary funds 16,450,688.60 27,390,680.84 Total 111,862,603.68 147,693,180.87Other instructions

Project June 30, 2025 December 31, 2024

performance bond

Other restricted monetary funds 16,998,718.23 16,122,373.68 Total 16,998,718.23 16,122,373.68

Trading financial assets

Unit: Yuan Item Ending balance Beginning balance

Among them:

Other instructions

Derivative financial assets

Unit: Yuan

Item Ending balance Beginning balance

Other instructions

Notes receivable

(1) Classified presentation of notes receivable

Unit: Yuan

Item Ending balance Beginning balance

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Bank acceptance notes 4,443,525.52 9,041,164.44 Total 4,443,525.52 9,041,164.44

(2) Classified disclosure according to bad debt accrual method

Unit: Yuan Ending balance Beginning balance

Book balance Provision for bad debts Book balance Provision for bad debts

Category Book price Book price provision ratio Provision ratio

Amount Ratio Amount Value Amount Ratio Amount Value Example

its

Medium:

its

Medium:

If bad debt provisions for notes receivable are made according to the general expected credit loss model:

□Applicable Not applicable

(3) Bad debt provisions accrued, recovered or reversed in the current period

Bad debt provisions for the current period:

Unit: Yuan Amount of changes in the current period

Category Opening balance Ending balance Provision Recovery or transfer Write-off Others

Among them, the amount of recovery or reversal of bad debt provisions for the current period is important:

□Applicable Not applicable

(4) Notes receivable pledged by the company at the end of the period

Unit: Yuan Project Amount pledged at the end of the period

(5) Notes receivable that have been endorsed or discounted by the company at the end of the period and have not yet matured on the balance sheet date

Unit: Yuan Item Amount derecognized at the end of the period Amount not derecognized at the end of the period

Bank acceptance notes 2,586,368.76

Total 2,586,368.76

(6) Notes receivable actually written off in the current period

Unit: yuan item write-off amount

Among them, the important write-off of bills receivable:

Unit: Yuan

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Whether the amount is paid by the related unit, the nature of the notes receivable, the write-off amount, the reason for the write-off, the write-off procedures performed

Instructions for writing off notes receivable resulting from transactions:

Accounts receivable

(1) Disclosure based on aging

Unit: Yuan

Aging Book balance at the end of the period Book balance at the beginning of the period

Within 1 year (including 1 year) 21,015,986.81 36,177,469.95 1 to 2 years 10,137,782.41 9,845,183.75 2 to 3 years 529,462.44 286,190.44 More than 3 years 8,829,332.50 8,824,617.10 3 to 4 years 3,108,613.37 3,027,213.94 4 to 5 years 175,824.00 175,774.00

More than 5 years 5,544,895.13 5,621,629.16 Total 40,512,564.16 55,133,461.24

(2) Classified disclosure according to bad debt accrual method

Unit: Yuan Ending balance Beginning balance

Book balance Provision for bad debts Book balance Provision for bad debts

Category Book price Book price provision ratio Provision ratio

Amount Ratio Amount Value Amount Ratio Amount Value

Example Example

By item

bad provision

7,285,6 7,285,6 7,285,6 7,285,6

Account provision 17.98% 100.00% 13.21% 100.00%

40.16 40.16 40.16 40.16

receivables

Accounts

its

Medium:

by combination

bad provision

33,226, 5,788,2 27,438, 47,847, 8,678,3 39,169, Account provision 82.02% 17.42% 86.79% 18.14%

Receivables of 924.00 80.74 643.26 821.08 87.20 433.88

Accounts

its

Medium:

Combination 1

Receivables

Joint payment

item

Combination 2

33,226, 5,788,2 27,438, 47,847, 8,678,3 39,169, aging group 82.02% 17.42% 86.79% 18.14%

924.00 80.74 643.26 821.08 87.20 433.88 combined

40,512, 13,073, 27,438, 55,133, 15,964, 39,169, total 100.00% 32.27% 100.00% 28.96%

564.16 920.90 643.26 461.24 027.36 433.88

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Category name of bad debt provision for individual items: Accounts receivable with significant single amount and bad debt provision for individual items

Unit: Yuan Beginning balance Ending balance

Name

Book balance Bad debt provision Book balance Bad debt provision Provision ratio Reason for provision Shenyang Liyuan Track

Transportation Equipment Co., Ltd. 4,175,837.67 4,175,837.67 4,175,837.67 4,175,837.67 100.00% It is expected that the company cannot be recovered

Zhongwei Qirun (North

Beijing) Technology Co., Ltd. 2,970,640.99 2,970,640.99 2,970,640.99 2,970,640.99 100.00% It is expected that the company cannot be recovered

Total 7,146,478.66 7,146,478.66 7,146,478.66 7,146,478.66

Category name of bad debt provision for individual items: Accounts receivable for which bad debt provision is made individually although the individual amount is not significant

Unit: Yuan Beginning balance Ending balance

Name

Book balance Bad debt provision Book balance Bad debt provision Provision ratio Reason for provision Although the individual amounts are not

Significant but individually calculated

139,161.50 139,161.50 139,161.50 139,161.50 100.00% It is expected that the provision for bad debts cannot be recovered

Accounts receivable

Total 139,161.50 139,161.50 139,161.50 139,161.50

Category name of provision for bad debts by combination: Aging combination

Unit: Yuan ending balance

Name

Book balance Bad debt provision Provision ratio

Aging combination 33,226,924.00 5,788,280.74 17.42% Total 33,226,924.00 5,788,280.74

Description of what this combination is based on:

If bad debt provisions for accounts receivable are made according to the general expected credit loss model:

□Applicable Not applicable

(3) Bad debt provisions accrued, recovered or reversed in the current period

Bad debt provisions for the current period:

Unit: Yuan Amount of changes in the current period

Category Beginning Balance Ending Balance

Provision Recovery or transfer Write-off Others

Single provision 7,285,640.16 7,285,640.16 Aging combination 8,678,387.20 13,911.63 2,893,875.46 10,142.63 5,788,280.74

15,964,027.3 13,911.63 2,893,875.46 10,142.63 13,073,920.9Total

6 0 Among them, the amount of bad debt provision recovery or reversal in the current period is important:

Unit: Yuan

Name of unit Amount recovered or reversed Reason for reversal Method of recovery Determination of original provision for bad debts Full text of Haochen Medical Technology Co., Ltd.'s 2025 semi-annual report

The basis of proportion and its rationality

(4) Accounts receivable actually written off in the current period

Unit: yuan item write-off amount

Important write-offs of accounts receivable:

Unit: Yuan Whether the amount is paid by the name of the related unit Nature of accounts receivable Amount of write-off Reason for write-off The write-off procedures performed

transaction generated

Instructions for writing off accounts receivable:

(5) Accounts receivable and contract assets with the top five closing balances collected by debtors

Unit: Yuan accounts receivable and combined accounts receivable, bad debts, quasi-accounts receivable, ending balance, contract assets, ending balance, accounts receivable and contracts

Unit name Closing balance of same assets Provision and contract asset reduction amount Closing balance of assets

Proportion of total amount Value preparation closing balance Shenyang Liyuan Rail Transit

4,175,837.67 4,175,837.67 10.31% 4,175,837.67 Tong Equipment Co., Ltd.

Anhui Baihaosheng Technology

3,180,588.67 3,180,588.67 7.85% 604,116.32 Co., Ltd.

Zhongwei Qirun (North

Beijing) Technology Co., Ltd. 2,970,640.99 2,970,640.99 7.33% 2,970,640.99 Company

Shanxi Huadian Transfer Senke

2,954,625.50 2,954,625.50 7.29% 517,354.93 Technology Co., Ltd.

Anhui Haoyuan Chemical Industry Group

2,812,981.29 2,812,981.29 6.94% 536,115.37 Tuan Co., Ltd.

Total 16,094,674.12 16,094,674.12 39.72% 8,804,065.28

Contract assets

(1) Contract assets

Unit: Yuan Ending balance Beginning balance

Project

Book balance Provision for bad debts Book value Book balance Provision for bad debts Book value

(2) Amount and reasons of major changes in book value during the reporting period

Unit: Yuan Item Amount of change Reason for change

(3) Classified disclosure according to bad debt accrual method

Unit: Full text of 2025 semi-annual report of Yuanhaochen Medical Technology Co., Ltd.

Ending balance Beginning balance

Book balance Provision for bad debts Book balance Provision for bad debts

Category Book price Book price provision ratio Provision ratio

Amount Ratio Amount Value Amount Ratio Amount Value Example

Among them:

Provision for bad debts based on the general expected credit loss model

□Applicable Not applicable

(4) Bad debt provisions accrued, recovered or reversed in the current period

Unit: Yuan Item Provision in the current period Recovery or transfer in the current period Write-off/write-off in the current period Reasons

Among them, the amount of recovery or reversal of bad debt provisions for the current period is important:

Unit: Yuan Determine the name of the original bad debt provision accrual unit, the recovery or reversal amount, the reason for the reversal, the recovery method, the basis for the ratio and its rationality

Other instructions

(5) Contract assets actually written off in the current period

Unit: yuan item write-off amount

Among them, the important write-off of contract assets

Unit: Whether the yuan amount is paid by the name of the related unit, nature of the amount, write-off amount, write-off reason, write-off procedures performed

transaction generated

Instructions for write-off of contract assets:

Other notes:

Accounts receivable financing

(1) Classified presentation of financing receivables

Unit: Yuan Item Ending balance Beginning balance

(2) Classified disclosure according to bad debt accrual method

Unit: Yuan Ending balance Beginning balance

Book balance Provision for bad debts Book balance Provision for bad debts

Category Book price Book price provision ratio Provision ratio

Amount Ratio Amount Value Amount Ratio Amount Value Example

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Among them:

Provision for bad debts based on the general expected credit loss model

Unit: Yuan Phase 1 Phase 2 Phase 3

Expected credit throughout the lifetime Credit expected throughout the lifetime

Provision for bad debts Expected credit in the next 12 months Total

Loss (no credit deduction has occurred Loss (credit deduction has occurred)

loss

value) value)

Balance as of January 1, 2025

In this issue

Basis for division of each stage and provision ratio for bad debts

Explanation of significant changes in the book balance of accounts receivable financing that have experienced changes in loss provisions in the current period:

(3) Bad debt provisions accrued, recovered or reversed in the current period

Unit: Yuan Amount of changes in the current period

Category Opening balance Ending balance Provision Recovery or reversal Write-off or write-off Other changes

Among them, the amount of recovery or reversal of bad debt provisions for the current period is important:

Other notes:

(4) Financing of the company’s pledged receivables at the end of the period

Unit: Yuan Project Amount pledged at the end of the period

(5) Financing of receivables that have been endorsed or discounted by the company at the end of the period and have not yet matured on the balance sheet date

Unit: Yuan Item Amount derecognized at the end of the period Amount not derecognized at the end of the period

(6) Financing of receivables actually written off in the current period

Unit: yuan item write-off amount

Important financing write-offs of receivables

Unit: Whether the yuan amount is paid by the name of the related unit, nature of the amount, write-off amount, write-off reason, write-off procedures performed

transaction generated

Write-off instructions:

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd. (7) Increases and decreases in receivables financing during the current period and changes in fair value

(8) Other instructions

Other receivables

Unit: Yuan Item Ending balance Beginning balance

Dividends receivable 22,700,000.00 22,700,000.00 Other receivables 19,092,999.65 17,626,226.96 Total 41,792,999.65 40,326,226.96 (1) Interest receivable

Classification of interest receivable

Unit: Yuan Item Ending balance Beginning balance

Important overdue interest

Unit: Yuan Whether impairment occurs and the borrowing unit is judged. Ending balance Overdue time Reason for overdue

Judgment basis

Other notes:

Classified disclosure according to bad debt accrual method

□Applicable Not applicable

Bad debt provisions accrued, recovered or reversed in the current period

Unit: Yuan Amount of changes in the current period

Category Opening balance Ending balance Provision Recovery or reversal Write-off or write-off Other changes

Among them, the amount of recovery or reversal of bad debt provisions for the current period is important:

Other notes:

Interest receivable actually written off in the current period

Unit: yuan item write-off amount

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Among them, the important write-off of interest receivable

Unit: Whether the yuan amount is paid by the name of the related unit, nature of the amount, write-off amount, write-off reason, write-off procedures performed

transaction generated

Write-off instructions:

Other notes:

(2) Dividends receivable

Classification of dividends receivable

Unit: yuan project (or invested unit) Closing balance Opening balance

Fushun Bank Co., Ltd. 22,700,000.00 22,700,000.00 Total 22,700,000.00 22,700,000.00

Important dividends receivable aged more than 1 year

Unit: Yuan project (or invested unit) Whether impairment has occurred and its balance at the end of the judgment period Aging Reason for non-recovery

bit) Breaking basis

Classified disclosure according to bad debt accrual method

□Applicable Not applicable

Bad debt provisions accrued, recovered or reversed in the current period

Unit: Yuan Amount of changes in the current period

Category Opening balance Ending balance Provision Recovery or reversal Write-off or write-off Other changes

Among them, the amount of recovery or reversal of bad debt provisions for the current period is important:

Other notes:

Dividends receivable actually written off in the current period

Unit: yuan item write-off amount

Among them, the important write-off of dividends receivable

Unit: Whether the yuan amount is paid by the name of the related unit, nature of the amount, write-off amount, write-off reason, write-off procedures performed

transaction generated

Write-off instructions:

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Other notes:

(3) Other receivables

Classification of other receivables according to nature of payment

Unit: Yuan

Nature of payment Book balance at the end of the period Book balance at the beginning of the period

Employee insurance 1,752,897.24 1,685,931.32 Deposits and guarantees 20,412,424.81 18,311,357.61 Current accounts with non-related parties 88,292,561.36 88,709,954.70 Current accounts with related parties

Total 110,457,883.41 108,707,243.63

Disclosure based on aging

Unit: Yuan

Aging Book balance at the end of the period Book balance at the beginning of the period

Within 1 year (including 1 year) 5,718,532.06 4,743,193.36 1 to 2 years 4,804,547.54 4,877,423.14 2 to 3 years 3,589,776.81 3,103,599.86 More than 3 years 96,345,027.00 95,983,027.27 3 to 4 years 2,082,034.71 1,262,059.66 4 to 5 years 636,865.10 4,156,218.33

More than 5 years 93,626,127.19 90,564,749.28 Total 110,457,883.41 108,707,243.63

Classified disclosure according to bad debt accrual method

Applicable □Not applicable

Unit: Yuan Ending balance Beginning balance

Book balance Provision for bad debts Book balance Provision for bad debts

Category Book price Book price provision ratio Provision ratio

Amount Ratio Amount Value Amount Ratio Amount Value

Example Example

By item

89,749, 89,749, 89,749, 89,749,

Bad provision 81.25% 100.00% 82.56% 100.00%

098.67 098.67 098.67 098.67

Account preparation

Among them:

by combination

20,708, 1,615,7 19,092, 18,958, 1,331,9 17,626, bad provision 18.75% 7.80% 17.44% 7.03%

784.74 85.09 999.65 144.96 18.00 226.96Account preparation

Among them:

Combination 1

20,708, 1,615,7 19,092, 18,958, 1,331,9 17,626, aging group 18.75% 7.80% 17.44% 7.03%

784.74 85.09 999.65 144.96 18.00 226.96 combined

110,457 91,364, 19,092, 108,707 91,081, 17,626, total 100.00% 82.71% 100.00% 83.79%

,883.41 883.76 999.65 ,243.63 016.67 226.96 Full text of the 2025 Semi-annual Report of Haochen Medical Technology Co., Ltd.

Category name of bad debt provision for individual items: Other receivables with significant individual amount and bad debt provision for individual items

Unit: Yuan Beginning balance Ending balance

Name

Book balance Bad debt provision Book balance Bad debt provision Provision ratio Reason for provision Rongyu Xintong Technology 75,564,060.1 75,564,060.1 75,564,060.1 75,564,060.1

100.00% Not expected to be recovered Co., Ltd. 1 1 1 1

Aberdeen, Shenzhen 10,914,070.0 10,914,070.0 10,914,070.0 10,914,070.0

100.00% is not expected to be recovered by Technology Co., Ltd. 0 0 0 0

86,478,130.1 86,478,130.1 86,478,130.1 86,478,130.1

total

1 1 1 1

Category name of bad debt provision for individual items: Other receivables for which bad debt provision is made individually although the individual amount is not significant

Unit: Yuan Beginning balance Ending balance

Name

Book balance Bad debt provision Book balance Bad debt provision Provision ratio Reason for provision Although the individual amounts are not

Significant but individually calculated

3,270,968.56 3,270,968.56 3,270,968.56 3,270,968.56 100.00% It is expected that the provision for bad debts cannot be recovered

Other receivables

Total 3,270,968.56 3,270,968.56 3,270,968.56 3,270,968.56

Category name of provision for bad debts by combination: Aging combination

Unit: Yuan ending balance

Name

Book balance Bad debt provision Provision ratio

Aging combination 20,708,784.74 1,615,785.09 7.80% Total 20,708,784.74 1,615,785.09

Description of what this combination is based on:

Provision for bad debts is made based on the general expected credit loss model:

Unit: Yuan Phase 1 Phase 2 Phase 3

Expected credit throughout the lifetime Credit expected throughout the lifetime

Provision for bad debts Expected credit in the next 12 months Total

Loss (no credit deduction has occurred Loss (credit deduction has occurred)

loss

value) value)

Balance on January 1, 2025 1,331,918.00 89,749,098.67 91,081,016.67 Balance on January 1, 2025

In this issue

Provision for the current period 283,867.09 283,867.09 Remainder as of June 30, 2025

1,615,785.09 89,749,098.67 91,364,883.76

Basis for division of each stage and provision ratio for bad debts

Changes in book balances with significant changes in loss provision during the current period

□Applicable Not applicable

Bad debt provisions accrued, recovered or reversed in the current period

Bad debt provisions for the current period:

Unit: Full text of 2025 semi-annual report of Yuanhaochen Medical Technology Co., Ltd.

Amount of changes in the current period

Category Opening balance Ending balance Provision Recovery or reversal Write-off or write-off Others

Other receivables bad 91,081,016.6 91,364,883.7 283,867.09

Account provision 7 6 91,081,016.6 91,364,883.7 Total 283,867.09

7 6 Among them, the amount of bad debt provision reversal or recovery in the current period is important:

Other receivables actually written off in the current period

Unit: yuan item write-off amount

Important write-offs of other receivables:

Unit: Whether the Yuan amount is paid by the related unit. Nature of other receivables. Write-off amount. Reason for write-off. Write-off procedures performed.

transaction generated

Instructions for writing off other receivables:

Other receivables with the top five closing balances based on debtors

Unit: Yuan accounted for other receivable period

Name of the unit with the ending balance of bad debt provision Nature of the payment Ending balance Aging Total ending balance

Proportion

Rongyu Information Technology Co., Ltd.

Current accounts with non-related parties 75,564,060.11 More than 5 years 68.41% 75,564,060.11 Co., Ltd.

Shenzhen Aberdeen Branch

Current accounts with non-related parties 10,914,070.00 More than 5 years 9.88% 10,914,070.00 Technology Co., Ltd.

Guangzhou Kaixing Real Estate 1-2 years, 2-3 years,

Deposit and security deposit 1,617,312.00 1.46%

Production Co., Ltd. 3-4 years, more than 5 years

Guangzhou Liangqiao Property

Deposit, security deposit 1,500,000.00 More than 5 years 1.36% 1,500,000.00 Management Co., Ltd.

Within 1 year, 1-2

Guangzhou Zhongsheng Real Estate Year, 2-3 years, 3-4

Deposit and margin 1,297,532.06 1.18%

Limited company Year, 4-5 years, 5 years

above

Total 90,892,974.17 82.29% 87,978,130.11

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Presented in other receivables due to centralized management of funds

Advance payment

(1) Prepayments are listed based on aging

Unit: Yuan Ending balance Beginning balance

Aging

Amount Ratio Amount Ratio

Within 1 year 15,340,830.07 88.17% 6,460,681.69 92.90% 1 to 2 years 1,125,286.32 6.47% 170,178.72 2.45% 2 to 3 years 318,206.14 1.83% 245,849.25 3.54% More than 3 years 615,684.48 3.54% 77,322.42 1.11% Total 17,400,007.01 6,954,032.08

Explanation of the reasons why prepayments with an aging of more than 1 year and important amounts are not settled in a timely manner:

(2) Prepayments with the top five closing balances by prepayment objects

Unit name June 30, 2025 Proportion of total prepayments Guangdong Complete Decoration Co., Ltd. 2,196,000.00 12.62 Hanhai Information Technology (Shanghai) Co., Ltd. 1,541,936.09 8.86 Hefei Huada Materials Co., Ltd. 1,244,950.00 7.15 Gansu Hengsheng Electrical Automation Co., Ltd. 897,000.00 5.16 Guangzhou Haosheng Industrial Development Co., Ltd. 741,310.54 4.26 Total 6,621,196.63 38.05 Other notes:

Inventory

Whether the company needs to comply with the real estate industry’s disclosure requirements

(1) Inventory classification

Unit: Yuan Ending balance Beginning balance

Provision for inventory decline Provision for inventory decline

Project

Book balance or contract performance costs Book value Book balance or contract performance costs Book value impairment provision

37,242,213.0 27,662,662.8 44,304,290.6 34,724,740.4 Raw materials 9,579,550.28 9,579,550.28

9 1 9 1 Work in progress 4,359,281.93 647,801.13 3,711,480.80 6,334,840.61 647,801.13 5,687,039.48

24,741,033.7 21,902,489.5 13,180,112.8 10,341,568.6 Inventory goods 2,838,544.18 2,838,544.18

1 3 4 6

66,342,528.7 13,065,895.5 53,276,633.1 63,819,244.1 13,065,895.5 50,753,348.5Total

3 9 4 4 9 5

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

(2) Data resources confirmed as inventory

Unit: Data resources processed by Yuan itself Data obtained through other methods

Item Outsourced data resource inventory Total

Inventory Resource Inventory

(3) Provision for inventory depreciation and provision for impairment of contract performance costs

Unit: Yuan Increase amount in this period Decrease amount in this period

Item Beginning balance Closing balance

Provision Others Reversal or write-off Others

Raw materials 9,579,550.28 9,579,550.28 Work in progress 647,801.13 647,801.13 Inventory goods 2,838,544.18 2,838,544.18

13,065,895.5 13,065,895.5Total

9 9 Provision for inventory depreciation is made on a group basis

Unit: End of the period Beginning of the period

Portfolio name Provision for decline in price Provision for decline in price Provision for decline in price Closing balance Provision for decline in price Opening balance Provision for decline in price

Proportion Proportion

37,242,213.0 44,304,290.6

Raw materials 9,579,550.28 25.72% 9,579,550.28 21.62% 9 9

24,741,033.7 13,180,112.8

Inventory goods 2,838,544.18 11.47% 2,838,544.18 21.54%

1 4

Work in progress 4,359,281.93 647,801.13 14.86% 6,334,840.61 647,801.13 10.23%

66,342,528.7 13,065,895.5 63,819,244.1 13,065,895.5

Total 19.69% 20.47%

3 9 4 9

Standards for accruing inventory depreciation provisions on a group basis

(4) Explanation that the closing balance of inventory includes the capitalized amount of borrowing costs

(5) Explanation of the amortization amount of contract performance costs for the current period

Assets held for sale

Unit: Yuan

Item Book balance at the end of the period Impairment provision Book value at the end of the period Fair value Estimated disposal costs Estimated disposal time Other instructions

Non-current assets due within one year

Unit: Yuan

Item Ending balance Beginning balance

(1) Debt investments due within one year

□Applicable Not applicable

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

(2) Other debt investments due within one year

□Applicable Not applicable

Other current assets

Unit: Yuan Item Ending balance Beginning balance

Prepaid tax 303,347.33 607,745.32 Value-added tax input tax to be deducted 1,957,508.38 1,877,378.75 Total 2,260,855.71 2,485,124.07 Other notes:

Debt investment

(1) Situation of debt investment

Unit: Yuan Ending balance Beginning balance

Project

Book balance Impairment provision Book value Book balance Impairment provision Book value Debt investment impairment provision Changes in the current period

Unit: Yuan Item Beginning balance Increase in the current period Decrease in the current period Ending balance

(2) Important debt investments at the end of the period

Unit: Yuan Ending balance Beginning balance

claims

Coupon interest Actual interest Overdue principal Coupon interest Actual interest Overdue principal Face value Maturity date Face value Maturity date

rate rate gold rate rate gold

(3) Provision of impairment provisions

Unit: Yuan Phase 1 Phase 2 Phase 3

Expected credit throughout the lifetime Credit expected throughout the lifetime

Provision for bad debts Expected credit in the next 12 months Total

Loss (no credit deduction has occurred Loss (credit deduction has occurred)

loss

value) value)

Balance as of January 1, 2025

In this issue

Basis for division of each stage and provision ratio for bad debts

(4) Debt investment actually written off in this period

Unit: yuan item write-off amount

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Among them, the important write-off of debt investment

Debt investment write-off instructions:

Changes in book balances with significant changes in loss provision during the current period

□Applicable Not applicable

Other notes:

Other debt investments

(1) Situation of other debt investments

Unit: Yuan Accumulative fair in other comprehensive income for the period Accumulative fair

Item Opening balance Accrued interest Interest adjustment Closing balance Cost Recognition in profit Remarks Value changes Value changes

provision for impairment

Changes in impairment provisions for other debt investments during the current period

Unit: Yuan Item Beginning balance Increase in the current period Decrease in the current period Ending balance

(2) Other important debt investments at the end of the period

Unit: Yuan Ending balance Beginning balance

Other debts

Coupon interest Actual interest Overdue principal Coupon interest Actual interest Overdue principal item Par value Maturity date Par value Maturity date Rate Rate Gold Rate Rate Gold

(3) Provision of impairment provisions

Unit: Yuan Phase 1 Phase 2 Phase 3

Expected credit throughout the lifetime Credit expected throughout the lifetime

Bad debt provision Expected total credit losses in the next 12 months (no credit deductions have occurred Losses (credit deductions have occurred)

loss

value) value)

Balance as of January 1, 2025

In this issue

Basis for division of each stage and provision ratio for bad debts

(4) Other debt investments actually written off in the current period

Unit: yuan item write-off amount

Among them, the write-off of other important debt investments

Instructions for write-off of other debt investments:

Changes in book balances with significant changes in loss provision during the current period

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

□Applicable Not applicable

Other notes:

Investment in other equity instruments

Unit: Yuan Designated as fair value included in the current period Included in the current period Accumulated at the end of the period Accumulated at the end of the period

Recognized and measured in the current period and its other comprehensive Other comprehensive accounting is included in its Other comprehensive accounting is included in its

Item name Dividend income at the beginning of the period Dividend income at the end of the period Changes included in income Loss of income Other comprehensive income Other comprehensive income

Income Other comprehensive gains and losses Gains and losses

original income

Because

Beijing Wantai

Zoomlion Technology 11,000,00 68,540,65 11,000,00

Co., Ltd. 0.00 0.00 0.00

company

11,000,00 68,540,65 11,000,00

total

0.00 0.00 0.00

There is termination confirmation in this period

Unit: yuan Project name Accumulated gains transferred to retained earnings Accumulated losses transferred to retained earnings Reasons for derecognition

Disclosure of non-trading equity instrument investments in the current period by items

Unit: Yuan designated as fair

Other comprehensive income Dividend income measured in value and recognized in other comprehensive income

Project name Accumulated profits Accumulated losses Transfer to retained earnings Changes are included in other Transfer to retained earnings

The amount of comprehensive income is the reason for

Because

Beijing Wantai Zhonglian

68,540,650.0 Not for sale

Technology Co., Ltd.

0 of

company

Other notes:

Long-term receivables

(1) Long-term receivables

Unit: Yuan Ending balance Beginning balance

Item Discount rate range Book balance Bad debt provision Book value Book balance Bad debt provision Book value

(2) Classified disclosure according to bad debt accrual method

Unit: Yuan Ending balance Beginning balance

Category Book balance Bad debt provision Book price Book balance Bad debt provision Book price amount Proportion Amount Provision ratio Value Amount Proportion Amount Provision ratio Value Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Example Example

Among them:

Provision for bad debts based on the general expected credit loss model

Unit: Yuan Phase 1 Phase 2 Phase 3

Expected credit throughout the lifetime Credit expected throughout the lifetime

Provision for bad debts Expected credit in the next 12 months Total

Loss (no credit deduction has occurred Loss (credit deduction has occurred)

loss

value) value)

Balance as of January 1, 2025

In this issue

Basis for division of each stage and provision ratio for bad debts

(3) Bad debt provisions accrued, recovered or reversed in the current period

Unit: Yuan Amount of changes in the current period

Category Opening balance Ending balance Provision Recovery or reversal Write-off or write-off Others

Among them, the amount of bad debt provision for the current period that is reversed or recovered is important:

Other notes:

(4) Long-term receivables actually written off in the current period

Unit: yuan item write-off amount

Among them, the important write-off situation of long-term receivables:

Unit: Whether the yuan amount is paid by the name of the related unit, nature of the amount, write-off amount, write-off reason, write-off procedures performed

transaction generated

Instructions for writing off long-term receivables:

Long-term equity investment

Unit: Yuan Increase or decrease in the current period

Beginning of period Equity declaration End of period

Impairment Impairment investment balance Other disbursement balance under the law

Preparation Other Provisions Provision Notes (Account Addition Decrease Confirmation Comprehensive Cash (Account

Equity Impairment at the Beginning of the Period Others Ending of the Period Face Price Investment Investment Income from Investment Dividends Face Price

Balance Change Provision Balance Value) Capital Loss Adjustment or Profit Value)

profit

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

1. Joint ventures

2. Joint ventures

Fushun

Bank 476,3 92,50 4,349 479,1 92,50

1,502

Shares 17,66 5,120 ,700. 64,62 5,120

,738.

Limited 0.06 .48 10 1.92 .48Company

Tianjin

Rong Yu

Interaction 1,782 1,782 Network ,811. ,811. Technology 93 93 Limited

company

476,3 94,28 4,349 479,1 94,28

1,502

Subtotal 17,66 7,932 ,700. 64,62 7,932 ,738.

0.06 .41 10 1.92 .41 -

476,3 94,28 4,349 479,1 94,28

1,502

Total 17,66 7,932 ,700. 64,62 7,932 ,738.

0.06 .41 10 1.92 .41

The recoverable amount is determined as the net amount after fair value minus disposal costs.

□Applicable Not applicable

The recoverable amount is determined based on the present value of expected future cash flows.

□Applicable Not applicable

Reasons for the obvious inconsistency between the aforementioned information and the information used in impairment testing in previous years or external information

Reasons for the discrepancy between the information used in the company's impairment testing in previous years and the actual situation of that year.

Other instructions

Other non-current financial assets

Unit: Yuan

Item Ending balance Beginning balance

Other notes:

Investment real estate

(1) Investment real estate using cost measurement model

Applicable □Not applicable

Unit: Yuan

Projects Houses and buildings Land use rights Construction in progress Total

1. Original book value

Balance at the beginning of the period 43,374,367.08 43,374,367.08 2. Increase in the current period

(1) Outsourcing

(2) Inventory\

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Fixed assets\construction in progress transfer

enter

(3) Enterprise cooperation

and increase

Reduction amount in this period

(1) Disposal

(2) Other transfers

out

Closing balance 43,374,367.08 43,374,367.08

2. Accumulated depreciation and accumulation

Amortization

Balance at the beginning of the period 12,132,774.84 12,132,774.84 2. Increased amount in the current period 686,760.84 686,760.84 (1) Provision or

686,760.84 686,760.84 Amortization

Reduction amount in this period

(1) Disposal

(2) Other transfers

out

Closing balance 12,819,535.68 12,819,535.68

3. Impairment provision

Opening balance
Increase amount in this period

(1) Provision

Reduction amount in this period

(1) Disposal

(2) Other transfers

out

Ending balance

4. Book value

Book value at the end of the period 30,554,831.40 30,554,831.40 2. Book value at the beginning of the period 31,241,592.24 31,241,592.24 The recoverable amount is determined based on the net amount of fair value minus disposal costs □ Applicable  Not applicable

The recoverable amount is determined based on the present value of expected future cash flows.

□Applicable Not applicable

Reasons for the difference between the above information and the information used in the impairment test of previous years or external information. Reasons for the difference between the information used in the company's impairment test in previous years and the actual situation of the year. Other explanations:

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

(2) Investment real estate using fair value measurement model

□Applicable Not applicable

(3) Converted to investment real estate and measured at fair value

Unit: Accounting Section before yuan conversion Amount of other comprehensive income items Reason for conversion Approval procedure Impact on profit and loss

Benefit impact

(4) Investment real estate that has not completed the ownership certificate

Unit: Yuan Item Book value Reasons for not completing the property rights certificate

Other instructions

Fixed assets

Unit: Yuan Item Ending balance Beginning balance

Fixed assets 156,077,277.45 160,462,952.57 Total 156,077,277.45 160,462,952.57

(1) Fixed assets

Unit: yuan office equipment and electricity

Items Houses and buildings Machinery and equipment Transportation equipment Special equipment Total

subdevice

1. Original books

Value:

Opening balance 179,362,883. 43,767,326.5 10,840,809.4 31,676,102.5 269,880,594. 4,233,473.03

Amount 15 3 9 6 76 2. Increase in this period

0.00 0.00 0.00 506,185.96 2,125,042.76 2,631,228.72 plus amount

506,185.96 2,125,042.76 2,631,228.72) Purchase

) Projects under construction transferred

enter

) Business merger increases

add

Less for this period

0.00 1,115,384.62 0.00 387,435.59 1,113,795.36 2,616,615.57 Small amount

1,115,384.62 387,435.59 1,113,795.36 2,616,615.57) Disposal or scrapping

Ending balance 179,362,883. 42,651,941.9 4,233,473.03 10,959,559.8 32,687,349.9 269,895,207.

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Amount 15 1 6 6 91

2. Accumulated depreciation

Opening balance 47,776,740.4 41,057,624.2 11,177,190.6 109,417,642.

3,372,494.31 6,033,592.61

Amount 2 2 3 19 2. Increase in this period

3,212,302.44 262,931.44 89,128.17 987,730.22 2,177,185.70 6,729,277.97 plus amount

3,212,302.44 262,931.44 89,128.17 987,730.22 2,177,185.70 6,729,277.97) Provision

Less for this period

0.00 1,059,615.39 0.00 368,152.04 901,222.27 2,328,989.70 Less amount

1,059,615.39 368,152.04 901,222.27 2,328,989.70) Disposal or scrapping

Ending balance 50,989,042.8 40,260,940.2 12,453,154.0 113,817,930.

3,461,622.48 6,653,170.79

6 7 6 46

3. Impairment provision

Balance at the beginning of the period

2.Increase in this period

Add amount

) accrual

Less for this period

small amount

) disposal or scrapping

End of period balance

4. Book value

Closing account 128,373,840. 20,234,195.9 156,077,277.

2,391,001.64 771,850.55 4,306,389.07

Face value 29 0 45 2. Opening account 131,586,142. 20,498,911.9 160,462,952.

2,709,702.31 860,978.72 4,807,216.88

Face value 73 3 57

(2) Temporarily idle fixed assets

Unit: Yuan

Item Original book value Accumulated depreciation Impairment provision Book value Remarks

(3) Fixed assets leased through operating leases

Unit: Yuan

Item Closing book value

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd. (4) Fixed assets with uncompleted property rights certificates

Unit: Yuan Item Book value Reasons for not completing the property rights certificate

Other instructions

(5) Impairment testing of fixed assets

□Applicable Not applicable

(6) Fixed assets liquidation

Unit: Yuan Item Ending balance Beginning balance

Other notes:

Projects under construction

Unit: Yuan Item Ending balance Beginning balance

(1) Projects under construction

Unit: Yuan Ending balance Beginning balance

Project

Book balance Impairment provision Book value Book balance Impairment provision Book value (2) Changes in important construction projects in progress during the period

Unit: Yuanqi

Engineering

Interest in this period:

Current period Cumulative Current period

Capital transferred in this period This period

Project Budget Beginning of Period Others End of Period Investment Project Interest Increase in Funds Fixed Accumulated Interest

Name Number Balance Decrease Balance Accounting for Advance Progress Capital Source Amount Asset Accounting Capital

Amount calculation ratio

Amount Amount Funding

Example

(3) Provision for impairment of projects under construction in the current period

Unit: Yuan Item Beginning balance Increase in the current period Decrease in the current period Closing balance Other explanations for the reasons for provision

(4) Impairment testing of projects under construction

□Applicable Not applicable

Full text of Haochen Medical Technology Co., Ltd. 2025 Semi-annual Report (5) Engineering Materials

Unit: Yuan

Ending balance Beginning balance

Project

Book balance Impairment provision Book value Book balance Impairment provision Other instructions for book value:

Productive biological assets

(1) Productive biological assets using cost measurement model

□Applicable Not applicable

(2) Impairment testing of productive biological assets using the cost measurement model

□Applicable Not applicable

(3) Productive biological assets using fair value measurement model

□Applicable Not applicable

Oil and gas assets

□Applicable Not applicable

Right-of-use assets

(1) Right-of-use assets

Unit: Yuan

Project House Rental Total

1. Original book value

Balance at the beginning of the period 216,172,875.54 216,172,875.54 2. Increase in the current period 18,052,455.33 18,052,455.33

18,052,455.33 18,052,455.33 3. Decrease amount in the current period 24,463,544.31 24,463,544.31

24,463,544.31 24,463,544.31 4. Closing balance 209,761,786.56 209,761,786.56

2. Accumulated depreciation

Balance at the beginning of the period 49,552,620.80 49,552,620.80 2. Increase in the current period 25,114,248.09 25,114,248.09

(1) Provision 25,114,248.09 25,114,248.09 3. Decrease amount in the current period 21,373,321.88 21,373,321.88

(1) Disposal 21,373,321.88 21,373,321.88 4. Closing balance 53,293,547.01 53,293,547.01

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

3. Impairment provision

Opening balance
Increase amount in this period

(1) Provision

Reduction amount in this period

(1) Disposal

Ending balance

4. Book value

Book value at the end of the period 156,468,239.55 156,468,239.55 2. Book value at the beginning of the period 166,620,254.74 166,620,254.74

(2) Impairment testing of right-of-use assets

□Applicable Not applicable

Other notes:

Intangible assets

(1) Intangible assets

Unit: Yuan

Project Land use rights Patent rights Non-patented technology Software Total

1. Original book value

Opening balance 38,555,387.10 3,984,440.46 14,545,259.54 10,581,601.41 67,666,688.51 2. Increase in this period

0.00 0.00 0.00 1,045,000.00 1,045,000.00Amount

(1) Purchase

1,045,000.00 1,045,000.00

(2) within

Ministry of R&D

(3) Enterprise

Increase in business mergers

Reduction in this period

0.00 0.00 0.00 0.00 0.00Amount

(1) place

set

Closing balance 38,555,387.10 3,984,440.46 14,545,259.54 11,626,601.41 68,711,688.51

2. Accumulated amortization

Opening balance 9,446,070.03 2,460,930.49 4,892,608.39 2,572,359.76 19,371,968.67 2. Increase in this period

385,553.88 333,146.50 661,309.12 512,116.04 1,892,125.54Amount

(1) Count

385,553.88 333,146.50 661,309.12 512,116.04 1,892,125.54

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Reduction in this period

0.00 0.00 0.00 0.00 0.00Amount

(1) place

set

Closing balance 9,831,623.91 2,794,076.99 5,553,917.51 3,084,475.80 21,264,094.21

3. Impairment provision

Opening balance

2.Increase in this period

Amount

(1) Count

mention

Reduction in this period

Amount

(1) place

set

Ending balance

4. Book value

Closing accounts

28,723,763.19 1,190,363.47 8,991,342.03 8,542,125.61 47,447,594.30 Value

Opening accounts

29,109,317.07 1,523,509.97 9,652,651.15 8,009,241.65 48,294,719.84Value

The proportion of intangible assets formed through the company's internal R&D to the balance of intangible assets at the end of the period

(2) Data resources recognized as intangible assets

Unit: Yuan Outsourcing intangible data resources Self-developed data resources Data items obtained through other means Total assets Intangible assets Resource intangible assets

(3) Land use rights for which property rights certificates have not been obtained

Unit: Yuan Item Book value Other explanations for reasons for not completing the property rights certificate

(4) Impairment testing of intangible assets

□Applicable Not applicable

Goodwill

(1) Original book value of goodwill

Unit: Yuan

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Name of invested unit Increase in this period Decrease in this period

Goodwill is called or formed. Opening balance Formed by business combination Disposal of closing balance

matters of

Beijing Rich Anxin

226,713.80 226,713.80 Technology Co., Ltd.

Guangdong Delun Medical 217,873,422. 217,873,422. Group Co., Ltd. 92 92 Guangzhou Delun Wanbo

The dental clinic has 2,988,680.65 2,988,680.65 Co., Ltd.

221,088,817. 221,088,817.Total

37 37

(2) Goodwill impairment provision

Unit: yuan Name of invested unit Increase in this period Decrease in this period

Goodwill is called or formed. Balance at the beginning of the period. Balance at the end of the period. Provision for disposal.

matters

Beijing Rich Anxin

226,713.80 226,713.80 Technology Co., Ltd.

Guangdong Delun Medical 18,200,663.7 18,200,663.7 Group Co., Ltd. 7 7 Guangzhou Delun Wanbo

The dental clinic has 2,988,680.65 2,988,680.65 Co., Ltd.

21,416,058.2 21,416,058.2Total

2 2

(3) Relevant information about the asset group or asset group combination where the goodwill is located

The composition of the asset group or portfolio to which it belongs and

Name, operating segment and basis. Is it consistent with previous years?

Basis

Changes in asset group or asset group combination

Name Composition before change Composition after change Objective facts and basis leading to change

Other instructions

Since the main cash flows generated by each of the above-mentioned subsidiaries are independent of the company's other subsidiaries, and the company manages the above-mentioned subsidiaries independently, the assets and liabilities related to goodwill of each subsidiary are regarded as the only asset group. At the end of the reporting period, the asset group in which the goodwill of each subsidiary was located was consistent with the asset group determined when the goodwill was formed on the acquisition date, and its composition has not changed.

(4) Specific determination method of recoverable amount

The recoverable amount is determined as the net amount after fair value minus disposal costs.

□Applicable Not applicable

The recoverable amount is determined based on the present value of expected future cash flows.

Applicable □Not applicable

Unit: Yuan

Year of the forecast period Off of the forecast period Off on the stable period Relevant items on the stable period Book value Recoverable amount Impairment amount

limited key parameter key parameter key parameter indeed

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Determination based on revenue growth rate revenue growth rate

Average annual compound rate The average annual compound rate is based on the asset Guangdong Delun Medical

691,489,63 703,496,60 Average 5%, Gross Average 0%, Gross Group Past Industrial Therapy Group Co., Ltd. 4 years

4.20 0.00 Interest Rate Interest Rate Performance and Market Company

51.89%, discount 51.48%, discount The expected current rate of development is 17.56%. The current rate is 17.56%

691,489,63 703,496,60

total

4.20 0.00

Reasons for the obvious inconsistency between the aforementioned information and the information used in impairment testing in previous years or external information

Reasons for the discrepancy between the information used in the company's impairment testing in previous years and the actual situation of that year.

(5) Completion of performance commitments and corresponding impairment of goodwill

There is a performance commitment when goodwill is formed and the reporting period or the previous period of the reporting period is within the performance commitment period

□Applicable Not applicable

Other instructions

Long-term deferred expenses

Unit: Yuan

Item Beginning balance Increase in the current period Amortization amount in the current period Other decreases Ending balance Housing decoration fee 59,178,810.20 5,778,095.80 6,959,561.18 57,997,344.82Technical service fee 948,301.72 335,824.87 612,476.85Total 60,127,111.92 5,778,095.80 7,295,386.05 58,609,821.67Other instructions

Deferred income tax assets/deferred income tax liabilities

(1) Deferred income tax assets without offset

Unit: Yuan Ending balance Beginning balance

Project

Deductible temporary differences Deferred income tax assets Deductible temporary differences Deferred income tax assets Asset impairment provision 51,495,034.45 9,873,156.78 54,098,423.37 10,260,799.55 Deductible losses 15,427,542.21 1,509,925.91 15,427,542.21 1,509,925.91 Overspending on advertising expenses 99,967,695.20 15,941,526.51 99,967,695.20 15,941,526.51 Gains and losses from changes in fair value 68,596,775.18 17,149,193.80 68,540,650.00 17,149,193.80 Temporary losses caused by the new lease standards

188,867,970.49 26,635,382.51 188,867,970.49 26,635,382.51 Temporal differences

Total 424,355,017.53 71,109,185.51 426,902,281.27 71,496,828.28

(2) Deferred income tax liabilities without offset

Unit: Yuan Ending balance Beginning balance

Project

Taxable temporary differences Deferred income tax liabilities Taxable temporary differences Deferred income tax liabilities

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Merger of enterprises not under common control

28,894,923.64 7,223,730.91 30,411,315.92 7,602,828.98 Added value of assets

Temporary changes caused by the new leasing standards

170,852,304.78 24,172,746.11 170,852,304.78 24,172,746.11 Temporal differences

Total 199,747,228.42 31,396,477.02 201,263,620.70 31,775,575.09

(3) Deferred income tax assets or liabilities presented on a net basis after offsetting

Unit: Yuan Deferred income tax assets and liabilities Deferred income tax assets after offset Deferred income tax assets and liabilities Deferred income tax items after offset

Offset amount at the end of the debt period Ending balance of assets or liabilities Offset amount at the beginning of the debt period Deferred income tax assets 24,172,746.11 46,936,439.40 24,172,746.11 47,324,082.17 Deferred income tax liabilities 24,172,746.11 7,223,730.91 24,172,746.11 7,602,828.98

(4) Details of deferred income tax assets not recognized

Unit: Yuan

Item Ending balance Beginning balance

(5) Deductible losses that have not been recognized as deferred income tax assets will expire in the following years

Unit: Yuan

Year Ending amount Beginning amount Remarks

Other instructions

Other non-current assets

Unit: Yuan Ending balance Beginning balance

Project

Book balance Impairment provision Book value Book balance Impairment provision Other instructions for book value:

Assets whose ownership or use rights are restricted

Unit: End of the period Beginning of the period

Project

Book balance Book value Restriction type Restriction situation Book balance Book value Restriction type Restriction situation time deposit time deposit

16,998,71 16,122,37

Monetary funds and litigation freeze and litigation freeze 8.23 3.68

End the aforementioned fixed assets. The aforementioned fixed assets are used for. The assets are used for

93,084,40 95,216,85

Fixed assets Company borrowings Company borrowings 0.69 6.49

Mortgage or counter Mortgage or counter guarantee Guarantee the aforementioned intangible The aforementioned intangible

28,723,76 assets are used for intangible assets 29,109,31 assets are used for intangible assets

3.19 Corporate borrowings 7.07 Corporate borrowings

mortgage mortgage

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Other receivables

22,700,00 22,700,00

Account - shares receivable Litigation freeze Litigation freeze

0.00 0.00

profit

Others mentioned above Others mentioned above

Equity instruments Equity instruments Other interests 11,000,00 11,000,00

Invest for Invest for tool investment 0.00 0.00

corporate borrowing corporate borrowing

Mortgage Mortgage long-term equity 479,164,6 476,317,6

Litigation freeze Investment litigation freeze 21.92 60.06

The aforementioned investment The aforementioned investment in investment housing 30,554,83 Sexual real estate 31,241,59 Sexual real estate 1.40 Used for the company 2.24 Used for the company's loan mortgage Mortgage loan

682,226,3 681,707,7

total

35.43 99.54

Other notes:

Note 1: Bank of Wenzhou Co., Ltd. and Zhejiang Zheshang Asset Management Co., Ltd. signed an "Asset Transfer Contract" numbered [2020 Zheshang Wen Bank Project-01] on December 29, 2020, and Bank of Wenzhou Co., Ltd. The claims and all subordinate rights under the "Wenzhou Bank Non-natural Person Loan Contract" No. [733002020 Qidai Zi No. 00151] and its supplementary agreement (hereinafter collectively referred to as the "subject claims") are transferred to Zhejiang Zheshang Asset Management Co., Ltd. Houhaochen Medical signed a debt recognition and installment repayment agreement with Zhejiang Zheshang Asset Management Co., Ltd. No. [2021 Zheshang-Wenxing-Rongyu Project-001]. The collateral for the loan is the property rights held by Jilin Yongda Electric Switch Co., Ltd., a subsidiary of Haochen Medical Technology Co., Ltd., which are Jilin (2018) Jilin City Real Estate No. 0104786 and Jilin (2018) Jilin City Real Estate No. No. 0104795, Jilin City (2018) Real Estate No. 0104788, and the property held by its subsidiary Beijing Rongyu Technology Co., Ltd. with the property number Jing (2017) Kaikai Real Estate No. 0016350. Since the relevant debts have been overdue, the company has frozen monetary funds of RMB 1,998,718.23. The company's 100% equity in Zhiyu Medical Investment Co., Ltd. (hereinafter referred to as "Zhiyu Medical") has been frozen by creditors. Since the equity investment has been offset in the consolidated financial statements, it is listed at RMB 0.

Note 2: Due to other contract disputes brought by Jin Haitang Asset Management Co., Ltd. (hereinafter referred to as "Jin Haitang") against Zuo Jiahua, Haochen Medical, and Yin Hongwei, Jin Haitang applied for property preservation to the Shanghai Financial Court on July 3, 2020, requesting to freeze the respondent's bank deposits totaling RMB 362,343,065.39 yuan or other properties of equivalent value owned by the respondent, including dividends receivable from Fushun Bank of 22,700,000.00 yuan and 227 million shares of Fushun Bank Co., Ltd. with a book value of 479,164,621.92 yuan.

Short-term borrowing

(1) Classification of short-term loans

Unit: Yuan

Item Ending balance Beginning balance

Mortgage loans 113,528,594.44 113,558,470.70

Guaranteed loans 77,900,000.00 78,029,833.33

Total 191,428,594.44 191,588,304.03

Description of short-term loan classification:

Mortgage guarantee loan of RMB 113,528,594.44, of which the loan principal is RMB 113,200,000.00 and the interest payable is RMB 328,594.44. It is a short-term loan of RMB 113.2 million obtained by the company from Shanxi Bank Co., Ltd., and the collateral is the property number held by its subsidiary Jilin Yongda Electric Switch Co., Ltd. They are Ji (2018) Jilin City Real Estate No. 010 No. 4786, Jilin (2018) Jilin City Real Estate No. 0104795, Jilin (2018) Jilin City Real Estate No. 0104788, Beijing Wantai Zhonglian Technology Co., Ltd. 20% equity investment. The subsidiary Beijing Rongyu Technology Co., Ltd. holds the property with the property number of Jing (2017) Real Estate Rights No. 0016350. The guarantor is Huzhou Zhongzhi Rongyun Investment Co., Ltd.
A mortgage guarantee loan of RMB 77,900,000.00 was provided by Jilin Yongda Electric Switch Co., Ltd., a subsidiary of the company, to Jilin Panshi Rural Commercial Bank Co., Ltd., Jilin Dongfeng Rural Commercial Bank Co., Ltd., Changbai North Korea The funds were obtained from a consortium composed of five banks including the Autonomous County Rural Credit Cooperative Union, Jilin Longtan Huayi Rural Bank Co., Ltd., and Meihekou Rural Credit Cooperative Union. The relevant loans were guaranteed by Haochen Medical and Zhiyu Medical Investment Co., Ltd. Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

(2) Overdue short-term borrowings that have not been repaid

The total amount of overdue and unpaid short-term borrowings at the end of the period was RMB, among which the important overdue and unpaid short-term borrowings are as follows:

Unit: yuan borrowing unit Ending balance Borrowing interest rate Overdue time Overdue interest rate

Other instructions

Trading financial liabilities

Unit: Yuan Item Ending balance Beginning balance

Among them:

Other notes:

Derivative financial liabilities

Unit: Yuan Item Ending balance Beginning balance

Other notes:

Notes payable

Unit: Yuan Type Ending balance Beginning balance

The total amount of bills payable that were due but not paid at the end of the period was Yuan, and the reasons for unpaid dues were.

Accounts payable

(1) Presentation of accounts payable

Unit: Yuan Item Ending balance Beginning balance

Within 1 year 58,500,152.82 55,321,102.64 1 to 2 years 1,868,256.40 1,389,919.73 2 to 3 years 438,866.41 202,739.83 More than 3 years 3,790,028.27 3,383,529.77Total 64,597,303.90 60,297,291.97

(2) Important accounts payable that are aged more than 1 year or are overdue

Unit: Yuan Item Closing balance Reason for outstanding or carry-forward

Other notes:

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Other payables

Unit: Yuan

Item Ending balance Beginning balance

Interest payable 78,447,928.18 69,657,936.53 Dividends payable 50,000.00

Other payables 262,710,319.94 263,205,630.95 Total 341,208,248.12 332,863,567.48

(1) Interest payable

Unit: Yuan

Item Ending balance Beginning balance

Overdue loan interest 78,447,928.18 69,657,936.53 Total 78,447,928.18 69,657,936.53 Important overdue and unpaid interest information:

Unit: Yuan

Borrowing unit Overdue amount Reasons for overdue

Other notes:

(2) Dividends payable

Unit: Yuan

Item Ending balance Beginning balance

Total 50,000.00

Other explanations, including important dividends payable that have not been paid for more than 1 year, should disclose the reasons for non-payment:

(3) Other payables

List other payables according to the nature of the payment

Unit: Yuan

Item Ending balance Beginning balance

Within 1 year 241,241,069.49 15,605,925.98 1 to 2 years 208,395.55 13,546,538.28 2 to 3 years 361,090.56 213,449,786.03 More than 3 years 20,899,764.34 20,603,380.66 Total 262,710,319.94 263,205,630.95

Important other payables aged more than 1 year or overdue

Unit: Yuan

Item Closing balance Reason for outstanding or carried forward

Other instructions

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Item Closing balance Reason for outstanding or carried forward

Compensation for Jin Haitang’s case 240,270,645.49 has not yet been settled

Jilin Chuanying Economic Development Zone Management Committee 17,888,266.10 yet to be settled

Total 258,158,911.59

Advance payments

(1) Presentation of advance receipts

Unit: Yuan Item Ending balance Beginning balance

(2) Important advances from customers aged more than 1 year or overdue

Unit: Yuan Item Closing balance Reason for outstanding or carry-forward

Unit: Yuan Item Amount of change Reason for change

Other notes:

Contract liabilities

Unit: Yuan Item Ending balance Beginning balance

Within 1 year 109,950,580.24 78,819,329.04 1 to 2 years 1,020,383.64 19,178,854.07 2 to 3 years 686,621.49 5,616,927.47 More than 3 years 5,538,629.77 21,122,017.47 Total 117,196,215.14 124,737,128.05 Important contract liabilities aged more than 1 year

Unit: Yuan Item Closing balance Reason for outstanding or carry-forward

Kingho Group Xinjiang Coal Chemical Co., Ltd. 3,907,448.68 Not settled yet

Total 3,907,448.68

Amount and reasons for significant changes in book value during the reporting period

Unit: yuan change fee

Item Reason for change

Employee compensation payable

(1) Presentation of employee benefits payable

Unit: Yuan

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Item Opening balance Increase in the current period Decrease in the current period Ending balance

Short-term salary 31,745,920.42 136,154,058.10 140,892,610.51 27,007,368.01

2. Post-employment benefits-settings

38,833.77 11,263,100.04 11,263,100.04 38,833.77 Withdrawal plan

Total 31,784,754.19 147,417,158.14 152,155,710.55 27,046,201.78

(2) Presentation of short-term remuneration

Unit: Yuan

Item Opening balance Increase in the current period Decrease in the current period Ending balance

Salary, bonus, allowance

30,578,445.23 125,842,310.70 130,581,956.56 25,838,799.37 and subsidies

Employee welfare fees 569,111.85 569,111.85 0.00
Social insurance premiums 23,986.75 4,218,240.98 4,218,240.98 23,986.75 including: medical insurance

23,064.87 3,996,408.61 3,996,408.61 23,064.87 fee

Work injury insurance

921.88 188,363.64 188,363.64 921.88 fee

maternity insurance

33,468.73 33,468.73 0.00 fee

Housing provident fund 15,753.00 5,324,180.00 5,322,849.00 17,084.00
Trade union funds and employee education

1,127,735.44 200,214.57 200,452.12 1,127,497.89 Education funds

Total 31,745,920.42 136,154,058.10 140,892,610.51 27,007,368.01

(3) Display of defined contribution plan

Unit: Yuan

Item Opening balance Increase in the current period Decrease in the current period Ending balance

Basic pension insurance 37,656.96 10,978,144.71 10,978,144.71 37,656.96
Unemployment insurance premium 1,176.81 284,955.33 284,955.33 1,176.81Total 38,833.77 11,263,100.04 11,263,100.04 38,833.77Other instructions
Taxes payable

Unit: Yuan

Item Ending balance Beginning balance

Value-added tax 233,503.51 1,909,539.59Corporate income tax 524,523.21 1,302,448.14Personal income tax 1,392,132.53 3,516,776.41Urban maintenance and construction tax 11,880.09 96,523.98 Education fee surcharge 6,999.24 57,416.62 Local education surcharge 4,666.16 38,277.75 Others 22,880.11 32,278.18 Total 2,196,584.85 6,953,260.67

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Other instructions

Liabilities held for sale

Unit: Yuan

Item Ending balance Beginning balance

Other instructions

Non-current liabilities due within one year

Unit: Yuan

Item Ending balance Beginning balance

Long-term borrowings due within one year 95,745,681.88 95,745,681.88 Lease liabilities due within one year 40,911,971.40 38,724,619.92 Total 136,657,653.28 134,470,301.80Other notes:

Among the long-term loans due within one year, 95,745,681.88 yuan are mortgage loans. The collateral for this loan is the property rights held by its subsidiary Jilin Yongda Electric Switch Co., Ltd., which are Ji (2018) Jilin City Real Estate No. 0104786, Ji (2018) Jilin City Real Estate No. No. 0104795, Jilin City Real Estate No. 0104788 (2018), and the property held by its subsidiary Beijing Rongyu Technology Co., Ltd. is Beijing (2017) Kai Real Estate No.

The guarantor of the property No. 0016350 is Beijing Shoutuo Ronghui Investment Co., Ltd., its subsidiary Rongyu Huatong Leasing (Tianjin) Co., Ltd. and its subsidiary Jilin Yongda Electric Switch Co., Ltd.

Note: Bank of Wenzhou Co., Ltd. and Zhejiang Zheshang Asset Management Co., Ltd. signed an "Asset Transfer Contract" numbered [2020 Zheshang Wen Bank Project-01] on December 29, 2020, and Bank of Wenzhou Co., Ltd. The claims and all subordinate rights under the "Wenzhou Bank Non-natural Person Loan Contract" No. [733002020 Qidai Zi No. 00151] and its supplementary agreement (hereinafter collectively referred to as the "subject claims") are transferred to Zhejiang Zheshang Asset Management Co., Ltd. Houhaochen Medical signed a debt recognition and installment repayment agreement with Zhejiang Zheshang Asset Management Co., Ltd. No. [2021 Zheshang-Wenxing-Rongyu Project-001]. According to the aforementioned installment repayment agreement, the company's relevant borrowings are overdue on the balance sheet date. The company accrues relevant borrowing interest based on the overdue interest rate in the current period, and the relevant borrowing interest is included in other payables - interest payable.

Other current liabilities

Unit: Yuan

Item Ending balance Beginning balance

Output tax to be transferred 1,354,242.24 1,140,508.95 Endorsed undue bills 3,241,708.04 Total 1,354,242.24 4,382,216.99 Increase or decrease in short-term bonds payable:

Unit: yuan per face

Overflow discount

Bond par value issuance Bond issuance Beginning of period Current period Value calculation Current period End of period Whether par value Price amortization

Name Interest Rate Date Term Amount Balance Issuance Profit Repayment Balance Default Cancellation

information

total

Other notes:

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Long-term borrowing

(1) Classification of long-term loans

Unit: Yuan Item Ending balance Beginning balance

Description of long-term loan classification:

Other instructions, including interest rate ranges:

Bonds payable

(1) Bonds payable

Unit: Yuan Item Ending balance Beginning balance

(2) Increases and decreases in bonds payable (excluding preference shares, perpetual bonds and other financial instruments classified as financial liabilities)

Unit: yuan per face

Overflow discount

Bond par value issuance Bond issuance Beginning of period Current period Value calculation Current period End of period Whether par value Price amortization

Name Interest Rate Date Term Amount Balance Issuance Profit Repayment Balance Default Cancellation

information

total

(3) Description of convertible corporate bonds

(4) Description of other financial instruments classified as financial liabilities

Basic information on preferred shares, perpetual bonds and other financial instruments outstanding at the end of the period

Statement of changes in outstanding preferred stocks, perpetual bonds and other financial instruments at the end of the period

Unit: yuan outstanding. Beginning of the period. Increase in the current period. Decrease in the current period. End of the period.

financial engineering

Quantity Book value Quantity Book value Quantity Book value Quantity Book value instrument

Explanation of the basis for classifying other financial instruments as financial liabilities

Other instructions

Lease liabilities

Unit: Yuan Item Ending balance Beginning balance

Lease liabilities 138,659,506.36 151,095,010.40 Full text of the 2025 Semi-annual Report of Haochen Medical Technology Co., Ltd.

Total 138,659,506.36 151,095,010.40Other instructions:

Long-term payables

Unit: Yuan Item Ending balance Beginning balance

(1) List long-term payables according to the nature of the payment

Unit: Yuan Item Ending balance Beginning balance

Other notes:

(2) Special accounts payable

Unit: Yuan Item Beginning balance Increase in the current period Decrease in the current period Ending balance Reasons for formation

Other notes:

Long-term employee benefits payable

(1) Long-term employee salary payable table

Unit: Yuan Item Ending balance Beginning balance

(2) Changes in defined benefit plans

Present value of defined benefit plan obligations:

Unit: Yuan Item Amount of the current period Amount of the previous period

Plan assets:

Unit: Yuan Item Amount of the current period Amount of the previous period

Net liabilities (net assets) of defined benefit plans

Unit: Yuan Item Amount of the current period Amount of the previous period

Description of the content of the defined benefit plan and the risks associated with it, as well as the impact on the company's future cash flows, timing and uncertainty:

Explanation of significant actuarial assumptions and sensitivity analysis results of defined benefit plans:

Other notes:

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Estimated liabilities

Unit: Yuan Item Ending balance Beginning balance Reason for formation

Other explanations, including important assumptions and estimation instructions related to important estimated liabilities:

Deferred income

Unit: Yuan Item Beginning balance Increase in the current period Decrease in the current period Ending balance Reasons for formation

Government subsidies 8,661,684.77 223,494.36 8,438,190.41 Related to assets

Total 8,661,684.77 223,494.36 8,438,190.41

Other notes:

Projects involving government subsidies:

December 2024 New additions in this period Included in operations in this period Included in others in this period Subtracted in this period June 2025 Asset-related/liability items Other changes

31st Amount of subsidy Amount of external income Amount of income Amount of expenses 30th day Related to income

Annual output of 1,200 units of 40.5kV permanent magnets

High voltage vacuum circuit breaker, 8000

Taiwan universal permanent magnet low-voltage vacuum circuit breaker 8,445,017.95 203,494.38 8,241,523.57 Special funds related to asset-related circuit breaker construction projects and

Public facilities supporting fee subsidies

enterprise resource planning system

(ERP), enterprise management informatization 216,666.82 19,999.98 196,666.84 Government subsidies for asset-related projects

Total 8,661,684.77 223,494.36 8,438,190.41

Other non-current liabilities

Unit: Yuan Item Ending balance Beginning balance

Other notes:

Share capital

Unit: Yuan Increase or decrease in this change (+, -)

Balance at the beginning of the period Balance at the end of the period Issuance of new shares Bonus shares Conversion of public reserve funds Others Subtotal

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

840,000,00 840,000,00 Total shares

0.00 0.00Other instructions:

Other equity instruments

(1) Basic information on preferred shares, perpetual bonds and other financial instruments outstanding at the end of the period

(2) Statement of changes in outstanding preferred stocks, perpetual bonds and other financial instruments at the end of the period

Unit: yuan outstanding. Beginning of the period. Increase in the current period. Decrease in the current period. End of the period.

financial engineering

Quantity Book value Quantity Book value Quantity Book value Quantity Book value

tools

Changes in other equity instruments during the current period, explanations of the reasons for the changes, and the basis for relevant accounting treatments:

Other notes:

Capital reserve

Unit: Yuan

Item Opening balance Increase in the current period Decrease in the current period Ending balance Capital premium (equity premium

417,969.67 417,969.67 price)

Other capital reserves 21,267,868.61 21,267,868.61 Total 21,685,838.28 21,685,838.28 Other explanations, including changes in increases and decreases in the current period and explanations of reasons for changes:

Treasury stocks

Unit: Yuan

Item Beginning balance Increase in the current period Decrease in the current period Other explanations of the closing balance, including changes in increases and decreases in the current period and explanation of reasons for changes:

Other comprehensive income

Unit: Yuan Amount incurred in the current period

Less: previous period Less: previous period

Income for the current period is included in other items and is included in other items. Attribution after tax

Item Opening balance Less: Income Attribution after tax Ending balance before tax Comprehensive income Comprehensive income Attributable to minority shares

Tax expenses at the parent company

Amount transferred in the current period Transferred in in the current period

Profit and loss Retained earnings

1. Can’t

Reclassified into - -Other comprehensive income of profit and loss 51,447,58 51,447,58 1.38 1.38

Others - -

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Equity instruments 51,447,58 51,447,58 Fair investment 1.38 1.38 Value changes

2. Will be heavy

Classified entry loss 2,791,913 1,289,382

1,502,531 1,502,531

Other benefits .86 .29

.57 .57

Comprehensive income

Among them: right

You can do it under the law - -

2,791,845 1,289,107 transferred to profit and loss 1,502,738 1,502,738

.64 .40Other comprehensive .24 .24

income

foreign currency

Financial statements 68.22 206.67 206.67 274.89 Translation difference

- - -Other comprehensive

48,655,66 1,502,531 1,502,531 50,158,19Total income

7.52 .57 .57 9.09 Other instructions, including adjustments to the initial recognition amount of the effective portion of cash flow hedging gains and losses converted into hedged items:

Special reserves

Unit: Yuan

Surplus reserve

Unit: Yuan

Item Beginning balance Increase in the current period Decrease in the current period Ending balance Statutory surplus reserve 40,813,718.28 40,813,718.28 Total 40,813,718.28 40,813,718.28 Description of the surplus reserve, including changes in the current period and reasons for changes:

Undistributed profits

Unit: Yuan

Projects in this issue Previous issue

Undistributed profits at the end of the previous period before adjustment -455,808,714.88 -418,117,817.07 Total undistributed profits at the beginning of the period before adjustment (adjustment +,

-455,808,714.88 -418,117,817.07 reduction-)

Adjusted opening undistributed profit -455,808,714.88 -418,117,817.07 plus: net profit attributable to owners of the parent company for the period

-23,751,065.12 553,485.18 profit

Undistributed profits at the end of the period -479,559,780.00 -417,564,331.89 Adjustment of undistributed profits at the beginning of the period:

Due to the retrospective adjustment of the "Accounting Standards for Business Enterprises" and its related new regulations, the undistributed profit at the beginning of the period was affected.
Due to changes in accounting policies, the undistributed profit at the beginning of the period is affected.

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Due to the correction of major accounting errors, the undistributed profit at the beginning of the period was affected.

4). Changes in the scope of consolidation due to the same control will affect the undistributed profit at the beginning of the period. 5) The total of other adjustments affects the opening undistributed profit yuan.

Operating income and operating costs

Unit: Yuan Amount of the current period Amount of the previous period Items

Revenue Cost Revenue Cost Main business 313,635,948.22 178,274,250.68 382,010,234.10 206,067,242.04Total 313,635,948.22 178,274,250.68 382,010,234.10 206,067,242.04 Decomposition information of operating income and operating costs:

Unit: Yuan

Division 1 Division 2 Total Contract Classification

Operating income Operating cost Operating income Operating cost Operating income Operating cost Operating income Operating cost Business type

Among them:

According to place of business

Distinguish classification

Among them:

market or customer

Household type

Among them:

Contract type

Among them:

Transfer by product

give time

Classification

Among them:

According to contract period

Limited classification

Among them:

According to sales channel

Road classification

Among them:

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

total

Information related to performance obligations:

The company's pre-payments, the company's performance obligations, and the important payment terms. The company's commitment to transfer is the main responsibility.

The item will be refunded to the customer during the period. The type and time of the quantity guarantee. The nature of the goods. Anyone.

Account’s money and other explanations of related obligations

Information related to the transaction price allocated to the remaining performance obligations:

At the end of this reporting period, the amount of revenue corresponding to the performance obligations that have been signed but have not been performed or have not been completed is RMB 0.00, of which RMB 0.00 is expected to be recognized as revenue in year 0, RMB 0.00 is expected to be recognized as revenue in year 0, and RMB 0.00 is expected to be recognized as revenue in year 0.

Information related to variable consideration in the contract:

Major contract changes or major transaction price adjustments

Unit: Yuan

Item Accounting treatment method Amount of impact on income

Other instructions

Taxes and surcharges

Unit: Yuan

Item Amount for the current period Amount for the previous period

Urban maintenance and construction tax 71,412.06 127,730.59 Education surcharge 70,044.44 126,078.07 Property tax 880,637.35 883,713.78 Land use tax 4,385.15 4,385.15 Vehicle and vessel use tax 4,350.00 1,800.00 Stamp duty 101,025.40 63,640.66 Other taxes and fees 14,577.64 20,956.48 Total 1,146,432.04 1,228,304.73 Other instructions:

Management expenses

Unit: Yuan

Item Amount for the current period Amount for the previous period

Employee compensation 45,916,309.23 51,008,494.05 Depreciation expense 3,455,340.37 3,590,866.70 Amortization of intangible assets 1,821,106.36 1,802,529.16 Office expenses 626,186.88 1,060,478.87 Business entertainment expenses 677,386.34 761,783.66 Travel expenses 345,629.41 416,857.54 House rental expenses 273,689.16 128,097.76 Service fees 2,553,945.56 2,932,174.00 Amortization of right-of-use assets 6,744,366.15 7,093,577.98 Property management expenses 2,039,182.45 2,090,381.34 Amortization of long-term prepaid expenses 4,055,979.90 3,668,248.33 Others 261,784.85 360,665.94 Total 68,770,906.66 74,914,155.33

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Other instructions

Sales expenses

Unit: Yuan

Item Amount for the current period Amount for the previous period

Employee compensation 25,056,868.30 29,467,598.04 Car expenses 129,416.30 202,877.15 Travel expenses 15,079.50 118,302.55 Office expenses 36,501.14 67,883.89 Business entertainment expenses 28,708.40 32,502.00 Service fee 438,005.96 64,020.07 Business promotion fee 48,605,805.09 57,082,927.37 Property management fee 454,738.51 408,173.22 Amortization of right-of-use assets 1,196,623.82 1,205,257.55 Others 979,009.41 1,097,785.60 Total 76,940,756.43 89,747,327.44

Other notes:

Research and development expenses

Unit: Yuan

Item Amount for the current period Amount for the previous period

Employee compensation 7,445,606.93 3,156,086.73 Material fee 174,057.12 198,700.54 Depreciation and amortization fee 107,736.93 60,876.68 Testing fee 0.00 0.00 Service fee 54,950.94 47,045.29 Others 184,228.54 142,767.27 Total 7,966,580.46 3,605,476.51

Other instructions

Financial expenses

Unit: Yuan

Item Amount for the current period Amount for the previous period

Interest expense 20,256,561.25 21,454,310.59 Less: Interest income 333,837.89 897,501.49 Net interest expense 19,922,723.36 20,556,809.10 Bank fees 723,632.22 2,108,275.82 Total 20,646,355.58 22,665,084.92

Other instructions

Other income

Unit: Yuan

Sources of other income Amount incurred in the current period Amount incurred in the previous period

Corporate value-added tax will be refunded upon collection 2,352,373.97 1,448,762.42 Government subsidies related to daily operating activities 370,301.18 254,626.64 Others 112,922.34 114,478.55 Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Total 2,835,597.49 1,817,867.61

Net exposure hedging income

Unit: Yuan Item Amount of the current period Amount of the previous period

Other instructions

Gains from changes in fair value

Unit: Yuan Source of income from changes in fair value Amount incurred in the current period Amount incurred in the previous period

Other notes:

Investment income

Unit: Yuan Item Amount of the current period Amount of the previous period

Long-term equity investment income calculated using the equity method 4,349,700.10 16,737,122.44 Total 4,349,700.10 16,737,122.44 Other notes

Credit impairment losses

Unit: Yuan Item Amount of the current period Amount of the previous period

Bad debt losses on accounts receivable 2,879,963.83 1,588,939.98 Bad debt losses on other receivables -283,867.09 260,383.47 Total 2,596,096.74 1,849,323.45 Other notes

Asset impairment losses

Unit: Yuan Item Amount of the current period Amount of the previous period

Other notes:

Income from asset disposal

Unit: Yuan Source of asset disposal income Amount incurred in the current period Amount incurred in the previous period

Asset disposal 678,017.94

Non-operating income

Unit: Yuan

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Gold items included in non-recurring profits and losses for the current period Amount incurred in the current period Amount incurred in the previous period

Others 129,009.74 165,728.27 129,009.74Total 129,009.74 165,728.27 129,009.74Other instructions:

Non-operating expenses

Unit: Yuan Financial items included in non-recurring gains and losses for the current period Amount incurred in the current period Amount incurred in the previous period

Late payment fees 221,292.11 221,292.11 Administrative fines 46,531.59 28,160.00 46,531.59 Breach of contract/litigation claims losses 0.00 Others 2,282,361.35 138,548.68 2,282,361.35 Total 2,550,185.05 166,708.68 2,550,185.05Other instructions:

Income tax expenses

(1) Income tax expense schedule

Unit: Yuan

Item Amount for the current period Amount for the previous period

Current income tax expense 2,928,926.22 1,540,836.51 Deferred income tax expense -385,641.63 -160,961.48 Total 2,543,284.59 1,379,875.03

(2) Adjustment process of accounting profits and income tax expenses

Unit: Yuan

Item Amount incurred in this period

Total profit -32,071,096.67 Income tax expense calculated at statutory/applicable tax rates -8,388,075.50 Impact of different tax rates applicable to subsidiaries 2,155,323.56 Impact of non-taxable income 1,412,574.97 Impact of non-deductible costs, expenses and losses 154,509.12 Deductible temporary differences or deductible temporary differences that have not been recognized as deferred income tax assets in this period

7,208,952.44 Impact of loss

Income tax expenses 2,543,284.59Other instructions

Other comprehensive income

See Note 57 for details

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Cash flow statement items

(1) Cash related to operating activities

Other cash received related to operating activities

Unit: Yuan Item Amount of the current period Amount of the previous period

Financial expenses and others 1,110,930.98 897,501.49 Current accounts 1,376,495.27 1,340,793.33 Total 2,487,426.25 2,238,294.82 Description of other cash received related to operating activities:

Other cash paid related to operating activities

Unit: Yuan Item Amount of the current period Amount of the previous period

Three expenses and others 45,837,288.84 58,760,309.66 Current accounts 4,094,229.42 4,552,495.06 Total 49,931,518.26 63,312,804.72 Description of other cash paid related to operating activities:

(2) Cash related to investing activities

Other cash received related to investing activities

Unit: Yuan Item Amount of the current period Amount of the previous period

Significant cash received related to investing activities

Unit: Yuan Item Amount of the current period Amount of the previous period

Description of other cash received related to investing activities:

Other cash paid related to investing activities

Unit: Yuan Item Amount of the current period Amount of the previous period

Significant cash payments related to investing activities

Unit: Yuan Item Amount of the current period Amount of the previous period

Description of other cash paid related to investment activities:

(3) Cash related to financing activities

Other cash received related to financing activities

Unit: Yuan Item Amount of the current period Amount of the previous period

Description of other cash received related to financing activities:

Other cash payments related to financing activities

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Unit: Yuan

Item Amount for the current period Amount for the previous period

Others 286,399.61 331,045.56 Total 286,399.61 331,045.56 Description of other cash paid related to financing activities:

Changes in various liabilities arising from financing activities

□Applicable Not applicable

(4) Explanation on presenting cash flow in net amount

Item Relevant facts and circumstances Basis for net presentation Financial impact

(5) Major activities and financial impacts that do not involve current cash receipts and payments but affect the company's financial status or may affect the company's cash flow in the future

Supplementary information for cash flow statement

(1) Supplementary information for cash flow statement

Unit: Yuan

Supplementary information Amount for the current period Amount for the previous period

1． Adjust net profit to cash flow from operating activities

Quantity:

Net profit -34,614,381.26 2,806,101.19 plus: asset impairment provision -2,881,096.74 -1,849,323.45 Depreciation of fixed assets, depreciation of oil and gas assets

5,518,734.04 6,924,930.18 Depreciation of consumption and productive biological assets

Depreciation of right-of-use assets 25,114,248.09 24,017,825.53 Amortization of intangible assets 1,897,125.54 1,873,548.34 Amortization of long-term prepaid expenses 1,517,290.25 7,094,230.97

Disposal of fixed assets, intangible assets and other

Loss of other long-term assets (income is listed with "-" sign -678,017.94 0.00)

Loss on scrapping of fixed assets (income based on

0.00 0.00 “-” (please fill in the column)

Loss from change in fair value (gain based on

0.00 0.00 “-” (please fill in the column)

Financial expenses (revenues are filled in with "-"

20,256,561.25 21,454,310.59 columns)

Investment losses (income is filled in with "-"

-4,349,700.10 -16,737,122.44 columns)

Deferred tax assets decreased (increased by

430,392.77 296,226.45 (Fill in “-”)

Deferred tax liabilities increased (decreased by

-379,098.07 -457,187.93 (Fill in “-”)

Decrease in inventory (increase marked with "-"

-2,523,284.59 -1,840,626.14 fill in the column)

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Decrease in operating receivables (increase in

39,871,991.74 420,750,058.52 (please fill in with "-")

Increase (decrease) in operating payables

-74,454,399.82 -462,902,878.28 (please fill in the list with "-")

Others -2,316,154.17 5,569,727.00

Net cash flow generated from operating activities -27,589,789.01 6,999,820.53 2. Major investments and financing that do not involve cash receipts or payments

Activities:

debt to capital

Convertible corporate bonds due within one year

Financing leased fixed assets

3． Net changes in cash and cash equivalents:

Closing balance of cash 94,863,885.45 126,094,525.40 Less: Opening balance of cash 131,570,807.19 141,916,655.64 Add: Closing balance of cash equivalents

Less: Opening balance of cash equivalents

Net increase in cash and cash equivalents -36,706,921.74 -15,822,130.24

(2) Net cash paid in the current period to acquire subsidiaries

(3) Net cash received from disposal of subsidiaries in the current period

(4) Composition of cash and cash equivalents

Unit: Yuan

Item Ending balance Beginning balance

Cash 94,863,885.45 131,570,807.19 Including: Cash on hand 73,091.08 34,518.08 Bank deposits that can be used for payment at any time 93,340,105.77 119,145,608.27 Other monetary resources that can be used for payment at any time

1,450,688.60 12,390,680.84 gold

Balance of cash and cash equivalents at the end of the period 94,863,885.45 131,570,807.19

(5) Situations where the scope of use is limited but still represents cash and cash equivalents

Unit: Yuan Items that are still cash and cash equivalents Amount for the current period Amount for the previous period

Reason

(6) Monetary funds that are not cash and cash equivalents

Unit: Yuan Items that are not cash and cash equivalents Amount for the current period Amount for the previous period

Reason

Other notes:

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

(7) Description of other major activities

Notes on the items in the statement of changes in owners' equity describe the names of "other" items and the amount of adjustments to be made to the closing balance of the previous year:
Foreign currency monetary items

(1) Foreign currency monetary items

Unit: Yuan

Item Foreign currency balance at the end of the period Conversion exchange rate Conversion of RMB balance at the end of the period Monetary Funds

Of which: US dollars

Euro

HKD 4,090.00 0.91195 3,729.88

Accounts receivable

Of which: US dollars

Euro

Hong Kong dollar

long term borrowing

Of which: US dollars

Euro

Hong Kong dollar

Other notes:

(2) Description of overseas operating entities, including for important overseas operating entities, their main overseas business location, accounting standard currency and basis for selection should be disclosed. If the accounting standard currency changes, the reasons should also be disclosed. □Applicable Not applicable

Leasing

(1) The company serves as the lessee

Applicable □Not applicable

Variable lease payments not included in the measurement of lease liabilities □Applicable Not applicable

Simplified treatment of short-term leases or lease payments for low-value assets Applicable □Not applicable

Situations involving sale and leaseback transactions

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

(2) The company as the lessor

Operating lease as lessor

Applicable □Not applicable

Unit: Yuan Including: Variable lease items not included in lease receipts Lease income

Payment related revenue

Beijing Economic Development Zone property leasing 1,038,523.86

Total 1,038,523.86

Finance lease as lessor

□Applicable Not applicable

Undiscounted lease payments for each of the next five years

□Applicable Not applicable

Reconciliation of undiscounted lease receipts and net lease investment

(3) Recognizing financial lease sales profits and losses as a manufacturer or distributor

□Applicable Not applicable

Data resources
Others

8. R&D expenditures

Unit: Yuan

Item Amount for the current period Amount for the previous period

Wages and salaries 7,445,606.93 3,156,086.73 Direct consumption of materials, fuel and power expenses 174,057.12 198,700.54 Amortization expenses 107,736.93 60,876.68 Other expenses directly related to R&D activities 239,179.48 189,812.56 Total 7,966,580.46 3,605,476.51 Including: Expenditure R&D expenditure 7,966,580.46 3,605,476.51

R&D projects that meet capitalization conditions

Unit: Yuan Increase amount in this period Decrease amount in this period

Item Opening balance Internal development Confirmed as N/A Transferred to current period Closing balance Others

Expenditure tangible assets Profit and loss

total

Significant Capitalized R&D Projects

Estimated economic benefits when capitalization begins Specific projects to begin capitalization R&D progress Estimated completion time

The full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Impairment provision for development expenditures

Unit: Yuan Item Beginning balance Increase in the current period Decrease in the current period Ending balance Impairment test situation

Important outsourced research projects

The criteria for judging capitalization or expense and the specific way in which economic benefits are expected to be generated based on the name of the project.

According to

Other notes:

9. Changes in consolidation scope

Business merger not under common control

(1) Business mergers not under common control that occurred during the current period

Unit: Yuan Purchase date to Purchase date to Purchase date to the purchased party Equity acquisition Equity acquisition Equity acquisition Equity acquisition Equity acquisition Purchased at the end of the period Acquired at the end of the period Acquired at the end of the period

Name Time Point Cost Proportion Method Determination Basis Buyer’s Income Buyer’s Net Buyer’s Cash Income Profit Cash Flow Other instructions:

(2) Merger costs and goodwill

Unit: Yuan combined cost

--cash

--Fair value of non-cash assets

--Fair value of debt issued or assumed

--Fair value of equity securities issued

--Fair value of contingent consideration

--The fair value of the equity held before the purchase date on the purchase date

--Others

Total combined costs

Less: Share of fair value of identifiable net assets acquired

Goodwill/merger cost is less than the fair value share of identifiable net assets acquired

Method for determining the fair value of merger costs:

Description of contingent consideration and its changes

The main reasons for the formation of large amounts of goodwill:

Other notes:

(3) The identifiable assets and liabilities of the purchased party on the purchase date

Unit: Yuan

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Fair value on acquisition date Book value assets on acquisition date:

Monetary funds

Accounts receivable

Inventory

fixed assets

intangible assets

Liabilities:

borrow money

Accounts payable

Deferred income tax liability

net worth

Less: Minority interests

Net assets acquired

Method for determining the fair value of identifiable assets and liabilities:

Contingent liabilities of the purchased party assumed in a business combination:

Other notes:

(4) Gains or losses arising from the remeasurement of equity held before the purchase date at fair value

Is there any transaction that realizes the business combination step by step through multiple transactions and obtains control during the reporting period Yes  No

(5) Relevant explanation that the merger consideration or the fair value of the acquiree’s identifiable assets and liabilities cannot be reasonably determined on the acquisition date or at the end of the current period of merger.

(6) Other instructions

Merger of enterprises under common control

(1) Business mergers under the same control that occurred in the current period

Unit: Yuan for the current period of the merger. The composition for the current period of the merger is the same.

Business combination from the beginning of the period to the merger period from the beginning of the period to the merger period Comparative period Comparative period Enterprises under the control of the merged party On the date of merger

Obtained from Merger date Merger date Merger date Merger name of merged party Determination basis of business merger

Equity ratio, merger’s acquisition, merger’s net income, basis of net profit

Other instructions for profit:

(2) Merger cost

Unit: Yuan

Merger costs

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

--cash

--Book value of non-cash assets

--The book value of debt issued or assumed

--The face value of the equity securities issued

--Contingent consideration

Description of contingent consideration and its changes:

Other notes:

(3) Book value of the assets and liabilities of the merged party on the merger date

Unit: Yuan

Merger date Closing assets of the previous period:

Monetary funds

Accounts receivable

Inventory

fixed assets

intangible assets

Liabilities:

borrow money

Accounts payable

net worth

Less: Minority interests

Net assets acquired

Contingent liabilities of the merged party assumed in business mergers: Other instructions:

Reverse purchase

Basic information of the transaction, the basis for the transaction to constitute a reverse purchase, whether the assets and liabilities retained by the listed company constitute business and the basis for it, the determination of the merger cost, the amount of equity adjustment when dealing with equity transactions and its calculation:

Disposal of subsidiaries

Is there any transaction or event that resulted in the loss of control of a subsidiary during this period Yes  No

Is there any situation where investments in subsidiaries are disposed of step by step through multiple transactions and control is lost in the current period Yes  No

Changes in the scope of consolidation due to other reasons

Explain the changes in the scope of consolidation caused by other reasons (such as the establishment of new subsidiaries, liquidation of subsidiaries, etc.) and their related circumstances:

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Subsidiary name Reason for change in consolidation scope Date of change Whether industrial and commercial changes have been made

Zhaoqing Delun Medical Management Co., Ltd. New subsidiary February 2025 Yes

Huizhou Haochendelun Medical Investment Co., Ltd. New subsidiary June 2025 Yes

Others

10. Interests in other entities

Interests in subsidiaries

(1) Composition of enterprise groups

Unit: Yuan

Shareholding ratio

Name of subsidiary company Registered capital Main place of business Place of registration Nature of business How to obtain

direct indirect

Jilin Yongda Electric

300,000,00 switch production and

Gas Switch Co., Ltd. Jilin City Jilin City 100.00% 0.00% Investment and establishment

0.00 sales

company

Jilin Chen Damao 2,000,000.

Jilin City Jilin City Switch sales 0.00% 100.00% Investment and establishment of Yi Co., Ltd. 00

Beijing Rongyuke 60,000,000 Technology development and

Beijing City Beijing City 100.00% 0.00% Investment to establish a technology co., Ltd. .00 Technical consultation

Rongyuhua Rental

170,000,00

Leasing (Tianjin) Tianjin City Tianjin City Financial leasing 100.00% 0.00% Investment establishment

0.00

Ltd.

Beijing Lu Luba

10,000,000 Technology promotion services Non-identical Control Technology Co., Ltd. Beijing Beijing 0.00% 100.00%

.00 Merger Division

Beijing Ruichian

1,000,000. Non-common control Information Technology Co., Ltd. Beijing Beijing Technical services 0.00% 100.00%

00 Merger company

Beijing Chenjiuke 1,000,000.

Beijing City Beijing City Technical Services 100.00% Investment to establish Technology Co., Ltd. 00

Zhiyu Medical Investment 50,000,000

Guangzhou City Guangzhou City Health Consulting 100.00% 0.00% Investment to establish a capital limited company .00

Zhiyu (fragrant

1,000,000. Hong Kong Special Tour Hong Kong Special Tour

Hong Kong) International Health Consulting 0.00% 100.00% Investment and establishment

00 Administrative Region Administrative Region

Ltd.

Guangdong Delun Medical

52,000,000 Non-identical Control Therapy Group Co., Ltd. Guangzhou City Guangzhou City Investment Management 0.00% 51.00%

.00 Merger Company

Delun, Guangzhou

2,000,000. Non-commonly controlled dental clinic Guangzhou City Guangzhou City Dental Medical Care 0.00% 51.00%

00 Merger Co., Ltd.

Guangzhou Kaituo

Baoye Delunkou 10,000,000 Not under common control

Guangzhou City Guangzhou City Dental Medicine 0.00% 51.00%

Cavity Clinic has .00 Amalgamated Ltd.

Guangzhou Kaituobin

Jiang Delun Dental 2,000,000. Not under the same control

Guangzhou City Guangzhou City Dental Medicine 0.00% 51.00%

Outpatient Department Limited 00 Merger Company

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Shunde, Foshan City

5,000,000. Non-common control Delun Stomatology Foshan City Foshan City Oral Medicine 0.00% 51.00%

00 Merger Institute Co., Ltd.

Guangzhou Delun Yue

5,000,000. Non-common control dental clinic Guangzhou City Guangzhou City Dental Medicine 0.00% 51.00%

00 Merger Department Co., Ltd.

Guangzhou Delun Yue

6,000,000. Non-common control guaranteed dental clinic Guangzhou City Guangzhou City Dental Medical Care 0.00% 51.00%

00 Merger Department Co., Ltd.

Guangzhou Delunli

6,000,000. Non-identical control of Thai Dental Clinic Guangzhou City Guangzhou City Dental Medical Care 0.00% 51.00%

00 Merger Department Co., Ltd.

Guangzhou Delungao

10,000,000 Non-common control Sheng Dental Clinic Guangzhou City Guangzhou City Dental Medical Care 0.00% 51.00%

.00 Merger Division Ltd.

Delun District, Guangzhou

6,000,000. Non-same controlled dental clinic Guangzhou City Guangzhou City Dental Medical Care 0.00% 51.00%

00 Merger Department Co., Ltd.

Guangzhou Delun Stone

2,000,000. Non-same control Xi Dental Clinic Guangzhou City Guangzhou City Dental Medical Care 0.00% 51.00%

00 Merger Department Co., Ltd.

Guangzhou Delun flower

2,000,000. Dental clinic in a place not under common control Guangzhou City Guangzhou City Oral Medical Care 0.00% 51.00%

00 Merger Department Co., Ltd.

Guangzhou Delunchi

6,000,000. Non-same control post dental clinic Guangzhou City Guangzhou City Dental Medical Care 0.00% 51.00%

00 Merger Department Co., Ltd.

Guangzhou Delun San

Yuanli Dental Hospital 6,000,000. Not under common control

Guangzhou City Guangzhou City Dental Medicine 0.00% 51.00%

Clinic Co., Ltd. 00 Merger Division

Guangzhou Delunxian

2,000,000. Dental clinic in non-same controlled villages Guangzhou City Guangzhou City Dental Medical Care 0.00% 51.00%

00 Merger Department Co., Ltd.

Guangzhou Delunjing

6,000,000. Non-same control Xi Dental Clinic Guangzhou City Guangzhou City Dental Medical Care 0.00% 51.00%

00 Merger Department Co., Ltd.

Guangzhou Delunhui

2,000,000. Non-common control Qiao Dental Clinic Guangzhou City Guangzhou City Dental Medical Care 0.00% 51.00%

00 Merger Department Co., Ltd.

Guangzhou Delunyi

2,000,000. Non-common control port dental clinic Guangzhou City Guangzhou City Dental Medicine 0.00% 51.00%

00 Merger Department Co., Ltd.

Guangzhou Delunxi

Door oral door 2,000,000. Not under the same control

Guangzhou City Guangzhou City Dental Medicine 0.00% 51.00%

Clinic Co., Ltd. 00 Merger Division

Guangzhou Delunxin

6,000,000. Non-identical Control Tang Dental Clinic Guangzhou City Guangzhou City Dental Medical Care 0.00% 51.00%

00 Merger Department Co., Ltd.

Delun, Foshan City

Wanyi Dental Hospital 6,000,000. Not under common control

Foshan City Foshan City Dental Medicine 0.00% 51.00%

Clinic Co., Ltd. 00 Merger Division

Guangzhou Delunwan

5,000,000. Non-identical Control Bo Dental Clinic Guangzhou City Guangzhou City Dental Medical Care 0.00% 51.00%

00 Merger Department Co., Ltd.

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Guangzhou Delunyu

6,000,000.

Three Dental Clinics Guangzhou City Guangzhou City Dental Medicine 0.00% 51.00% Investment and Establishment Department Co., Ltd.

Guangzhou Delunjin

4,000,000.

Platinum Dental Clinic Guangzhou City Guangzhou City Dental Medical Care 0.00% 51.00% Investment and Establishment Department Co., Ltd.

Foshan Shunderong

Guilun Dental 4,500,000.

Foshan City Foshan City Dental Medical Care 0.00% 51.00% Investment to establish outpatient department Co., Ltd. 00

company

Guangzhou Delunfeng

2,500,000.

Ya Dental Clinic Guangzhou City Guangzhou City Dental Medical Care 0.00% 51.00% Investment and Establishment Department Co., Ltd.

Guangzhou Delunyi

6,000,000.

Da Dental Clinic Guangzhou City Guangzhou City Dental Medical Care 0.00% 51.00% Investment and Establishment Department Co., Ltd.

Guangzhou Delunzheng

6,000,000.

Sheng Dental Clinic Guangzhou City Guangzhou City Dental Medicine 0.00% 51.00% Investment and Establishment Department Co., Ltd.

Foshan Nanhaikang

Yidelun Dental 6,000,000.

Foshan City Foshan City Dental Medical Care 0.00% 51.00% Investment to establish outpatient department Co., Ltd. 00

company

Foshan Nanhai Gui

Dadron Oral 6,000,000.

Foshan City Foshan City Dental Medical Care 0.00% 51.00% Investment to establish outpatient department Co., Ltd. 00

company

Zhaoqing Delun Hospital

7,000,000.

Dental Management Co., Ltd. Zhaoqing City Zhaoqing City Dental Medicine 0.00% 51.00% Investment to establish a company

Huizhou City Haochen

10,000,000

Delun Medical Investment Huizhou City Huizhou City Dental Medicine 0.00% 51.00% Investment and establishment

.00

Capital Co., Ltd.

Explanation on the difference between the proportion of shareholding in subsidiaries and the proportion of voting rights:

Basis for holding half or less of the voting rights but still controlling the invested unit, and holding more than half of the voting rights but not controlling the invested unit:

For important structured entities included in the scope of consolidation, the basis for control is:

Basis for determining whether a company is agent or principal:

Other notes:

(2) Important non-wholly owned subsidiaries

Unit: Yuan

Attributable to minority shareholders in this period. Announcement to minority shareholders in this period. Name of remaining company with minority shareholders’ equity at the end of the period. Shareholding ratio of minority shareholders.

The amount of dividends distributed by Guangdong Delun Medical Group is

49.00% -10,863,316.14 35,618,803.91 Co., Ltd.

Explanation on the difference between the shareholding ratio of minority shareholders of subsidiaries and the voting rights ratio:

Other notes:

(3) Main financial information of important non-wholly owned subsidiaries

Unit: Yuan

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Ending balance Beginning balance

Zigong

Non-current Non-current Non-current Non-current company name Current assets Current liabilities Current assets Current liabilities

Dynamic assets Dynamic assets Dynamic assets Assets Total Liabilities Total Assets Total Liabilities Total

Property Debt Property Debt Guangdong

Delenn

134,0 306,8 440,9 225,0 145,6 370,6 166,8 320,3 487,1 236,5 158,6 395,2Medical

12,58 89,37 01,95 15,11 19,97 35,09 10,34 20,81 31,15 71,84 97,83 69,68Group

4.48 3.28 7.76 4.25 8.61 2.86 3.98 3.59 7.57 8.70 9.38 8.08Limited

company

Unit: Yuan

Amount for the current period Amount for the previous period

Subsidiary name

Comprehensive Income Operating Activities Comprehensive Income Operating Activities Operating Income Net Profit Operating Income Net Profit

Total Cash Flow Total Cash Flow Guangdong Delun - - -

288,484,5 349,200,2 4,872,024 4,872,024 6,495,088 Medical Group 21,024,60 21,024,60 31,001,27

49.17 94.17 .83 .83 .48 Co., Ltd. 4.59 4.59 3.63

Other notes:

(4) Significant restrictions on the use of enterprise group assets and settlement of enterprise group debts

(5) Financial support or other support provided to structured entities included in the scope of consolidated financial statements

Other notes:

Transactions in which the ownership share of the subsidiary changes and the subsidiary is still controlled

(1) Description of changes in owner’s equity shares of subsidiaries

(2) The impact of the transaction on minority shareholders’ equity and owner’s equity attributable to the parent company

Unit: Yuan

Purchase cost/disposal consideration

--cash

--Fair value of non-cash assets

Total purchase cost/disposal consideration

Less: Share of net assets of subsidiaries calculated based on the proportion of equity acquired/disposed of

difference

Including: Adjustment of capital reserve

Adjust the surplus reserve

Adjust undistributed profits

Other instructions

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Interests in joint ventures or associated enterprises

(1) Important joint ventures or associates

Shareholding ratio Investment in joint ventures or joint ventures or associates Main place of business Registration place Nature of business

Name of operating enterprise Direct indirect accounting treatment method

French Fushun Bank

Liaoning Province Liaoning Province Financial Industry 6.68% Equity Method Accounting Co., Ltd.

Explanation on the difference between the proportion of shareholdings in joint ventures or associates and the proportion of voting rights:

Basis for holding less than 20% of the voting rights but having significant influence, or holding 20% or more of the voting rights but not having significant influence:

On October 22, 2014, the company received the "China Banking Regulatory Commission's Approval on the Change of Equity Interest in Fushun Bank" issued by the China Banking Regulatory Commission, agreeing to Jilin Yongda Group Co., Ltd. (now renamed Haochen Medical Technology Co., Ltd.) to acquire Fushun Bank shares. Co., Ltd. (hereinafter referred to as "Fushun Bank") 9.28% equity (the shareholding ratio as of December 31, 2024 is 6.68%). The company completed the equity transfer procedure on October 30, 2014 and became the largest shareholder of Fushun Bank. According to the resolutions of Fushun Bank's 2014 annual board of directors and shareholders' meeting, the company obtained a director seat on the board of directors of Fushun Bank and obtained the power to participate in decision-making on the financial and operating policies of Fushun Bank. It has a significant influence on Fushun Bank. Therefore, the company's investment in Fushun Bank is accounted for using the equity method.

(2) Main financial information of important joint ventures

Unit: Yuan

Ending balance/amount of the current period Beginning balance/amount of the previous period

current assets

Of which: cash and cash equivalents

non-current assets

Total assets

current liabilities

non-current liabilities

Total liabilities

minority interests

Equity attributable to shareholders of the parent company

Share of net assets calculated based on shareholding ratio

Adjustments

--Goodwill

--Unrealized profits from internal transactions

--Others

Book value of equity investments in joint ventures

There are publicly quoted equity investments in joint ventures

fair value

operating income

financial charges

income tax expense

net profit

Net profit from discontinued operations

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

other comprehensive income

Total comprehensive income

Dividends received from joint ventures during the year

Other instructions

(3) Main financial information of important associates

Unit: Yuan

Ending balance/amount of the current period Beginning balance/amount of the previous period

Current assets 67,282,225,029.95 67,924,654,151.23 Non-current assets 74,019,890,185.17 68,705,292,074.39 Total assets 141,302,115,215.12 136,629,946,225.62 Current liabilities 130,819,049,152.27 124,291,138,915.47 Non-current liabilities 2,181,558,345.70 3,749,391,055.93 Total liabilities 133,000,607,497.97 128,040,529,971.40

Minority shareholders’ equity 74,105,168.31 Equity attributable to shareholders of the parent company 8,301,507,717.15 8,515,311,085.91 Share of net assets calculated based on shareholding ratio 554,540,715.51 568,822,780.54 Adjustment matters

--Goodwill

--Unrealized profits from internal transactions

--Others

Book value of equity investments in associates 554,540,715.51 568,822,780.54 Equity investments in associates with publicly quoted prices

fair value

Operating income 693,813,918.12 911,702,010.61 Net profit 65,115,256.41 250,555,725.11 Net profit from discontinued operations

Other comprehensive income -22,496,081.42 51,684,627.68 Total comprehensive income 42,619,174.99 302,240,352.79

Dividends received from associates during the year

Other instructions

(4) Summary financial information of unimportant joint ventures and associates

Unit: Yuan

Ending balance/amount of the current period Beginning balance/amount of the previous period

Joint Venture:

The total of the following items calculated based on shareholding ratio

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd. Associates:

The total of the following items calculated based on shareholding ratio

Other instructions

(5) Explanation of significant restrictions on the ability of joint ventures or associates to transfer funds to the company

(6) Excess losses incurred by joint ventures or associates

Unit: Yuan Unrecognized losses in the current period (or names of joint ventures or associates in the current period Accumulated unrecognized losses in previous periods Net profits shared in accumulated unrecognized losses at the end of the period)

Other instructions

(7) Unconfirmed commitments related to investment in joint ventures

(8) Contingent liabilities related to investments in joint ventures or associates

Important joint operations

Shareholding ratio/share joint business name Main place of business Registration place Nature of business

Explanation on whether the proportion of direct or indirect shareholdings or shares enjoyed in a joint operation is different from the proportion of voting rights:

If the joint operation is a separate entity, the basis for classifying it as a joint operation is:

Other instructions

Equity in structured entities not included in the scope of consolidated financial statements

Relevant instructions for structured entities not included in the scope of consolidated financial statements:

Others

11. Government subsidies

Government subsidies recognized according to the amount receivable at the end of the reporting period

□Applicable Not applicable

Reasons for failure to receive the estimated amount of government subsidy at the estimated time

□Applicable Not applicable

Liability items involving government subsidies

Applicable □Not applicable

Unit: Yuan New additions in the current period are included in the operating income in the current period and are transferred to others in the current period. Other changes in the current period are related to assets/receipt accounting accounts. Beginning balance. Ending balance. Subsidy amount. Non-professional income amount. Other income amount. Moving profit related.

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

8,661,684. 8,438,190.

Deferred income 223,494.36 Related to assets 77 41

8,661,684. 8,438,190.

223,494.36

77 41

Government subsidies included in current profits and losses

Applicable □Not applicable

Unit: Yuan

Accounting accounts Amount for the current period Amount for the previous period

Other income 2,835,597.49 1,817,867.61Other instructions:

12. Risks related to financial instruments

Various risks arising from financial instruments

The company's financial assets include notes receivable, accounts receivable, and other receivables. The company's financial liabilities include short-term loans, notes payable, accounts payable, other payables, non-current liabilities due within one year, and long-term borrowings. For detailed descriptions of each financial instrument, see the relevant items in Note 5. The Company faces risks from various financial instruments in its daily activities, mainly including credit risk, liquidity risk, and market risk. The Board of Directors is solely responsible for establishing and supervising the Company's risk management structure, as well as formulating and monitoring the Company's risk management policies.

Credit risk

Credit risk refers to the risk that one party to a financial instrument fails to perform its obligations, causing financial losses to the other party. If the customer or counterparty involved in the financial instrument is unable to perform its obligations under the contract, the financial losses caused to the company are credit risks. Credit risk mainly arises from accounts receivable from customers. The carrying amount of accounts receivable, notes receivable and other receivables represents the Company's maximum credit risk for financial assets.

Liquidity risk

Liquidity risk is the risk that the Company encounters a shortage of funds when fulfilling its obligations related to financial liabilities. The Company ensures that it has sufficient liquidity to fulfill maturing debts under normal and tight funding conditions, conducts financing negotiations with financial institutions, and maintains a certain level of standby credit lines to reduce liquidity risks.

Market risk

Market risk of financial instruments refers to the risk that the fair value or future cash flows of financial instruments fluctuate due to market price changes, including exchange rate risk, interest rate risk and other price risks.

 Exchange rate risk

Exchange rate risk refers to the risk that the fair value or future cash flows of financial instruments will fluctuate due to changes in foreign exchange rates. Exchange rate risk can arise from financial instruments denominated in foreign currencies other than the functional currency of accounting. The Company does not have significant exchange rate risk.

 Interest rate risk

Interest rate risk refers to the risk that the fair value or future cash flows of financial instruments will fluctuate due to changes in market interest rates. Interest rate risk can arise from both recognized interest-bearing financial instruments and unrecognized financial instruments (such as certain loan commitments).

The company's borrowings are mainly RMB borrowings, which are mainly floating rate borrowings. The borrowing interest rates fluctuate according to the People's Bank of China's benchmark loan interest rate. The company currently mainly avoids cash flow risks caused by interest rate changes by reasonably arranging the proportion of short-term and medium- and long-term borrowings.

 Other price risks

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Other price risks refer to the risk of fluctuations caused by market price changes other than exchange rate risk and interest rate risk, whether these changes are caused by factors related to a single financial instrument or its issuer, or due to factors related to all similar financial instruments traded in the market. Other price risks may arise from changes in commodity prices or equity instrument prices, for example.

Hedging

(1) The company carries out hedging business for risk management

□Applicable Not applicable

(2) The company carries out qualified hedging business and applies hedging accounting

Unit: Yuan Confirmed hedged items

The effectiveness of the hedge and the absence of a hedge are included in the hedged item and the carrying value of the hedge. Hedge accounting has a negative impact on the company's financial items.

The related book value of period instruments and the cumulative fair effect of hedged items are partly derived from the relevant impact on financial statements.

Value Hedge Adjustment

Hedging risk type

Hedging category

Other instructions

(3) The company carries out hedging business for risk management and expects to achieve risk management objectives but does not apply hedging accounting □ Applicable  Not applicable

Financial assets

(1) Classification of transfer methods

□Applicable Not applicable

(2) Financial assets derecognized due to transfer

□Applicable Not applicable

(3) Asset transfer financial assets that continue to be involved

□Applicable Not applicable

Other instructions

13. Disclosure of fair value

Closing fair value of assets and liabilities measured at fair value

Unit: Yuan Ending Fair Value

Item Level 1 Fair Value Measurement Level 2 Fair Value Measurement Total Level 3 Fair Value Measurement

quantity quantity quantity

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

1. Sustained fair value

Measurement

(3) Other equity instruments

11,000,000.00 11,000,000.00 Investment

Measured at fair value on an ongoing basis

11,000,000.00 Total assets of 11,000,000.00

2. Non-sustainable fair price

value measurement

Basis for determining the market price of continuous and non-continuous first-level fair value measurement items
Continuous and non-continuous second-level fair value measurement items, valuation techniques used and qualitative and quantitative information on important parameters
Continuous and non-continuous third-level fair value measurement projects, valuation techniques used and qualitative and quantitative information on important parameters

Project Fair value on December 31, 2024 Valuation technology Important parameters Unlisted company equity 11,000,000.00 Investment target income method evaluation Related asset valuation report

Continuous third-level fair value measurement items, reconciliation information between the opening and closing book values and sensitivity analysis of unobservable parameters
For ongoing fair value measurement items, if there is a conversion between various levels during the current period, the reasons for the conversion and the policy for determining the time of conversion
Valuation technology changes that occurred during the current period and reasons for the changes
Fair value of financial assets and financial liabilities not measured at fair value
Others

14. Related parties and related transactions

Information about the parent company of this enterprise

Parent company to this enterprise Parent company to this enterprise Parent company name Place of registration Nature of business Registered capital

The proportion of shareholding and the proportion of voting rights. Explanation of the parent company of the enterprise.

As of the disclosure date of this report, the company's largest shareholder is Huiyin Rifeng, holding 23.81% of the company's shares. The general partner and executive partner of Huiyin Rifeng is Huiyin Aofeng.

The ultimate controlling party of this enterprise is.

Other notes:

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Information about the company’s subsidiaries

Please refer to Note 10.1 for details of the company's subsidiaries.

Information on joint ventures and associated enterprises of the enterprise

Please refer to Note 10.3 for details of the company's important joint ventures or associates.

The situation of other joint ventures or associates that have related party transactions with the company in the current period, or related party transactions with the company in previous periods that resulted in balances is as follows:

Name of joint venture or associated enterprise Relationship with this enterprise

Other instructions

Other related parties

Names of other related parties Relationship between other related parties and the company

Beijing Shoutuo Ronghui Investment Co., Ltd. is an affiliated enterprise ultimately controlled by the same party as the company.

Huzhou Zhongzhi Rongyun Investment Co., Ltd. is an affiliated enterprise ultimately controlled by the same party as the company.

Guangzhou Dedao Dental Clinic Co., Ltd. An enterprise controlled by the directors of the Company

Other instructions

Related transactions

(1) Related transactions related to the purchase and sale of goods, provision and receipt of services

Procurement of goods/service acceptance form

Unit: Yuan Whether it exceeds the transaction amount

Related parties Related party transaction content Amount incurred in the current period Approved transaction quota Amount incurred in the previous period

Guangzhou Dedao Dental Clinic

Providing labor services 145,611.65

Clinic Co., Ltd.

List of goods sold/services provided

Unit: Yuan Related party Contents of related transactions Amount incurred in the current period Amount incurred in the previous period Explanation of related transactions related to purchase and sale of goods, provision and receipt of services

(2) Related entrusted management/contracting and entrusted management/outsourcing situation

The company's entrusted management/contracting status table:

Unit: yuan trusteeship income/contract entrusted party/contractor confirmed in the current period trustee/contractor entrusted/contracting capital entrusted/contracted from entrusted/contracted end

Package revenue pricing is based on managed revenue/contractor name party name product type start date end date

According to the income-related custody/contracting situation

The company’s entrusted management/outsourcing status table:

Unit: Yuan entruster/contractor Entrustee/contractor Entrust/contract fund Entrust/contract start Entrust/contract end Trusteeship fee/contract The full text of the 2025 semi-annual report of Tuohaochen Medical Technology Co., Ltd. confirmed in this issue

Party name Party name Product type Start date End date Fee pricing basis Management fee/outsourcing fee related management/outsourcing situation description

(3) Related leasing situation

As a lessor, our company:

Unit: Yuan Name of the lessee Type of leased assets Lease income recognized in the current period Lease income recognized in the previous period The company, as the lessee:

Unit: Yuan Short-term simplified treatment not included in lease liabilities

Leases and low-value assets Variable leases measured Lease liabilities assumed Increased rent paid for right-of-use assets

Lessor Lease asset Rental payment (if appropriate) Interest expense Asset

Name Product Category Use (if applicable)

Issued in this period Issued in the previous period Issued in this period Issued in the previous period Issued in this period Issued in the previous period Issued in this period Issued in the previous period Issued in this period

(4) Related guarantees

The company acts as a guarantor

Unit: Yuan guarantee has been fulfilled by the guaranteed party. Guarantee amount. Guarantee start date. Guarantee expiry date.

Complete

The company as the guaranteed party

Unit: Yuan guarantee has been fulfilled by the guarantor. Guarantee amount. Guarantee starting date. Guarantee expiry date.

Complete

Beijing Shoutuo Ronghui Investment Co., Ltd.

162,490,000.00 October 16, 2020 December 20, 2025 No

Ltd.

Huzhou Zhongzhi Rongyun Investment Co., Ltd.

120,000,000.00 No

Ltd.

Description of related guarantees

(5) Fund lending from related parties

Unit: Yuan Related Party Lending Amount Start Date Maturity Date Description

dismantle

take out

(6) Asset transfer and debt restructuring of related parties

Unit: Yuan Related party Contents of related transactions Amount incurred in the current period Amount incurred in the previous period

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd. (7) Remuneration of key management personnel

Unit: Yuan Item Amount for the current period Amount for the previous period (8) Other related transactions

Accounts receivable and payable from related parties

(1) Items receivable

Unit: Yuan Closing balance Opening balance Item name Related parties

Book balance Bad debt provision Book balance Bad debt provision Guangzhou Dedao Dental Clinic

Accounts receivable 306,588.15 336,369.69

Clinic Co., Ltd.

(2) Items payable

Unit: yuan Project name Related party Book balance at the end of the period Book balance at the beginning of the period

Related party commitments
Others

15. Share-based payment

Overall situation of share-based payment

□Applicable Not applicable

Equity-settled share-based payment

□Applicable Not applicable

Share-based payment settled in cash

□Applicable Not applicable

Share-based payment expenses for this period

□Applicable Not applicable

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Modification and termination of share-based payment
Others

16. Commitments and contingencies

Important commitments

Important commitments existing at the balance sheet date

As of June 30, 2025, the Company had no major commitments that would affect the reading and understanding of these financial statements.

Contingent matters

(1) Important contingencies existing on the balance sheet date

As of June 30, 2025, the Company had no balance sheet contingencies that would affect the reading and understanding of these financial statements. (2) If the company has no important contingencies that need to be disclosed, this should also be explained.

The company has no important contingencies that need to be disclosed.

Others

17. Events after the balance sheet date

Important non-adjustment matters

Unit: yuan Impact items on financial status and operating results Content Reasons why the impact cannot be estimated

number of rings

Profit distribution
Sales return
Description of other post-balance sheet events

As of August 28, 2025, the Company had no other post-balance sheet events that would affect the reading and understanding of these financial statements.

18. Other important matters

Correction of accounting errors in the previous period

(1) Retrospective restatement method

Unit: Yuan

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd. Statements for each affected comparative period

Contents of accounting error correction Processing procedures Cumulative impact number

Project name

(2) Prospective applicable law

Contents of correction of accounting errors Approval process Reasons for adopting prospective application

Debt restructuring
Asset replacement

(1) Non-monetary asset exchange

(2) Other asset swaps

Annuity plan
Termination of operations

Unit: Yuan Attributable to Parent Company Items Revenue Expenses Total Profit Income Tax Expense Net Profit Termination of Owner

Other explanations of operating profit

Branch information

(1) Determination basis and accounting policies of reporting segments

The company determines its operating segments based on its internal organizational structure, management requirements, internal reporting system, etc. A company's operating segments refer to components that simultaneously meet the following conditions:

This component can generate income and incur expenses in daily activities;
The management can regularly evaluate the operating results of the component to decide to allocate resources to it and evaluate its performance;
Be able to obtain relevant accounting information such as the financial status, operating results and cash flow of the component through analysis.

The company mainly determines reporting segments based on industry/product segments, and the assets and liabilities commonly used with each segment are allocated among different segments in proportion to their scale. At the end of the period, it is mainly divided into three segments. Segment one is the group and electrical industry segment, that is, the group and traditional switch and switch cabinet business; segment two is the house leasing and other business segments, that is, the company's house leasing and other sporadic businesses; segment three is the oral medical business segment, that is, the company's oral medical services and oral medical product sales business.

(2) Financial information of reporting segments

Unit: Yuan

Item Segment 1 Segment 2 Segment 3 Inter-segment elimination Total

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Operating income 24,112,875.19 1,038,523.86 288,484,549.17 313,635,948.22 Operating cost 14,782,582.40 824,253.00 162,667,415.28 178,274,250.68

1,444,406,852.8 Total assets 1,329,160,394.17 164,472,977.57 664,651,895.62 -713,878,414.55

1,036,006,471.4 Total liabilities 794,534,567.88 100,326,705.40 370,702,707.93 -229,557,509.78

(3) If the company has no reportable segments, or cannot disclose the total assets and total liabilities of each reportable segment, the reasons should be explained

(4) Other instructions

Other important transactions and matters that have an impact on investors’ decision-making
Others

19. Notes on main items of the parent company’s financial statements

Accounts receivable

(1) Disclosure based on aging

Unit: Yuan

Aging Book balance at the end of the period Book balance at the beginning of the period

More than 3 years 15,000.00 15,000.00

More than 5 years 15,000.00 15,000.00Total 15,000.00 15,000.00

(2) Classified disclosure according to bad debt accrual method

Unit: Yuan Ending balance Beginning balance

Book balance Provision for bad debts Book balance Provision for bad debts

Category Book price Book price provision ratio Provision ratio

Amount Ratio Amount Value Amount Ratio Amount Value Example

its

Medium:

by combination

bad provision

15,000. 15,000. 15,000. 15,000.

Account preparation 100.00% 100.00% 0.00 100.00% 100.00% 0.00

00 00 00 00

receivables

Accounts

its

Medium:

Combination 2

15,000. 15,000. 15,000. 15,000.

Aging group 100.00% 100.00% 0.00 100.00% 100.00% 0.00

00 00 00 00

combine

15,000. 15,000. 15,000. 15,000.

Total 100.00% 100.00% 100.00% 100.00%

00 00 00 00

Category name of provision for bad debts by combination: Aging combination

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Unit: Yuan ending balance

Name

Book balance Bad debt provision Provision ratio

Aging combination 15,000.00 15,000.00 100.00% Total 15,000.00 15,000.00

Description of what this combination is based on:

If bad debt provisions for accounts receivable are made according to the general expected credit loss model:

□Applicable Not applicable

(3) Bad debt provisions accrued, recovered or reversed in the current period

Bad debt provisions for the current period:

Unit: Yuan Amount of changes in the current period

Category Opening balance Ending balance Provision Recovery or transfer Write-off Others

Aging combination 15,000.00 15,000.00Total 15,000.00 15,000.00 Among them, the amount of bad debt provision recovery or reversal in the current period is important:

(4) Accounts receivable actually written off in the current period

Unit: yuan item write-off amount

Important write-offs of accounts receivable:

Unit: Yuan Whether the amount is paid by the name of the related unit Nature of accounts receivable Amount of write-off Reason for write-off The write-off procedures performed

transaction generated

Instructions for writing off accounts receivable:

(5) Accounts receivable and contract assets with the top five closing balances collected by debtors

Unit: Yuan accounts receivable and combined accounts receivable, bad debts, quasi-accounts receivable, ending balance, contract assets, ending balance, accounts receivable and contracts

Unit name Closing balance of same assets Provision and contract asset reduction amount Closing balance of assets

Proportion of Total Value Preparation Closing Balance

Other receivables

Unit: Yuan Item Ending balance Beginning balance

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Dividends receivable 22,700,000.00 22,700,000.00 Other receivables 180,649.39 166,727.04 Total 22,880,649.39 22,866,727.04

(1) Interest receivable

Classification of interest receivable

Unit: Yuan Item Ending balance Beginning balance

Important overdue interest

Unit: Yuan Whether impairment occurs and the borrowing unit is judged. Ending balance Overdue time Reason for overdue

Judgment basis

Other notes:

Classified disclosure according to bad debt accrual method

□Applicable Not applicable

Bad debt provisions accrued, recovered or reversed in the current period

Unit: Yuan Amount of changes in the current period

Category Opening balance Ending balance Provision Recovery or reversal Write-off or write-off Other changes

Among them, the amount of recovery or reversal of bad debt provisions for the current period is important:

Other notes:

Interest receivable actually written off in the current period

Unit: yuan item write-off amount

Among them, the important write-off of interest receivable

Unit: Whether the yuan amount is paid by the name of the related unit, nature of the amount, write-off amount, write-off reason, write-off procedures performed

transaction generated

Write-off instructions:

Other notes:

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

(2) Dividends receivable

Classification of dividends receivable

Unit: yuan project (or invested unit) Ending balance Beginning balance

Fushun Bank 22,700,000.00 22,700,000.00 Total 22,700,000.00 22,700,000.00

Important dividends receivable aged more than 1 year

Unit: Yuan Whether impairment occurs and the judgment item (or invested unit) Closing balance Aging Reason for non-recovery

Judgment basis

Classified disclosure according to bad debt accrual method

□Applicable Not applicable

Bad debt provisions accrued, recovered or reversed in the current period

Unit: Yuan Amount of changes in the current period

Category Opening balance Ending balance Provision Recovery or reversal Write-off or write-off Other changes

Among them, the amount of recovery or reversal of bad debt provisions for the current period is important:

Other notes:

Dividends receivable actually written off in the current period

Unit: yuan item write-off amount

Among them, the important write-off of dividends receivable

Unit: Whether the yuan amount is paid by the name of the related unit, nature of the amount, write-off amount, write-off reason, write-off procedures performed

transaction generated

Write-off instructions:

Other notes:

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

(3) Other receivables

Classification of other receivables according to nature of payment

Unit: Yuan

Nature of payment Book balance at the end of the period Book balance at the beginning of the period

Employee insurance 225.00 225.00 Deposit and security deposit 286,969.54 286,969.54 Current accounts with non-related parties 20,615,380.90 20,574,397.43 Current accounts with related parties

Total 20,902,575.44 20,861,591.97

Disclosure based on aging

Unit: Yuan

Aging Book balance at the end of the period Book balance at the beginning of the period

Within 1 year (including 1 year) 41,208.47 225.00 1 to 2 years 286,969.54 156,969.54 2 to 3 years 0.00 130,000.00 More than 3 years 20,574,397.43 20,574,397.43 3 to 4 years 0.00 725.00 4 to 5 years 725.00 1,091,687.53

More than 5 years 20,573,672.43 19,481,984.90 Total 20,902,575.44 20,861,591.97

Classified disclosure according to bad debt accrual method

Unit: Yuan Ending balance Beginning balance

Book balance Provision for bad debts Book balance Provision for bad debts

Category Book price Book price provision ratio Provision ratio

Amount Ratio Amount Value Amount Ratio Amount Value

Example Example

By item

20,673, 20,673, 20,673, 20,673,

Bad provision 98.90% 100.00% 99.10% 100.00%

672.43 672.43 672.43 672.43

Account preparation

its

Medium:

by combination

228,903 48,253. 180,649 187,919 21,192. 166,727 Bad provision 1.10% 21.08% 0.90% 11.28%

.01 62 .39 .54 50 .04Account preparation

its

Medium:

Combination 1

228,903 48,253. 180,649 187,919 21,192. 166,727Aging group 1.10% 21.08% 0.90% 11.28%

.01 62 .39 .54 50 .04 combined

20,902, 20,721, 180,649 20,861, 20,694, 166,727Total 100.00% 99.14% 100.00% 99.20%

575.44 926.05 .39 591.97 864.93 .04 Category name of provision for bad debts on an individual basis: Other receivables with significant individual amounts and provision for bad debts on an individual basis

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Unit: Yuan Beginning balance Ending balance

Name

Book balance Bad debt provision Book balance Bad debt provision Provision ratio Reason for provision Shenzhen Aberdeen 10,914,070.0 10,914,070.0 10,914,070.0 10,914,070.0

100.00% is not expected to be recovered by Technology Co., Ltd. 0 0 0 0

Rongyu Information Technology

9,629,602.43 9,629,602.43 9,629,602.43 9,629,602.43 100.00% Expected to be unrecoverable Co., Ltd.

20,543,672.4 20,543,672.4 20,543,672.4 20,543,672.4

total

3 3 3 3

Category name of bad debt provision for individual items: Other receivables for which bad debt provision is made individually although the individual amount is not significant

Unit: Yuan Beginning balance Ending balance

Name

Book balance Bad debt provision Book balance Bad debt provision Provision ratio Reason for provision Although the individual amounts are not

Significant but individually calculated

130,000.00 130,000.00 130,000.00 130,000.00 100.00% It is expected that the provision for bad debts cannot be recovered

Other receivables

Total 130,000.00 130,000.00 130,000.00 130,000.00

Category name of provision for bad debts by combination: Aging combination

Unit: Yuan ending balance

Name

Book balance Bad debt provision Provision ratio

Aging combination 228,903.01 48,253.62 21.08% Total 228,903.01 48,253.62

Description of what this combination is based on:

Provision for bad debts is made based on the general expected credit loss model:

Unit: Yuan Phase 1 Phase 2 Phase 3

Expected credit throughout the lifetime Credit expected throughout the lifetime

Provision for bad debts Expected credit in the next 12 months Total

Loss (no credit deduction has occurred Loss (credit deduction has occurred)

loss

value) value)

Balance on January 1, 2025 21,192.50 20,673,672.43 20,694,864.93 Balance on January 1, 2025

In this issue

Provision for the current period 27,061.12 27,061.12 Remainder as of June 30, 2025

48,253.62 20,673,672.43 20,721,926.05

Basis for division of each stage and provision ratio for bad debts

Changes in book balances with significant changes in loss provision during the current period

□Applicable Not applicable

Bad debt provisions accrued, recovered or reversed in the current period

Bad debt provisions for the current period:

Unit: Full text of 2025 semi-annual report of Yuanhaochen Medical Technology Co., Ltd.

Amount of changes in the current period

Category Opening balance Ending balance Provision Recovery or reversal Write-off or write-off Others

Other receivables bad 20,694,864.9 20,721,926.0 27,061.12

Account provision 3 5 20,694,864.9 20,721,926.0 Total 27,061.12

3 5 Among them, the amount of bad debt provision reversal or recovery in the current period is important:

Unit: Yuan Determine the name of the original bad debt provision accrual unit, the reversal or recovery amount, the reason for the reversal, the recovery method, the basis for the ratio and its rationality

Other receivables actually written off in the current period

Unit: yuan item write-off amount

Important write-offs of other receivables:

Unit: Whether the Yuan amount is paid by the related unit. Nature of other receivables. Write-off amount. Reason for write-off. Write-off procedures performed.

transaction generated

Instructions for writing off other receivables:

Other receivables with the top five closing balances based on debtors

Unit: Yuan accounted for other receivable period

Name of the unit with the ending balance of bad debt provision Nature of the payment Ending balance Aging Total ending balance

Proportion

Presented in other receivables due to centralized management of funds

Unit: Yuan Other instructions:

Long-term equity investment

Unit: Yuan Ending balance Beginning balance

Project

Book balance Impairment provision Book value Book balance Impairment provision Book value 777,131,559. 777,131,559. 777,131,559. 777,131,559. Investment in subsidiaries

96 96 96 96 Associates and joint ventures 571,669,742. 92,505,120.4 479,164,621. 568,822,780. 92,505,120.4 476,317,660. Enterprise investment 40 8 92 54 8 06 1,348,801,30 92,505,120.4 1,256,296,18 1,345,954,34 92,505,120.4 1,253,449,22Total

2.36 8 1.88 0.50 8 0.02

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

(1) Investment in subsidiaries

Unit: Yuan

Beginning balance Increase or decrease in the current period Ending balance of invested orders Impairment provision Impairment provision

(Book price Provision for impairment (Book price Beginning balance Additional investment Decrease investment Others Closing balance

value) prepare value)

Jilin Yongda

311,011,3 311,011,3 Electrical switch

18.96 18.96 Ltd.

Beijing Rongyu

60,000,00 60,000,00 Technology Co., Ltd.

0.00 0.00Company

Rongyu Huatong

Leasing (day 170,000,0 170,000,0jin) Co., Ltd. 00.00 00.00 Company

Zhiyu Medical

236,120,2 236,120,2 Investment limited

41.00 41.00Company

777,131,5 777,131,5Total

59.96 59.96

(2) Investment in associates and joint ventures

Unit: Yuan

Increases and decreases in the current period

Beginning of period Equity declaration End of period

Impairment Impairment Balance Other Disbursement Balance Investment Provision Other Disbursement Provision (Account Addition Decrease Confirmation Comprehensive Cash (Billing Unit Beginning Equity Impairment Others Ending Face Price Investment Income from Investment Dividend Face Price

Balance Change Provision Balance Value) Capital Loss Adjustment or Profit Value)

profit

1. Joint ventures

2. Joint ventures

Fushun

Bank 476,3 92,50 4,349 479,1 92,50

1,502

Shares 17,66 5,120 ,700. 64,62 5,120

,738.

Limited 0.06 .48 10 1.92 .48Company

476,3 92,50 4,349 479,1 92,50

1,502

Subtotal 17,66 5,120 ,700. 64,62 5,120

,738.

0.06 .48 10 1.92 .48

476,3 92,50 4,349 479,1 92,50

1,502

Total 17,66 5,120 ,700. 64,62 5,120

,738.

0.06 .48 10 1.92 .48

The recoverable amount is determined as the net amount after fair value minus disposal costs.

□Applicable Not applicable

The recoverable amount is determined based on the present value of expected future cash flows.

□Applicable Not applicable

Reasons for the obvious inconsistency between the aforementioned information and the information used in impairment testing in previous years or external information

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Reasons for the significant inconsistency between the company's information used for impairment testing in previous years and the actual situation of that year (3) Other explanations

Operating income and operating cost unit: Yuan Amount incurred in the current period Amount incurred in the previous period Items

Revenue Cost Revenue Cost Decomposition information of operating income and operating costs: Unit: Yuan Division 1 Division 2 Total contract classification

Operating income Operating cost Operating income Operating cost Operating income Operating cost Operating income Operating cost Business type

Among them:

According to place of business

Distinguish classification

Among them:

market or customer

Household type

Among them:

Contract type

Among them:

Transfer by product

give time

Classification

Among them:

According to contract period

Limited classification

Among them:

According to sales channel

Road classification

Among them:

total

Information related to performance obligations:

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

The company's pre-payments, the company's performance obligations, and the important payment terms. The company's commitment to transfer is the main responsibility.

The item will be refunded to the customer during the period. The type and time of the quantity guarantee. The nature of the goods. Anyone.

Account’s money and other explanations of related obligations

Information related to the transaction price allocated to the remaining performance obligations:

Major contract changes or major transaction price adjustments

Unit: Yuan

Item Accounting treatment method Amount of impact on income

Other notes:

Investment income

Unit: Yuan

Item Amount for the current period Amount for the previous period

Long-term equity investment income calculated using the cost method 10,000,000.00 10,000,000.00 Long-term equity investment income calculated using the equity method 4,349,700.10 16,737,122.44 Total 14,349,700.10 26,737,122.44

Others

20. Supplementary information

Detailed statement of non-recurring profits and losses for the current period

Applicable □Not applicable

Unit: Yuan

Item Amount Description

Profit and loss from disposal of non-current assets 678,017.94

Government subsidies included in current profits and losses (related to the company’s regular

Closely related to regular business operations and in compliance with national policies

483,223.52

stipulates, enjoys according to determined standards, and treats the company

Except for government subsidies that have a lasting impact on profits and losses)

Other non-operating income other than the above items and

-2,421,175.31

expenditure

Less: Income tax impact -391,582.28

Amount of impact on minority shareholders’ equity (after tax) -675,821.02

Total -192,530.55 --

Details of other profit and loss items that meet the definition of non-recurring profits and losses:

□Applicable Not applicable

The company has no other specific circumstances of profit and loss items that meet the definition of non-recurring profits and losses.

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd. Applicable □Not applicable

Item Amount involved (yuan) Reason

Closely related to the company's normal business operations, it complies with the VAT levy and refund 2,352,373.97 national policies, and is based on certain standard quotas or

Quantity for continued enjoyment.

Return on net assets and earnings per share

earnings per share

Profit for the reporting period Weighted average return on equity

Basic earnings per share (yuan/share) Diluted earnings per share (yuan/share) Net attributable to the company’s ordinary shareholders

-6.15% -0.0283 -0.0283Profit

After deducting non-recurring gains and losses, attributable to

-6.10% -0.0280 -0.0280 Net profit of the company’s common shareholders

Differences in accounting data under domestic and foreign accounting standards

(1) Differences in net profit and net assets in financial reports disclosed in accordance with both international accounting standards and Chinese accounting standards

□Applicable Not applicable

(2) Differences in net profit and net assets in financial reports disclosed in accordance with both foreign accounting standards and Chinese accounting standards

□Applicable Not applicable

(3) Explanation of the reasons for the differences in accounting data under domestic and foreign accounting standards. If differences are adjusted for data that have been audited by an overseas audit institution, the name of the overseas institution should be indicated.

Others

Full text of the 2025 semi-annual report of Haochen Medical Technology Co., Ltd.

Section 9 Other reporting data

1. Other major social security issues

Whether the listed company and its subsidiaries have other major social security issues

□Yes No □Not applicable

Whether there was any administrative penalty during the reporting period

□Yes No □Not applicable

2. Registration form for reception of research, communication, interviews and other activities during the reporting period

Applicable □Not applicable

The main topic of discussion

Basic information of the survey: reception time, reception location, reception method, type of reception objects, reception objects, content and information provided.

condition index information

For details, please refer to "002622 Haochen's participation in the company's online company operations" disclosed by Juchao Information Network

May 2025 Network platform online Medical investor relations online Others Collective reception of daily activities and replies to investors

Exchange on the 27th. Questions from investors in the department of management information.

20250527》(No.: 2025-001)

3. Capital transactions between listed companies and controlling shareholders and other related parties

□Applicable Not applicable